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Network analysis (NA) has been used for studying many social aspects. Employing of network 
analysis as an approach in the field of public health, to study the relations between patients or 
health workers and their potential effects in many medical perspectives, took a good share of 
researchers’ efforts as well. Few attempts have been conducted to use network analysis to study 
drug-drug relations using medicines as the main actors in the network instead of persons. 
We aimed at two primary objectives; a methodological objective and a clinical one. The 
methodological is to define the co-medication in a more reliable way and to use NA as an 
approach to map and extract the co-medication patterns in the elderly. Afterwards, to comment 
on the relevant clinical information represented in these networks.   
We represented two examples of drug-drug relations in the form of networks; i) The elderly co-
medication in Norway in three years (2012-2014). The data was extracted from the Norwegian 
Prescription Dataset (NorPD) and included 61,930,313 prescriptions of 342,451 men (45%) 
and 419,455 women (55%), in total 761,906 patients. The mean age of the study population is 
75 years. ii) The severe Drug-drug Interactions (DDI) based on the drug-drug interactions from 
the Prescribing and Dispensing Support dataset (FEST) with a total of 57,151 sever interactions. 
In our thesis, co-medication was defined as treatment episodes. Determining these episodes 
depends on the time of prescriptions’ dispensing, the Defined Daily Dose (DDD) of each drug, 
assuming 80% of patients’ adherence. We used the Proportion of Days Covered (PDC) to 
measure the adherence. We allowed a gap of 14 days as an accepted medical-free period 
between the treatment episodes. After defining the treatment episodes for each patient, a 
prevalence point was chosen to study the co-medication pattern in it. This approach in defining 
co-medication allows flexibility in choosing the studied prevalence points.  
Six different elderly co-medications patterns were extracted from our primary network. 
Comparing co-medication patterns in two prevalence time points, with a one-year difference, 
revealed changes in use, number of users, and prescribed patterns.  
We used “betweenness centrality”, a specific NA measure, to obtain the drugs with the most 
contribution in the severe interactions. The network showed 662 severe DDI in the studied 
treatment episode with a range of 1 to 2320 patients who were exposed to these severe 
interactions. 
We concluded that network analysis, as an approach, can be effectively used in visualizing and 























































Studying the patterns of co-medications has increasingly become an essential part of the 
medical field study. Its importance arises, among others, from that it highlights prescribing 
quality (1), contributes in finding out undesired medications’ side effects, decreasing the risk 
of drug-drug interactions (DDIs) and studying patterns’ change across time and space (2).  
 
As known, the elderly are more exposed to cumulative, continuous and simultaneous 
polypharmacy (3) than younger ones. Although medicines can reduce elderly morbidity and 
mortality, they also may have adverse effects (ADEs) which can represent a potential danger 
(4, 5). Integrative and systematic reviews1 held on ADEs and DDIs on elderly reinforced that 
co-medication, polypharmacy and unfortunate prescribing are global significant issues among 
the elderly. In a systemic review of 14 studies which subjected the elderly (³ 65 years), the 
prevalence of inappropriate drug use ranged from 27% to 56% (7). Another integrative review 
of 47 studies form different countries with about 14 million patients ,in total, aged ≥ 60 years 
emphasizes that ADEs and DDIs related to polypharmacy in elderly populations are significant 
issues worldwide (8).   
 
In addition to this; the elderly have many other factors which can increase the risk of undesired 
medicines’ effects such as renal (9), hepatic (10), which are mainly responsible for drugs 
metabolism, and mental conditions compared to younger people. 
  
In particular, Norwegian elderly have a high mean of age (1 of 9 persons are aged 70 years or 
older), this percentage is expected to be 1 of each five persons in 2060 (11). Elderly poses a 
significant proportion of drug users in Norway. Statistics from Norwegian prescription dataset 
(NorPD) shows that 91% in 2011 and 92% in 2017 of the elderly population had at least one 
drug dispensed. The data also indicates that 57% in 2011 and 58% in 2017 of the elderly 
population used more than five drugs. In 2017, 23% of drug users over 65 years were prescribed 
more than 10 different drugs during the year (12, 13).  
                                               
1  The primary difference between systematic and integrative reviews is the types of studies included. The 
systematic reviews often include randomized clinical trials, while integrative studies may include other types of 
research. Furthermore, integrative studies are more of discussion to findings. (6. McGrath MJ. Systematic and 
Integrative Reviews of the Literature: How Are They Changing Our Thoughts About Practice? The Journal of 
Perinatal & Neonatal Nursing. 2012;26(2):193-5.). 
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Because of this, it is important to study the co-medication patterns and DDI in the elderly 
population in order to provide solutions for the potential problems related to polypharmacy 
(14).  
   
Before moving on, it is important to define and explain some basic concepts and terms. The 
next paragraphs will therefore focus on defining the elderly, co-medication, and network 
analysis. 
 
 1.2 “Elderly” definition  
Although there are commonly used definitions of the elderly (15), there is no general agreement 
on the age in which a person becomes old. The Norwegian Institute of Public Health has 
accepted defining elderly as ≥ 65 years in age (13) based on a paper written in 2002 to define 
the elderly. This paper was published on the website of World Health Organization (WHO) 
claiming that determining of elderly definition starts with 65 years old (16). 
 
In a statistical study published in 1999 by “Statistics Norway”, the elderly were defined as 
people who are 67 years of age or older (17). In this thesis, we will define the elderly as 65 
years old or older. 
 
1.3 Co-medication definition 
It’s important to shed light on what is meant with co-medication since it will consequently 
define which kind of results will be extracted. For instance, if co-medication is explained as the 
group of drugs which were prescribed from the same prescriber, results will reflect the quality 
of prescribing (18) and to what extent it follows the guidelines, meanwhile if it is interpreted as 
simultaneously use of some drugs regardless of the prescriber, results will revolve around, 
among others, co-morbidity, drug-drug interactions (DDI) (19), and undesired drug 
combinations (1).  
 
The prefix ‘co-’ means joint; mutual, or common (20). Hence, “co-medication” means jointly 
using two or more medications. Generally, four main aspects are to be taken into consideration 
when co-medication is being defined: patient, prescribers, time of prescriptions’ dispensing and 
overlapping use of drugs in a ‘time window’ either based on Defined Daily Dose (DDD) (21) 
or not (22). 
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1.4 Network analysis 
According to John Scott (23), the principal types of data are “Attribute data” and “Relational 
data”. Attribute data studies the characteristics of objects (observations), for example, 
education, income, etc. while relational data care about ties and connections between these 
objects themselves. The suitable way of studying attributes data is variable analysis, however, 
in the case of relational data, network analysis is the appropriate type of analysis (24). 
 
Network Analysis science (NA) has its roots in many sciences such as mathematics, statistics, 
sociology, and computer science. NA can represent a description of a real world system, a 
mathematical model or a simulation (25). It introduces also an ecological research approach 
which is uniquely suited for describing and discovering the structure of relational data. Today, 
it is increasingly common to employ network analysis for the study of complex systems in fields 
of biology, sociology and information science. 
 
Like all other fields, the healthcare sector has become rich in electronic databases such as 
prescription databases and patients’ journals. These types of databases are rich sources of 
information for researchers and decision makers. Different data analytical techniques are now 
used to understand and interpret many aspects of medical healthcare such as the economic side, 
effectiveness, and quality of services. Social Network Analysis (SNA) as a quite new analytical 
approach for healthcare study is believed to introduce a unique ability to explore the medical 
data (26). Rather than the other analytical approaches, NA focuses on relationships between 
subjects themselves not relationships between subjects’ attributes (i.e., variables) (25). 
 
1.4.1 A little on network analysis history 
 
Developing the concept of the network as a pattern studying tool started about two centuries 
ago. “Leonhard Euler” (1707-1783) founded the graph theory in order to solve a famous 
problem in the18th-century. The problem issued if it was possible to walk around the town of 
Königsberg, (now Kaliningrad, Russia) crossing each of its seven bridges only once and return 
to the starting point. By using a network of nodes and links Euler showed that the famous 
mathematical problem wasn’t possible to solve and that it was impossible to walk through the 





1.4.2 Graph theory 
G = (V, E) 
 
The theory of NA has its bases in two separate fields; social sciences and mathematics (i.e. 
graph theory) (28). Graph theory is one of the mathematical foundations for NA in which a 
graph (G) consists of two elements vertices (V) or nodes and Edges (E), links or ties.  
 
Another early attempt in the 19th century carried out by the Norwegian ethnologist “Eilert 
Sundt” (1817-1875), who noticed the formation of social circles among rural Norwegian 
farmers. Eilert wrote about what he called “bedelag” (29) or an “invitation group” which means 
in the old Norwegian traditions that neighbors who live nearby invite each other to their 
occasions, such as weddings, and hence forming a sort of isolated circles. (30, 31). 
 
Since that; the attempts from different sociologists, phycologist, and mathematicians were 
continued to use and develop NA bases, structures and models. Over the past decades, NA use 
has been developed in an extensive variety of fields such as psychology, sociology, political 
science, communications, business, statistics, and computer science. Today there is an 
organization called “International Network for Social Network Analysis” (INSNA), a 
professional association which publishes only researches concern social network analysis (25). 
 
1.4.3 Social Network analysis and public health 
Public health is an important observational field of study with some descriptive and relational 
characteristics. Using NA in this field is not a new approach. Transmission networks have been 
used to examine the potential risk of diseases transmission based on the relation between the 
infected people with the surrounding people (28, 32-34). This approach allowed researchers to 
predict (from the first few cases) the scale of close outbreaks and to take preventive measures. 
 
Another form of the transmission network is the information transmission network which helps 
to show the dissemination of public health information to different organizations and 
consumers. Some network characteristics (such as centrality measures) reveal which actors 
contribute the most at spreading of such information.  
Furthermore, researchers have developed simulation networks that describe diffusion properties 
and predict how could the information spread be faster or more efficient (35).  
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Studying health workers’ behavior depending on SNA took a good share of researchers’ efforts 
as well. Interaction social networks have been studied to expose these workers’ impact on health 
services (36). This is considered a form of Organizational network analysis (ONA) which cares 
about the formal/informal relations inside the one organization and their reflection on 
information spread and business effectiveness. (37). 
 
Researchers moved a step forward in the concept of using SNA nodes to apply the idea on 
organizations not on individuals and hence starting a new field called Interorganizational 
network analysis, which reveals interactions exist between collaborative agencies and mainly 
differs from SNA in that networks’ nodes comprise of agencies or organizations, not individuals 
(38, 39). 
 
In the field of biomedicine and systems pharmacology network analysis is now widely and 
effectively used to analyze and map the effects and interactions of different lead compounds 
and drugs on drug targets, promising to increase the knowledge of the mechanisms underlying 
the multiple actions of drugs (40, 41).  
 
1.4.4 Drug Prescription Network (DPN) 
 
Another step in-depth, a few tries have been held to apply the approach on drugs themselves as 
actors; the same fundamental idea of network analysis, but this time with using medicines or 
drugs as actors instead of individuals or organizations.  
 
To our knowledge, a few studies have been conducted using NA as an approach to understand 
and analyze drug-drug relations patterns. Cavallo et al. published in 2013 an important paper 
on the co-medication pattern based on six-month prescriptions by 99 General Practitioner (GPs) 
in Italy. The study was mainly conducted for visualizing of co-prescription pattern and 
proposed that it was possible to apply network science as a tool to study public health 
phenomena from a new, different perspective. To reduce the complexity of networks, they 
shortened the ATC codes to the second ATC-level (anatomical, therapeutic level) showing and 
comparing the frequency of combining between different anatomical groups in different age 
and sex segments of the study population (42). 
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Another important paper which studied the co-medication pattern was published by Bazzoni et 
al. in 2015. The study aimed to generate, analyze and compare various drug prescription 
network (DPN) to unveil possible differences in drug co-prescription patterns across time and 
space.  By time they meant a temporal change in co-prescription pattern in different periods, 
while space indicates different regions or wider territories in Italy. By studying of density, 
modularity, and other networks’ measures of DPN the researchers concluded the importance of 
NA as an approach to analyzing co-medication networks with a recommendation of further 
studies in this concern. They highlighted also that one of the significant features of the new 
network-based method is the ability to display trends in the co-prescription of a given drug 
within the context of the general co-prescription practice (2). The paper was a sort of technical 
study more than a clinical one. 
 
These two studies had some limitations; due to the few nodes scale and shortening of the ATC 
codes to the second level (i.e. Cavallo) or showing a few relevant clinical results (i.e. Bazzoni). 
Hence, this thesis is an extension to these attempts on a larger scale of data (on both 
prescriptions and patients scale) and on the complete ATC level. 
 
In a conference abstract by “Kristian Svendsen” for studying changes in drug utilization in 
elderly patients before and after being admitted to geriatric ward, the abstract showed a change 
in the trend of co-medicated drugs after hospitalizing (43). 
 
To our knowledge, no published study has used network analysis to study the general DDI as 
a form of a relation between medicines. Uses of network analysis in public health are 




Figure 1.1: Uses of Network analysis in Public Health field 
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1.5 Structure and types of networks 
Networks consist primarily of “Nodes” which represents individuals or actors and “Edges” or 
“Links” which correspond a kind of relation between these actors (44).  
A network can be directed which means the edges go in a specific order from a node (A) to (B), 
for example, or undirected which means there is no distinction between the two connected 




Figure 1.2: Directed, undirected and weighed (valued) networks (Source: The Oxford Handbook of Quantitative 
Methods in Psychology, Vol. 1)(45) 
 
Network edges can also be weighed or unweighted (figure 1.2), unweighted means that the two 
nodes are either linked or not (0 or 1) (a qualitative type of analysis), while weighed considers 
how many times these two nodes were connected by a sort of relation (also called edge thickness 
or tie strength) (46). In other words, it shows the intensity of this sort of relationship between 
these two nodes (a quantitative type of analysis).  
 
1.5.1 Network matrix 
To plot a network, the collected data must be held in what is called the data matrix (figure1.3) 
(47). In the case of attribute analysis, the data is arranged in a case-by-variable matrix. For 
relational data (i.e. network analysis), the matrix represents the intensity of the affiliation 
between the actors (nodes) in the form of numbers which represent if there is an affiliation or 
not (0,1) or how many times were these actors connected together in the studied context 







Figure (1.3) and (1.4) represent a matrix of a simple weighed network and the resulted network. 
This example matrix gives us the network in the following diagram; the thicker lines between 
ATC codes indicate higher intensity of co-medication. 
 
 ATC1 ATC2 ATC3 ATC4 ATC5 ATC6  ATC7 
ATC1 - 1 14 6 9 11 0 
ATC2 1 - 22 5 10 26 2 
ATC3 14 22 - 3 15 5 4 
ATC4 6 5 3 - 4 0 7 
ATC5 9 10 15 4 - 0 8 
ATC6 11 26 5 0 0 - 0 
ATC7 0 2 4 7 8 0 - 
 
Figure 1.3: An example of a “weighed edges” matrix of actors, ATC codes, showing how many times where each 
ATC codes were combined with other ATC codes (i.e. weighed edges). 
 
 
Figure 1.4: Showing the final form of an undirected weighed network; where ATC codes are nodes and co-
medication are edges, thicker edges means more users (combining times) for this drug-drug combination.  
 
1.6 Results of network analysis 
Generally, in NA there are three broad outcomes are resulted; visualization, descriptive analysis 
and constructing of inferential or longitudinal network models (25). Visualizing allows 
researchers to represent the network information in a graphic format (with a wide variety of 











A Network is fundamentally descriptive; this capability can highlight roles of important actors, 
how central they are for the network, which sub-groups and clusters are present in the network 
in many more other results than traditional descriptive analysis ways. Finally, Inferential (48) 
and longitudinal models (49) vary and are developed to fit the supposed hypothesis. 
 
1.7 Important network measures 
1.7.1 Density  
It is one of the NA primary measures. The density of a network is the total number of 
actual edges (ties) divided by the total possible number of edges that could occur (50). 
It is scaled between 0 and 1, in which 1 indicates high density and 0 refers to low density. 
For instance, if we have six actual edges and all the possible edges that could exist in 
the network are 10, so the density of this network will be 0,6. The density measure is 
useful as a tool for comparing networks to show the crowdedness of each network and 
the difference in coordination between actors in different networks (51). 
 
1.7.2 Modularity class 
It is also called “community structure detection” and is concerned about finding sub-
networks (clusters) in the large-scale networks. Different algorithms can be used to shed 
light on the locations of “communities” in the complex networks (52) with advantages 
and disadvantages of each. Gephi (the software used in this thesis) uses Louvain method 
for community detection. This method has many benefits, such as it is easy to 
implement, and it can handle complex and weighted networks. This method also 
provides higher quality results in terms of community detection compared to many other 
algorithms  (53). 
 
1.7.3 Eigenvector centrality 
It is a measure of the importance of a node in a network based on the node's connections 
with the other vital nodes. Relative scores are then given to all nodes in the network 
based on the concept that; connections to high-scored nodes give a higher score to the 
node than equal connections to low-scored nodes. In other words, high eigenvector 
score means that a node is connected to many nodes which, themselves, are connected 
to important nodes in the network and have high scores of eigenvector centrality. This 
means that a node with high eigenvector centrality score isn’t necessarily linked to the 
highest number of nodes in a network but is necessarily linked to the most critical ones 
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(54). This type of centrality differs from Degree centrality which counts all the 
connection to the studied node equally.  
 
1.7.4 Betweenness centrality 
A node betweenness centrality measures how often this node appears on the shortest paths 
between the other nodes in the network. In other words, it is the number of times a node 
connects pairs of other nodes, which ,otherwise, would not be able to reach each other (50). 
This means if we remove theses nodes first, there is a high probability to cut the network  
into many unconnected components. Higher betweenness score indicates higher power or 



























The primary objective of this thesis is to test network analysis as a method to study drug-
drug relations.  To be able to do this, we created a definition for co-medication.  
We used network analysis to study two types of drug-drug relations; co-medication and 
severe drug-drug interactions as examples of the relevant clinical analysis. 
- Studying co-medication patterns 
By mapping the co-medication pattern(s) in the elderly, comparing pattern change between 
two different years (temporal change), determining if there is a geographic pattern change 
choosing five different counties in Norway (spatial change), and discovering underlying 
patterns in the whole network. 
 
- Studying Drug-drug interactions (DDI) pattern 
We aim also to study severe drug-drug interactions, first, for all substances. Further, to 
apply this network on the generated co-medication network to highlight the interactions in 

























3. Materials and Methods 
3.1 Data source  
3.1.1 NorPD 
Elderly prescriptions’ dispensing data from the Norwegian Prescription dataset (NorPD) 
from 2012-2014 was used (figure 3.1). In Norway, it is mandatory for all pharmacies to 
send a monthly electronic data report of all prescriptions dispensed to patients to the 
Norwegian Institute of public health since 1. January 2004. All the data is then gathered in 
NorPD. This means that only the prescriptions were dispensed to patients, rather than 
prescribed, are included in the database (55).  
NorPD dataset variables can be grouped into four main categories:  
1. Prescriber information: which includes anonymous ID, date of birth and sex 
2. Patient information: which involves anonymous ID, birth and death date, sex and 
municipality 
3. Dispensing information: date of dispensing 
4. Prescription information: which contains information about dispensed medicines, 
ATC codes, Defined Daily Dose (DDD), and refund information. (56) 
 
Figure 3.1: Study timeline 
3.1.2 FEST database (Prescribing and Dispensing Support Database) 
FEST is the Norwegian Medicines Agency’s (SLV Statens legemiddelverk) database of 
information which is used for decision support in electronic prescriptions (E-resepter) and 
Electronic Patient Record (EPR) systems. The database is also used by the computer 
systems in the community pharmacies. FEST is used in online services such as e.g. 
interaksjoner.no (interactions checker) and felleskatalogen.no (Norwegian online drug 
formulary). The database, generally, contains the basis of information that physicians, 
hospitals and pharmacies need. Drug-drug interactions is a part of FEST database. 
Our data file has eight variables; ATC code, name, and group for drug 1” and same for drug 




1st prevalence point 
01/01/2013
Day “0”Study start 
01/01/2012





interactions variable; [1] indicates dangerous interactions which is the concern of this thesis, 
[2] indicates moderate, and [3] indicates minor interactions. In the dataset we have, the 
interactions between ATC codes are, mostly, mentioned in a directed way, this means if 
there is an interaction between A and B substances for example, these interactions will be 
mentioned two times once from AàB and another from BàA. Meanwhile, some 
interactions were just mentioned once. 
 
3.2 Study design 
Study design varies according to the targeted result as follows in (table 3.1). 
Table 3.1: Represents types of study design according to the targeted results 
Targeted result Type of study 
Co-medication pattern visualizing Cross-sectional 
Drug-drug interaction Cross-sectional 
Temporal change (change over time) Longitudinal 
Spatial change (change over the place) Cross-sectional 
 
     3.2 Study population 
Patients who were ³ 65 in 2013 and had one or more prescription in the NorPD dataset 
are included in our study. The dataset we got from NorPD contains 61,930,313 
prescriptions of 342,451 men (45%) and 419,455 women (55%), in total 761,906 
patients. The mean age of the study population is 75 years. According to Statistical 
Yearbook of Norway (the year 2013), the total elderly population in 1st January 2013 
was 790,614 (57) which means that our study has involved approximately 96,4 % of the 
total elderly population in this period. 
     3.3 Inclusion/exclusion criteria 
All patients who were 65 or older in 2013 and had at least one prescription or more in 
NorPD in the study period. 
     3.3.1 Co-medication database exclusions 
a) Age:  Only patients aged 65 years or older in 2013 were included, patients who were 
born after 1948 (younger than 65 years in 2013) with total 49,244 prescriptions 
excluded. 
b) Missing ATC values: 0 observations were excluded 
c) ATC code without DDD: As comes after (methods 3.6), DDD is central for our 
definition of co-medication, so ATC codes without DDD were filtered out (figure 
3.2). Major drug groups which have no definite DDDs are: topical products (most 
products in anatomical group D), immune sera (ATC group J06), vaccines (ATC 
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group J07), antineoplastic agents (ATC group L01), anesthetics (ATC group N01), 
ophthalmological and otologicals (most ATC in group S) (58).  
 
Total unique ATC codes without DDD found were 357 codes, divided into 217 non-systemic 
medicines and 140 systemic medicines. Total prescriptions excluded out was 2,411,888 which 
forms 3,9 % of overall prescriptions. Detailed information of excluded ATC codes and their 
classifications are attached in (appendix 2). 
 
 
Figure 3.2: Exclusion criteria for co-medication prescription dataset  
 
3.3.2 Interactions database exclusions 
a) We excluded substances without ATC codes, for example, substances which may have 
interactions with medicines but have no ATC codes (e.g. Alcohol and natural products). 
b) All ATC codes shorter than 5th level (incomplete ATC) were excluded.  
c) Repeated names and ATC codes to avoid having the same substances which have more 
than one ATC code. 
d) Only severe interactions were included. 
e) A separate variable for combination products (i.e. drugs which contains more than one 
active ingredient) is created to be able to exclude/include them in the analysis if needed, 
(figure 3.3) (combinations were included in the study). 
Co-medication Exclusion criteria 
0 observations 
excluded





















Figure 3.3: Exclusion criteria for DDI from FEST dataset 
 
3.4 Data preparation 
3.4.1 Splitting and merging 
The raw material of data we had was chunked into 15 files. We split each of these 15 
files into two files in terms of the time format of prescriptions dispensing variable, we 
had two different time of dispensing forms (as follows in 3.5.2) one for patients who 
were hospitalized (in form of difference in days of the of hospitalizing) and the other 
for NorPD prescriptions (in the form of date of dispensing).  
Then each group of files with the same form of time of dispensing were merged to form 
two big files for each; difference in days of dispensing (hospitalized) with (21,067,741) 
prescriptions and normal dispensing date includes (40,853,892) prescriptions (figure 
3.4). 





































Figure 3.4: Representing data splitting and merging preparation plan. 
3.5 Variables 
The dataset consists of 29 variables (detailed prescription on variables attached in 
appendix 3). Not all the variables are used; only a few variables are central for our study. 
 
3.5.1 Central variables 
The variables of the most interest are “pasientlopenr” (patient’s anonymized 
identification number), “diff_utleveringdato” (difference, in days, of prescriptions’ 
dispensed dates from the first day of hospitalization for the patients who were 
hospitalized in the study period), “utleveringsdato” (date of prescriptions’ dispensing), 
“ordinasjonantallddd” (number of defined daily doses (DDD) dispensed in a 
prescription) and “atckode” (ATC codes). Sorting of observations is done in the 
following order; first, the patient number, then ATC codes and at last on date of 
dispensing. 
Split each file of these 15 into 2 files according to the time 
format of prescription dispensing (a file for diffrernce in 
days (hospitalized patients in the period of study) and the 
other file for dispensing date (in form of 
(year.month.day))= 30 filesli
 15 combined files (for hospitalized/non-hospitalized 
patients) with two different forms of time of 
dispensing variables
Data preparation plan
Combining all files for difference in 
dispensing day in one file  (21,067,741 
obseravtions)
Combining all files for dispensing day 
in form of (year.month.day) in one file 
(40,853,892 obseravtions)
Converting date to despinsing 
time difference to be able to 
merge the files with common 
time of despinsing variable Combining both files in one 
big main file which then used 
for study (61,921,633 
observations)    
Apply coding, co-medication definition 
and making treatment episodes
Using prevelance point = 0 
which corresponds 
(01.01.2013)
Using prevelance point = 365 
which corresponds 
(01.01.2014)








3.5.2 A Little on “time of dispensing” variables 
Our dataset has two different forms of time of dispensing. The time of dispensing 
variable for non-hospitalized patients in the study period in the form of a complete date 
“YYYY-MM-DD” and this the normal time dispensing format in NorPD (59), while for 
patients who were hospitalized during the period of study the time variable is in a form 
of difference in days between the prescription dispensing date and the date of first 
hospitalizing which is unknown for us (for anonymization purposes) and differs from a 
patient to another. For example, if a patient was hospitalized in 1st of March 2012 and 
later picked up a prescription in the pharmacy in 15th of April 2012 then the time of 
dispensing for this particular prescription will be “46” which corresponds the difference 
in days between the day of hospitalizing and the day of prescription dispensing.  
 
We created a new variable for dates in order to have a single form of time format. We 
converted the dispensing date variable to a difference in days from a particular day we 
chose which is 1st of January 2013.  
 
3.5.3 Ordinasjonsantall DDD 
It represents the total number of DDDs dispensed to a patient for each dispensed 
prescription. For example, if a patient picked up two boxes of a drug (A) which has 100 
tablets each, and the defined daily dose of this drug is two tablets daily, then the 
“ordinasjonantallddd” is 100 which corresponds 100 days’ supply. 
 
3.6 Defining co-medication  
Our study period is three years, this period can contain many medication (i.e. treatment) 
episodes with a probability of medicine-free periods or periods with different 
medications, thus taking the whole three years (as a number of days) will create a 
potential information bias. Therefore, another approach depends on Defined Daily Dose 
(DDD), prescription date of dispensing combined with assumed patients’ adherence 
(defined as the proportion of days covered (PDC)) and a specific gap period, was 
obtained. After that, we chose specific dates to study the co-medication as prevalence 
time points as follows. 
 
DDD is central for co-medication definition in this thesis. DDD is defined as the assumed 
average maintenance dose per day for a drug used for its main indication for adults (58). 
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Treatment episodes are made up based on DDD of each medicine after sorting prescriptions 
after patient and ATC codes, then DDD of each ATC code is summed, and the difference in 
days between two followed prescriptions for the same ATC codes is calculated.  
 
Adherence is defined as to what extent a person’ compliance to medical instructions 
corresponds with agreed recommendations from a health care provider (60) (61).  
Studies show that most elderly with polypharmacy are associated with poor adherence (62). 
There is no absolute guarantee for researchers to assure 100% of patients’ compliance. 
However, the advantage of including adherence in our defining approach is that it will, 
somehow, specify the patients’ actual use of medicines. Consequently, this will make the results 
more reliable. 
The threshold of adherence was chosen to be 80% adherence (63); this means the patient has a 
80% of compliance to his daily dose. 
 
We chose to use the Proportion of days covered (PDC) as an approach of measuring adherence. 
In PDC we count the actual number of days covered by a prescription, taking into consideration 
if there was an overlapping of medicines refill (carryover) (64) (figure 3.5). This carryover 
concept of PDC method may give an advantage over the other ways of measuring adherence 










Figure 3.5: An example of calculating MRP and PDC, source: Zhu VJ, A Comparison of Data Driven-based 
Measures of Adherence to Oral Hypoglycemic (65) 
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By comparing the number of days which are ,theoretically, covered by the delivered amount of 
medicine ,using the sum of DDD multiplied by with 80% which is assumed adherence, with 
the difference of days between each two followed prescriptions of the same drug can we also 
calculate how much medicine is assumed to be left with patient (i.e. carryover) for next 
treatment episode. Hence, if we have an overlapping of two refills, this overlapped amount will 
be transferred to the next treatment episode and so on.  
 
The start and end points for each treatment episode were created allowing 14 days as an 
acceptable medicine-free gap between the supposed and the actual dispensing dates and still 
considered within the same treatment episode. In other words, if the gap between the refill due 
and actual refill is more than two weeks, then a new treatment episode is started, (figure 3.6). 
The treatment episodes start with first prescription picking date and end if the gap between the 
assumed number of days covered by the amount of drug the patient had and the next prescription 
dispensing date is more than 14 days or if the patient is not using this medicine anymore. 
 
 
Figure 3.6: Representing the defining of treatment episodes (inspired from “Use of analgesics in the general 
population” PhD of Samuelsen, Per-Jostein 2016 at Uit) (66) 
 
After defining the starts and the ends of the treatment episodes, we selected the prevalence 
points in which we will study the co-medication. Two prevalence point were chosen in this 
thesis; day 0 which corresponds 1st of January 2013 and day 365 which corresponds 1st of 
January 2014. These two-prevalence time points will allow us to study if there is any difference 
1st January 2012 31th December 2014
A treatment episode:
First treatment episode Last treatment episode
End date Start date 









- PDC is used to define adherence, calculating a «carry over» = extra amount of medicine
took in consideration in treatment episodes defining.
- Assumed patient’s adherence is 80%
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in co-medication patterns from the perspective of the time change. In all other studied networks, 
day 0 will be our prevalence point. 
 
3.6.1 A detailed example to clarify the method 
If we suppose we have a patient who’s receiving a drug (X) which has 100 tablets per 
package and this drug (X) define daily dose is 2 tablets a day, then one package of this 
medicine corresponds, theoretically, to 50 days of consumption. Then we assume that 
the patient’s compliance is not perfect, and his medical adherence is only 80%. This 
means that this package will cover the patients need for (62,5 days) instead of 50 days 
(50/0.8).  
 
If we now say that the patient picked up his first prescription of drug (X) at 1st of 
December 2012 (-31 day of 1st of January 2013 which is our day 0) then we have four 
scenarios. The first is that the patient will pick up his next prescription within 62 days 
(e.g. 1st of February 2013) of his earlier pickup. In this case, there will be no problem 
since the drug is still in the same treatment episode. The second scenario is that the 
patient picks up his second prescriptions later than 1st of February, but within less than 
14 days, and similarly, the drug is still also in the same treatment episode.  
The third one is to pick up the refill later than 14 days from 1st of February 2013.  In 
this case, the first treatment episode of this drug is expired, and the patient started a new 
treatment episode of this drug.  
 
If the second prescription dispensing was before 62 days from the first one let’s say in 
(e.g. 15th of January 2013) and the patient received another package of 100 tablets. This 
means that the patient has an extra (overlapping) amount of medicine more than he 
needs for this treatment episode (16,5 days). This amount is transferred to the end of 
next treatment episode (carryover) and will be calculated in this episode first before we 
begin to calculate the allowed 14 days of medicine-free gap, and this is the fourth 
scenario, (figure 3.7). 
 
The same was applied for all prescriptions which have the same ATC code. After this 
was done, we are able to pick up a day in our study period and study the treatment 





Figure 3.7: Represents how treatment episodes were defined 
 
3.7 For Studying co-medication patterns in 2013 network 
To identify which co-medication patterns included in the network of 2013 we used a 
network measure called “Modularity”. We grouped the ATC codes in the same 
“module” according to the therapeutic indications. The extracted patterns were then 
compared to the findings of another study depended on Factor Analysis (FA) to discover 
the underlying patterns. The study was done in Spain in 2008 to demonstrate 
polypharmacy patterns using exploratory factor analysis (EFA) on drug medical records 
dispensing information, the patterns they extracted is in (table 4.9) (67).  Each pattern 
was then studied in a separate network. More information on Modularity and Factor 
analysis comes at the discussion chapter. 
 
3.8 For Studying the temporal change in the co-medication pattern  
Two different time points, prevalence points, were selected, the first is day “0” 
which indicates 1st of January 2013 and the second is day “365” which corresponds 
the 1st of January 2014. We will directly compare between these two networks.  
In addition to directly comparing these two networks, we will generate a new 
network which is the difference between 2013 network and 2014 network. This is 
to be done by dividing the number of users of each combination (i.e. edges) in the 
1st  Dec. 2012
(First dispensing date)
Second dispensing date
1st  Feb. 2013
Within 14 days after
1st  Feb. 2013
Within the 1st package
coverage period
More than 14 days after













two networks and eliminate the unmatched edges between the two networks. As an 
example, if we have two medicines which were combined 20 times in day 0 network 
and 10 times in day 365 network the new edge in the generated network will equal 
to two which means that this combination was used twice as many times in 2013 
compared to 2014.  
 
3.9 For studying the spatial difference in pattern  
Five counties are chosen to explore if there was a change in the co-medication 
patterns in different counties in Norway. We selected five out of 19 counties that 
represent north, west, east and south of Norway with the highest population. These 
five counties are Oslo, Akershus, Hordaland, Rogaland, and Nordland. The five 
counties form 68 666 km2 (68) and total 2 526 895 citizens of the total population 
in 2018. For studying of co-medication in these counties; day “0” was selected as a 
prevalence point. 
 
For spatial difference we investigated if a patient were registered in more than one 
municipality. Total patients registered in more than one municipality makes about 
1% of the total population. As this percent is low and won’t remarkably affect the 
result, we chose to; if a patient is registered in more than one municipality, only one 
registration of them is considered when we study spatial change. 
 
3.10 Generated networks 
In the figure below (figure 3.8), the generated networks in this thesis are listed. Detailed 
description of each comes gradually in results and discussion sections.  
In this thesis, the nodes will represent medicines and edges will represent either 
simultaneous use of these medicines (co-medication) or severe drug-drug interactions 
relations. All our networks in this thesis are undirected. Generated networks are 
weighed for co-medication to show how often is a combination between two or more 





Figure 3.8: The generated networks in this study 
 
3.11 Software 
- Stata 15.1 
- Microsoft office package version 16.19 and later updates 
- Endnote 9 as a reference organizing program 
- Gephi 0.9.2 
Gephi is a visualizing tool for all types of networks. It is a free open-source software which 
can, beside visualizing, perform network measures and some statistical analysis. After 
generating networks using Stata, all networks are imported to Gephi which allows a variety of 
filters which makes the networks’ patterns understandable and interpretable. 
- General filters used in Gephi: 
  
The structure of most networks is complex. In order to make networks more 
understandable and interpretable a group of filters in some networks are applied in the 
visualizing program (Gephi). The filters used were one or more of the following filters: 
1. Number of users for each node 
2. Edges weight  
3. Nodes degree 
4. Modularity class 
Generated Networks
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The project uses patient data from a national registry, the NorPD. This registry does not require 
patient consent to collect and use data. The master project is part of a larger project looking at 
medicine use in the elderly and this study has approval from the regional ethics committee 
(REK number: 2014/2182). The project also has a permission from the Norwegian Data 
Protection Authority. The master student has been included as a part of the overall project and 
did not need any further approvals for conducting the master project. The data is encrypted for 

























The Results are subdivided into four sections: 
Part I: Co-medication day 0 network (primary network):  
In this section, we will study the network of treatment episode around 1st of January 2013 
in terms of:  
a. Descriptive analysis and some network measures of this network 
b. Network modularity (clusters) 
c. Studying of six different elderly co-medication patterns 
Part II: Temporal change study: Comparing day 0 and day 365 (1st January 2014) networks. 
a. Direct comparison of descriptive analysis and network measures for day 365 
network and day 0 network.  
b. Indirect comparison by generating a new network in which its edges are the division 
of the two prevalence points networks.  
Part III: Spatial change study: Comparing co-medication in five selected counties in 
Norway in a direct comparison.  
Part IV: Drug-drug interactions networks. 
a. DDI network for severe interactions (general network with all complete ATC 
codes). 
b. Applying of DDI network on the day 0 co-medication network. 
For all the coming network graphs, the nodes (ATC codes) are colored according to their 
anatomical classes to make them easier to notice (table 4.1). 
Table 4.1 Represents the anatomical groups with their defining colors in the thesis’s networks 
Anatomical class Description Color 
A Alimentary tract and metabolism   
B Blood and blood forming organs   
C Cardiovascular system   
D Dermatologicals   
G Genito-urinary system and sex hormones   
H Systemic hormonal preparations, excluding sex hormones and insulins   
J Anti-infectives for systemic use   
L Antineoplastic and immunomodulating agents   
M Musculo-skeletal system   
N Nervous system   
P Antiparasitic products, insecticides and repellents   
R Respiratory system   
S Sensory organs   
V Various   
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For all networks some important network measures will be mentioned first, these measures 
are: Density, number of edges, minimum and maximum edges’ weight if the network is 
weighted. 
4.1 Part I: Results of Co-medication day 0 network (primary network) 
4.1.1 Network description 
Table 4.2: Day 0 Network main characteristics 
 
 
Number of nodes represents the number of actors (medicines) in the network, while the number 
of edges corresponds how many times were these two nodes (i.e. drugs) were co-medicated 
together. In other words, how many patients who have combined these two medicines (table 
4.2). 
Table 4.3: Distribution of ATC anatomical groups in day 0 network arranged in terms of being involved in drug-
drug combinations from highest to lowest  
 
    
Table 4.3 shows that nervous and cardiovascular systems (N and C-groups) are the most 
frequently used medicines in the drug-drug combinations in the day 0 network, while 
dermatologicals and various (D and V-groups) are the least frequently combined medicines 















Anatomical group No. of times involved in a combination Percent
N (Nervous system) 15423 20.55 %
C (Cardiovascular system) 14077 18.76 %
A (Alimentary tract and metabolism) 11280 15.03 %
R (Respiratory system) 8334 11.10 %
B (Blood and blood forming organs) 4318 5.75 %
J (Antiinfectives for systemic use) 4196 5.59 %
G (Genito-urinary system and sex hormones) 4092 5.45 %
M (Musculo-skeletal system) 4057 5.41 %
L (Antineoplastic and immunomodulating agents) 3905 5.20 %
H (Systemic hormonal preparations, excluding sex hormones and insulins) 2350 3.13 %
S (Sensory organs) 2164 2.88 %
P (Antiparasitic products, insecticides and repellents) 382 0.51 %
D (Dermatologicals) 282 0.38 %
V (Various) 192 0.26 %





Figure 4.1: Represents the full network of day 0, no filters applied. Edges were removed for simplifying. Different 
colors indicate different anatomical groups. Size of nodes corresponds the number of edges each node has (co-
medication with other nodes).  
 




The network (figure 4.1) shows cardiovascular system anatomical group drugs, in the orange 
color, to be most frequent in the network’s center along with nervous system, in purple, and 
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Table 4.4: Represents the most important nodes according to their eigenvector centrality score with the 
percentage of users in the dataset population  
  
 
Table 4.4 shows Acetyl salicylic acid to be the node with highest eigenvector centrality score 
(i.e. most important in network). Simvastatin and zopiclone come next with equal score for 
both. Last of the highest 15 scores in network was codeine/paracetamol combination (Paralgin 
forteâ).  
Table 4.5: Represents the most 20 combined medicines with the number of times they were combined and the 
proportion of users in the overall and dataset populations in 2013  
 
 
Table 4.5 shows the most 20 combined medicines (i.e. thickest edges in the network) in the 
network with the proportion of users in the overall elderly population in Norway in 2013 
(790,614), and the study population (761,906). The combination of Acetylsalicylic acid with 
simvastatin had the highest number of patients in this treatment episode representing 10% of 
the total population, while Acetylsalicylic acid with Losartan/diuretics, on the other hand, was 
ATC Substance No. of users % patients in dataset population Eigenvector centrality Degree cen.
B01AC06 Acetyl salicylic acid 228535 30 % 1.0 663
C10AA01 Simvastatin 155725 20 % 0.994 630
N05CF01 Zopiklon 85229 11 % 0.994 629
C07AB02 Metoprolol 100780 13 % 0.989 606
N02BE01 Paracetamol 47351 6 % 0.987 607
C08CA01 Amlodipin 73881 10 % 0.980 581
H03AA01 Levotyroksinnatrium 55106 7 % 0.979 586
C10AA05 Atorvastatin 78377 10 % 0.979 580
A02BC05 Esomeprazol 35651 5 % 0.979 573
A02BC02 Pantoprazol 34983 5 % 0.978 579
H02AB06 Prednisolon 31653 4 % 0.977 578
C03CA01 Furosemid 42564 6 % 0.976 569
R06AE07 Cetirizin 30150 4 % 0.973 563
B01AA03 Warfarin 47794 6 % 0.970 556
N02AJ06 Kodein og paracetamol 20702 3 % 0.969 552
No. Drug 1 Drug 2 No. of patients combined them % of elderly population % of dataset population
1 Acetyl salicylic acid Simvastatin 82948 10 % 11 %
2 Acetyl salicylic acid Metoprolol 52577 7 % 7 %
3 Acetyl salicylic acid Atorvastatin 42753 5 % 6 %
4 Metoprolol Simvastatin 36792 5 % 5 %
5 Acetyl salicylic acid Amlodipin 32628 4 % 4 %
6 Acetyl salicylic acid Zopiklon 29173 4 % 4 %
7 Amlodipin Simvastatin 22554 3 % 3 %
8 Acetyl salicylic acid Ramipril 19660 2 % 3 %
9 Simvastatin Zopiklon 18845 2 % 2 %
10 Metformin Acetyl salicylic acid 18507 2 % 2 %
11 Acetyl salicylic acid Furosemid 18175 2 % 2 %
12 Metoprolol Atorvastatin 17266 2 % 2 %
13 Acetyl salicylic acid Levotyroksinnatrium 16654 2 % 2 %
14 Acetyl salicylic acid Paracetamol 16380 2 % 2 %
15 Metoprolol Amlodipin 16271 2 % 2 %
16 Warfarin Metoprolol 16005 2 % 2 %
17 Metformin Simvastatin 15647 2 % 2 %
18 Acetyl salicylic acid Kandesartan 14306 2 % 2 %
19 Acetyl salicylic acid Isosorbidmononitrat 14236 2 % 2 %
20 Acetyl salicylic acid Losartan og diuretika 14007 2 % 2 %
 32 
the least frequent combination of the 20 combinations listed with 2% users of entire elderly 
population (a list of the most 200 combined medicines is attached in appendix 4). 
 
4.1.2 Modularity classes 
Modularity or community detection:  
 
Table 4.6: Modularity classes with number of nodes and percentage of each module of the whole network 
 
 
Four modularity classes were detected in the network [0,1,2,3] (table 4.6). Module [0] is the 
biggest one with 530 ATC codes out of 762 which forms 68% of the network. Module [3] on 
the other hand, is the smallest one with only 2% of the overall ATC codes. The following figure 
(figure 4.2) represents the four classes with different color of each. 
 
 
Figure 4.2: Representing day 0 network modularity classes. Bigger nodes indicate greater number of users, colors 
here do not represent the anatomical group colors.  
To figure out the underlying patterns in these modules, the ATC codes were shortened to the 
second level of ATC (anatomical, therapeutic group) (table 4.7). 
Module Number of nodes Percent
0 530 68 %
1 49 24 %
2 167 6 %
3 16 2 %












































































































































































































































































































































































































































































































































































































































































































































































Table 4.7: Day 0 network modularity classes after shortening of ATC codes to the second level (3 
characters=therapeutic level) sorted after the number of users for each ATC code group. 
 
Group No. users Theraputic indications
N05 149142 HYPNOTICS AND SEDATIVES
R03 125913 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
A02 107657 ACID DISORDERS
N02 87051 ANTIMIGRAINE PREPARATIONS
N06 78403 PSYCHOANALEPTICS
M01 60442 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
B03 57100 ANTIANEMIC PREPARATIONS
H03 56354 IODINE THERAPY
R06 53993 ANTIHISTAMINES FOR SYSTEMIC USE
J01 40218 ANTIBACTERIALS FOR SYSTEMIC USE
M05 35792 Bone diseases
H02 35343 CORTICOSTEROIDS FOR SYSTEMIC USE
G04 23622 UROLOGICALS (prostatic hypertrphy)
R01 21306 NASAL PREPARATIONS
G03 20842 SEX HORMONES 
N03 17032 ANTIEPILEPTICS
R05 16266 COUGH AND COLD PREPARATIONS
C03 14703 DIURETICS
L04 12827 IMMUNOSUPPRESSANTS
N04 10016 ANTI-PARKINSON DRUGS
A06 7932 DRUGS FOR CONSTIPATION
A07 6774 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
L02 5189 ENDOCRINE THERAPY (HORMONS RELATED)
A11 5113 VITAMINS
B01 4793 ANTITHROMBOTIC AGENTS
A03 4159 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
C07 3349 BETA BLOCKING AGENTS
C10 3309 LIPID MODIFYING AGENTS
N07 1823 OTHER NERVOUS SYSTEM DRUGS
A12 1631 MINERAL SUPPLEMENTS
A09 1519 DIGESTIVES, INCL. ENZYMES
P01 1342 ANTIPROTOZOALS
D01 1262 ANTIFUNGALS FOR DERMATOLOGICAL USE
H01 804 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
M03 742 MUSCLE RELAXANTS
A04 735 ANTIEMETICS AND ANTINAUSEANTS
A05 595 BILE AND LIVER THERAPY
A08 516 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
L01 476 ANTINEOPLASTIC AGENTS
J05 392 ANTIVIRALS FOR SYSTEMIC USE
L03 288 IMMUNOSTIMULANTS
J04 269 ANTIMYCOBACTERIALS
D05 247  ANTIPSORIATICS
J02 188 ANTIMYCOTICS FOR SYSTEMIC USE
A01 185 STOMATOLOGICAL PREPARATIONS
H05 131 CALCIUM HOMEOSTASIS






(Table 4.7) shows module [0] to be the largest and most complex module, with 47 out of 75 
ATC groups after shortening (approximately 63%). Hypnotics and sedative groups (N05) 
represent the highest number of users in this module (149,142) users, followed by the drugs for 
obstructive airways diseases (R03) with (125,913) patients.  
We tried to find the underlying pattern(s) in this large module by rearranging the ATC groups, 
according to the assumed clinical indication (table 4.8). Otherwise, the co-medication patterns 
in the other modules [1, 2, 3] were quite clear and easy to uncover. 
 
C03 70736 DIURETICS
B01 52433 ANTITHROMBOTIC AGENTS
M04 15650 ANTIGOUT PREPARATIONS
C01 15616 CARDIAC THERAPY
C07 13343 BETA BLOCKING AGENTS
C08 7445 CALCIUM CHANNEL BLOCKERS
A12 5858 MINERAL SUPPLEMENTS
A11 1635 VITAMINS
B03 1282 ANTIANEMIC PREPARATIONS
V03 487 ALL OTHER THERAPEUTIC PRODUCTS
H05 240 CALCIUM HOMEOSTASIS
A02 194 DRUGS FOR ACID RELATED DISORDERS
C02 163 ANTIHYPERTENSIVES
L04 161 IMMUNOSUPPRESSANTS
C09 293008 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
B01 260482 ANTITHROMBOTIC AGENTS
C10 258050 LIPID MODIFYING AGENTS
C07 128165 BETA BLOCKING AGENTS
C08 126834 CALCIUM CHANNEL BLOCKERS
A10 96241 DRUGS USED IN DIABETES
S01 67468 OPHTHALMOLOGICALS
G04 45302 UROLOGICALS (prostatic hypertrphy)
C01 26825 CARDIAC THERAPY
C03 22963 DIURETICS
L02 11148 ENDOCRINE THERAPY
C02 10313 ANTIHYPERTENSIVES
L01 708 ANTINEOPLASTIC AGENTS
C04 467 PERIPHERAL VASODILATORS
A07 171 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS





Table 4.8: Represents the assumed patterns in each of the four modularity classes after sorting of module [0]  
 
 
Group No. users Theraputic indications Pattern
N05 149142 HYPNOTICS AND SEDATIVES
N02 87051 ANTIMIGRAINE PREPARATIONS
N06 78403 PSYCHOANALEPTICS
N03 17032 ANTIEPILEPTICS
N04 10016 ANTI-PARKINSON DRUGS
N07 1823 OTHER NERVOUS SYSTEM DRUGS
R03 125913 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R06 53993 ANTIHISTAMINES FOR SYSTEMIC USE
R01 21306 NASAL PREPARATIONS
R05 16266 COUGH AND COLD PREPARATIONS
J01 40218 ANTIBACTERIALS FOR SYSTEMIC USE
J05 392 ANTIVIRALS FOR SYSTEMIC USE
A02 107657 ACID DISORDERS
M01 60442 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
H03 56354 IODINE THERAPY
M05 35792 BONE DISEASES
G04 23622 UROLOGICALS (prostatic hypertrphy)
G03 20842 SEX HORMONES 
L02 5189 ENDOCRINE THERAPY 
L01 476 ANTINEOPLASTIC AGENTS
H05 131 CALCIUM HOMEOSTASIS
G02 115 OTHER GYNECOLOGICALS
C03 14703 DIURETICS
C07 3349 BETA BLOCKING AGENTS
C10 3309 LIPID MODIFYING AGENTS
B01 4793 ANTITHROMBOTIC AGENTS
B02 113 ANTIHEMORRHAGICS
L03 288 IMMUNOSTIMULANTS
B03 57100 ANTIANEMIC PREPARATIONS
A06 7932 DRUGS FOR CONSTIPATION
A07 6774 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A03 4159 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
A04 735 ANTIEMETICS AND ANTINAUSEANTS
H02 35343 CORTICOSTEROIDS FOR SYSTEMIC USE
A11 5113 VITAMINS
A12 1631 MINERAL SUPPLEMENTS
A09 1519 DIGESTIVES, INCL. ENZYMES
P01 1342 ANTIPROTOZOALS
D01 1262 ANTIFUNGALS FOR DERMATOLOGICAL USE
M03 742 MUSCLE RELAXANTS
A05 595 BILE AND LIVER THERAPY
A08 516 ANTIOBESITY PREPARATIONS, EXCL. DIET PRODUCTS
J04 269 ANTIMYCOBACTERIALS
D05 247  ANTIPSORIATICS
J02 188 ANTIMYCOTICS FOR SYSTEMIC USE
A01 185 STOMATOLOGICAL PREPARATIONS
Anxiety pattern
Various drugs or can 
match with many 
patterns







Table 4.8 represents the patterns we found after sorting ATC codes in module [0] according to 
therapeutic indications. In total six patterns were discovered; three patterns of them were under 
module [0]. Module [1] were nearly to be a cardiac pattern while module [2] represents diabetes 
pattern. The last pattern is module [3] which consisted only of some antivirals for systemic use 













B01 52433 ANTITHROMBOTIC AGENTS
M04 15650 ANTIGOUT PREPARATIONS
C01 15616 CARDIAC THERAPY
C07 13343 BETA BLOCKING AGENTS
C08 7445 CALCIUM CHANNEL BLOCKERS
A12 5858 MINERAL SUPPLEMENTS
A11 1635 VITAMINS
B03 1282 ANTIANEMIC PREPARATIONS
V03 487 ALL OTHER THERAPEUTIC PRODUCTS
H05 240 CALCIUM HOMEOSTASIS
A02 194 DRUGS FOR ACID RELATED DISORDERS
C02 163 ANTIHYPERTENSIVES
L04 161 IMMUNOSUPPRESSANTS
C09 293008 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
B01 260482 ANTITHROMBOTIC AGENTS
C10 258050 LIPID MODIFYING AGENTS
C07 128165 BETA BLOCKING AGENTS
C08 126834 CALCIUM CHANNEL BLOCKERS
A10 96241 DRUGS USED IN DIABETES
S01 67468 OPHTHALMOLOGICALS
G04 45302 UROLOGICALS (prostatic hypertrphy)
C01 26825 CARDIAC THERAPY
C03 22963 DIURETICS
L02 11148 ENDOCRINE THERAPY
C02 10313 ANTIHYPERTENSIVES
L01 708 ANTINEOPLASTIC AGENTS
C04 467 PERIPHERAL VASODILATORS
A07 171 ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS







4.1.3 Patterns of elderly co-medication 
Table 4.9: The conducted polypharmacy patterns in the mentioned paper by Exploratory Factor Analysis (EFA) 
with the used ATC codes in each pattern 
 
 
Comparing the two previous tables, our sorted modules table and the six patterns identified by 
factor analysis, reveals quite a consistency between the patterns we found with the patterns was 




6 elderly co-mediaction patters
Name of pattern ATC ATC group
1 Cardiovascular pattern A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A10A INSULIN 
A10B BLOOD GLUCOSE LOWERING
B01A ANTITHROMBOTIC AGENTS
C01A CARDIAC GLYCOSIDES
C01D VASODILATORS FOR CARDIAC DISEAS 
C03 DIURETICS
C03D POTASSIUM-SPARING DIURETIC
C07A BETA BLOCKING AGENTS
C08D SELECTIVE CALCIUM CHANNEL BLOCKER
C09A ACE INHIBITORS
C10A LIPID MODIFYING AGENTS
2 Depression-anxiety pattern H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN







N06B PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
3 Acut respiratorty infection pattern (ARI) R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01B NASAL DECONGESTANTS FOR SYSTEMIC USE
R03A ADRENERGICS, INHALANTS
R05CA Expectorants
R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
R06A ANTIHISTAMINES FOR SYSTEMIC USE
J01 ANTIBACTERIALS FOR SYSTEMIC USE
J05 ANTIVIRALS FOR SYSTEMIC USE
4 Chronic obstructive pulmonary disease pattern (COPD) R03A ADRENERGICS, INHALANTS
R06A ANTIHISTAMINES FOR SYSTEMIC USE
S02A ANTIINFECTIVES
S01C ANTIINFLAMMATORY AGENTS AND ANTIINFECTIVES IN COMBINATION
M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
H02A CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN
R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
R05C EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS
R03B OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES, INHALANTS
5 Pain pattern M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
R05D COUGH SUPPRESSANTS, EXCL. COMBINATIONS WITH EXPECTORANTS
A02B DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
M03B MUSCLE RELAXANTS, CENTRALLY ACTING AGENTS
N02A OPIOIDS
N02BG Other analgesics and antipyretics
M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
6 Menopause pattern A12A CALCIUM
M05B DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
G03C ESTROGENS
S01G DECONGESTANTS AND ANTIALLERGICS
 38 
4.1.4 Studying the six patterns 
4.1.4.a Cardiac pattern 
Table 4.10: Network characteristics for cardiac subnetwork 
 
 
Table 4.11: The most used medicines in cardiac subnetwork, degree centrality shows how many times these 
medicines were combined with other nodes 
 
 
Table 4.11 shows acetyl salicylic acid, metformin and esomeprazole to have the highest number 
of connections to the other nodes (i.e. high degree centrality) and highest scores of eigenvector 
centrality as well. 
Table 4.12: Represents the most combined medicines in cardiac network showing number of times each two 
nodes were combined 
 
 
Acetylsalicylic acid (ASA) is present in eight of the most 10 used combinations in the network. 
The most used combinations are ASA with simvastatin, then ASA with metoprolol (table 4.12).  
 











ATC Substance No. of users Degree Cen. Eigenvector Cen.
B01AC06 Acetyl salisylic acid 228535 101 1.0
C10AA01 Simvastatin 155725 57 0.66
C07AB02 Metoprolol 100780 56 0.66
C10AA05 Atorvastatin 78377 53 0.65
B01AA03 Warfarin 47794 94 0.98
C03CA01 Furosemid 42564 56 0.66
A10BA02 Metformin 38995 98 0.99
A02BC05 Esomeprazol 35651 97 0.99
C09AA05 Ramipril 35578 53 0.65
A02BC02 Pantoprazol 34983 95 0.98
ATC 1 Drug 1 ATC 2 Drug 2 No. of times combined
B01AC06 Acetyl salisylic acid C10AA01 Simvastatin 82948
B01AC06 Acetyl salisylic acid C07AB02 Metoprolol 52577
B01AC06 Acetyl salisylic acid C10AA05 Atorvastatin 42753
B01AC06 Acetyl salisylic acid C09AA05 Ramipril 19660
A10BA02 Metformin B01AC06 Acetyl salisylic acid 18507
B01AC06 Acetyl salisylic acid C03CA01 furosemide 18175
B01AA03 Warfarin C07AB02 Metoprolol 16005
A10BA02 Metformin C10AA01 Simvastatin 15647
B01AC06 Acetyl salisylic acid C01DA14 Isosorbide mononitrate 14236
A02BC02 Pantoprazol B01AC06 Acetyl salisylic acid 13560





Figure 4.3: Cardiac weighted network, filtered for number of users>460 and edge weight >250, bigger nodes 
indicate greater number of users. 
The full network in PDF format (full resolution) is available here:  
https://www.dropbox.com/s/f4e67u5okk0g8dd/cardiac.pdf?dl=0  
 
The cardiac pattern network (figure 4.3) shows some important nodes with the highest number 
of users (e.g. acetylsalicylic acid, warfarin (in light red color), simvastatin, atorvastatin, and 
metoprolol (in yellow color). Acetylsalicylic acid with simvastatin, metoprolol, and atorvastatin 
are the most combined medicine in the network, respectively. Warfarin combination with 








4.1.4.b Anxiety pattern 
Table 4.13: Network characteristics for Anxiety subnetwork 
 
 
Table 4.14: The most used medicines in Anxiety subnetwork with degree and eigenvector centrality  
 
 
Table 4.14 shows that oxazepam is the node with the most importance in the network in both 
eigenvector and degree centrality. Prednisolone on the other hand is the most used medicine in 
the network.  
 
Table 4.15: The most combined medicines in Anxiety subnetwork showing number of times each two nodes were 
combined 
 
   
Table 4.15 shows that prednisolone and escitalopram are involved in most of the combinations 
among the 10 highest used combinations in the network. Prednisolone is present in five 
combinations of the top 10 used combinations in the network. 
 
 











ATC Substance No. of users Degree Cen. Eigenvector Cen.
H02AB06 Prednisolon 31653 94 0.99
N06AB10 Escitalopram 21669 96 0.99
N05BA01 Diazepam 15521 97 0.99
M01AB05 Diklofenak 14081 86 0.97
N05BA04 Oksazepam 13956 99 1.0
M04AA01 Allopurinol 13826 80 0.94
M01AX05 Glukosamin 10867 84 0.95
M01AE01 Ibuprofen 10107 87 0.97
N06AX11 Mirtazapin 8570 90 0.97
N06AB04 Citalopram 7790 87 0.97
ATC 1 Drug 1 ATC 2 Drug 2 No. of times combined
N05BA04 Oksazepam N06AB10 Escitalopram 1800
N06AB10 Escitalopram N06AX11 Mirtazapin 1421
H02AB06 Prednisolon N06AB10 Escitalopram 1351
N05BA01 Diazepam N06AB10 Escitalopram 1337
H02AB06 Prednisolon N05BA04 Oksazepam 1315
H02AB06 Prednisolon M04AA01 Allopurinol 1168
H02AB06 Prednisolon N05BA01 Diazepam 1116
N05BA04 Oksazepam N06AX11 Mirtazapin 1096
N06AB10 Escitalopram N06AX03 Mianserin 707
H02AB06 Prednisolon M01AB05 Diklofenak 679







Figure 4.4: Anxiety weighted network filtered for number of users >96 and edge weight >100, bigger nodes 
indicate greater number of users. 
 
The full network in PDF format (full resolution) is available here:  
https://www.dropbox.com/s/j6j8ilqqc0q2q5s/Anxiety.pdf?dl=0 
 
Anxiety network (figure 4.4) shows prednisolone node in the green color to be the most used 
medicine. Escitalopram, diazepam, oxazepam have also a good share of users. Diclofenac, 
Ibuprofen, and glucosamine appears in dark blue nodes with a quite high number of users. 
Combinations between escitalopram with oxazepam, diazepam and mirtazapine are frequent 





4.1.4.c Acute Respiratory Infection (ARI) pattern 
Table 4.16: Network characteristics for ARI subnetwork 
 
 
Table 4.17: The most used medicines in ARI subnetwork, degree centrality shows how many times these 
medicines were connected to other nodes 
 
 
Table 4.17 shows antihistaminic drugs (e.g. cetirizine, loratadine, and desloratadine) and 
adrenergic inhalations are the most central nodes with the greatest number of links with other 
nodes and highest number of users.  
 




Table 4.18 shows the most combined medicines are inhalations (long-acting beta II agonist and 















ATC Substance No. of users Degree Cen. Eigenvector Cen.
R06AE07 Cetirizin 30150 40 1.0
R03AK06 Salmeterol og flutikason 25227 40 0.996
R03AC02 Salbutamol 18450 40 0.990
R03AK07 Formoterol og budesonid 17314 40 0.97
R01AD09 mometasone 10699 40 0.94
R06AX13 Loratadin 7213 40 0.91
R06AX27 Desloratadin 6006 40 0.92
J01CE02 Fenoksymetylpenicillin 5607 40 0.94
J01CA08 Pivmecillinam 4530 39 0.86
R06AD01 Alimemazin 4348 39 0.902
ATC 1 Drug 1 ATC 2 Drug 2 No. of times combined
R03AC02 Salbutamol R03AK06 Salmeterol og flutikason 6599
R03AK06 Salmeterol og flutikason R06AE07 Cetirizin 2870
R03AC02 Salbutamol R03AK07 Formoterol og budesonid 2534
R03AC02 Salbutamol R06AE07 Cetirizin 2187
R03AK07 Formoterol og budesonid R06AE07 Cetirizin 2020
R01AD09 Mometasone R06AE07 Cetirizin 1452
R01AD09 Mometasone R03AK06 Salmeterol og flutikason 1126
R03AC03 Terbutalin R03AK07 Formoterol og budesonid 804
R01AD09 Mometasone R03AK07 Formoterol og budesonid 762
R03AK06 Salmeterol og flutikason R06AX13 Loratadin 740








Figure 4.5: ARI weighted network, filtered for number of users and edge weight >100, bigger nodes indicate 
greater number of users 
The full network in PDF format (full resolution) is available here:  
https://www.dropbox.com/s/47ef7txfdoxekc2/ARI%20new.pdf?dl=0  
 
The network (figure 4.5) shows two anatomical groups the sky blue one represents the anti-
infectives for systemic use, and the brown one represents respiratory system drugs. Cetirizine 
is the most used medicine in this network along with salbutamol and salmeterol/fluticasone 
combination. The thickest edge represents the most combined medicines in the network 





4.1.4.d Chronic Obstructive Pulmonary Disease pattern (COPD) 
Table 4.19: Network characteristics for COPD subnetwork 
 
 
Table 4.20: The most used medicines in COPD subnetwork, degree centrality shows how many times these 
medicines were connected to other nodes 
 
 
Table 4.20 shows esomeprazole to be the most connected node to other important nodes in the 
network with greatest number of users. Inhalations and systemic prednisolone along with 
cetirizine are the most central nodes in this pattern. 




Table 4.21 shows the most frequented combinations were between selective beta-2-
adrenoreceptor agonists Salbutamol (Ventolin®) long-acting beta2 agonists (LABA) combined 
with corticosteroid like Salmeterol and Fluticasone (Seretide®) and long-acting muscarinic 











ATC Substance No. of users Degree Cen. Eigenvector Cen.
A02BC05 Esomeprazol 35651 71 1.0
A02BC02 Pantoprazol 34983 68 0.99
H02AB06 Prednisolon 31653 70 0.99
R06AE07 Cetirizin 30150 66 0.98
R03AK06 Salmeterol og flutikason 25227 70 0.99
R03BB04 Tiotropium bromide 22140 67 0.98
R03AC02 Salbutamol 18450 70 0.99
R03AK07 Formoterol og budesonid 17314 69 0.98
M01AB05 Diklofenak 14081 64 0.96
A02BC03 Lansoprazol 14040 62 0.94
ATC 1 Drug 1 ATC 2 Drug 2 No. of times combined
R03AK06 Salmeterol og flutikason R03BB04 Tiotropium bromide 6930
R03AC02 Salbutamol R03AK06 Salmeterol og flutikason 6599
R03AC02 Salbutamol R03BB04 Tiotropium bromide 5335
R03AC02 Salbutamol R03BB01 Ipratropium bromide 4536
R03AK07 Formoterol og budesonid R03BB04 Tiotropium bromide 4202
H02AB06 Prednisolon R03AC02 Salbutamol 4000
A02BC02 Pantoprazol H02AB06 Prednisolon 3751
H02AB06 Prednisolon R03BB04 Tiotropium bromide 3686
H02AB06 Prednisolon R03AK06 Salmeterol og flutikason 3569
R03AK06 Salmeterol og flutikason R03BB01 Ipratropium bromide 3193
Most combined medicines 
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Figure 4.6: COPD weighted network, filtered for edges >100. Bigger nodes indicate greater number of users 
The full network in PDF format (full resolution) is available here:  
https://www.dropbox.com/s/6zqxb7s79ttdexp/COPD.pdf?dl=0  
 
The network (figure 4.6) shows pantoprazole and esomeprazole, in the red color, are the most 
used PPIs. Prednisolone, in green, shows a high number of users. Inhalations combination such 
as salmeterol/fluticasone with tiotropium bromide or with salbutamol are the most used 






4.1.4.e Pain pattern  




Table 4.23: The most used medicines in Pain subnetwork, degree centrality shows how many times these 
medicines were connected to other nodes 
 
 
Table 4.23 shows PPIs (Pantoprazole and Esomeprazole) are the most vital nodes in the 
network. Only three types of analgesics exist in the top most used in this network. The other 
drugs are drugs related to obstructive airways diseases. 
 
Table 4.24: The most combined analgesics with other drugs in Pain subnetwork showing number of times each 
two nodes were combined 
 
 
Table 4.24 shows the most combined drugs with analgesics. In this table we chose to show the 
most frequented combinations with analgesics (i.e. not the most combined medicines in the 
overall network). The most used analgesic was codeine and paracetamol combination (Paralgin 











ATC Substance No. of users Degree Cen. Eigenvector Cen.
A02BC02 Pantoprazol 34983 55 1.0
A02BC05 Esomeprazol 35651 55 0.99
N02AJ06 Kodein og paracetamol 20702 55 0.99
R03AK06 Salmeterol og flutikason 25227 51 0.98
R03AC02 Salbutamol 18450 52 0.98
A02BC03 Lansoprazol 14040 50 0.97
A02BC01 Omeprazol 13645 50 0.96
R03AK07 Formoterol og budesonid 17314 49 0.95
M01AB05 Diklofenak 14081 47 0.94
M01AX05 Glukosamin 10867 44 0.92
ATC 1 Drug 1 ATC 2 Drug 2 No. of times combined
A02BC05 Esomeprazol N02AJ06 Codein and paracetamol 1946
A02BC02 Pantoprazol N02AJ06 Codein and paracetamol 1743
N02AJ06 Codein and paracetamol R03AK06 Salmeterol og flutikason 1308
N02AJ06 Codein and paracetamol R03AC02 Salbutamol 1295
M01AB05 Diklofenak N02AJ06 Codein and paracetamol 1148
A02BC05 Esomeprazol N02AX02 Tramadol 886
A02BC05 Esomeprazol M01AB05 Diklofenak 872
N02AJ06 Codein and paracetamol N02AX02 Tramadol 855
A02BC02 Pantoprazol N02AX02 Tramadol 825
N02AJ06 Codein and paracetamol R03AK07 Formoterol og budesonid 818
Most combined medicines 
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forte®) either combined with other analgesics or another therapeutic group, then comes 




Figure 4.7: Pain weighted network, filter for edges weight> 50. Bigger nodes indicate greater number of users 
The full network in PDF format (full resolution) is available here:  
https://www.dropbox.com/s/q6ow7ov0evrxtsk/Pain.pdf?dl=0  
 
Figure 4.7 shows Proton Pump Inhibitors (PPIs), in the red color, to represent the highest 
number of users. Codeine with paracetamol combination with Tramadol, in purple color, show 
also a high number of users. Non-steroidal anti-inflammatory drugs (NSAIDs) (e.g. diclofenac, 
ibuprofen) in the dark blue color have a good share of users as well. Combinations of salbutamol 
with salmeterol/fluticasone and formoterol/budesonide inhalations are frequently used from 




4.1.4.f Menopause pattern 
Table 4.25: Network characteristics for Menopause subnetwork 
 
 
Table 4.26: The most used medicines in Menopause subnetwork, degree centrality shows how many times these 
medicines were connected to other nodes 
 
 
Table 4.26 shows calcium combination with vitamin D and Alendronic acid had the biggest 
share of users. The most important nodes were calcium combination which is attached to all 
nodes in the network. Estriol and estradiol comes next in terms of importance with high 
eigenvector centrality score. 
 




Calcium/vitamin D with Alendronic acid combination had the highest frequency of being used 
together with a significant difference from the next most frequented combination in the network 
(i.e. calcium/vitamin D with denosumab). 










ATC Substance No. of users Degree Cen. Eigenvector Cen.
A12AX Kalsium, vitamin D 44690 12 1.0
M05BA04 Alendronic acid 33484 8 0.82
G03CA03 estradiol 6381 10 0.94
G03CA04 estriol 4691 11 0.96
G03CX01 Tibolon 1542 7 0.77
M05BX04 denosumab 1436 8 0.85
M05BA07 Risedronsyre 471 6 0.69
M05BA06 Ibandronsyre 243 6 0.64
A12AA06 Kalsiumlaktoglukonat 225 7 0.77
M05BB01 Etidronsyre og kalsium 133 4 0.46
ATC 1 Drug 1 ATC 2 Drug 2 No. of times combined
A12AX Kalsium, komb. vit. D M05BA04 Alendronic acid 16325
A12AX Kalsium, komb. vit. D M05BX04 Denosumab 860
A12AX Kalsium, komb. vit. D G03CA04 Estriol 629
A12AX Kalsium, komb. vit. D G03CA03 Estradiol 511
G03CA04 Estriol M05BA04 Alendronic acid 466
G03CA03 Estradiol M05BA04 Alendronic acid 366
A12AX Kalsium, komb. vit. D M05BA07 Risedronic acid 178
A12AX Kalsium, komb. vit. D G03CX01 Tibolon 95
A12AX Kalsium, komb. vit. D M05BA06 Ibandronsyre 86











Figure 4.8: Menopause weighted network, no filters applied. Bigger nodes indicate greater number of users 
The full network in PDF format (full resolution) is available here:  
https://www.dropbox.com/s/qrlgxh9ckvmunt6/menopause.pdf?dl=0  
 
Figure 4.8 shows few nodes with clear priority to Alendronic acid with calcium combination 







4.2 Part II: Comparison of day 0 and 365 networks (Temporal change) 
Table 4.28: Comparing basic network characteristics for network day 0 and 365 
 
Table 4.28 represents a minor change in number of nodes, edges and maximum edges’ weight.  
 
Table 4.29: Network characteristics for the generated network 
 
 
Table 4.29 shows some characteristics of the generated division network. Density remains 
almost the same. Edges range here represents a ratio of usage not a number.  
 
Table 4.30: Number and percentage of unique edges in both networks 
  
 
About 84 % percent of edges were common in both networks (basically generated network).  
Each of 2013 and 2014 networks had approximately 16% of unique edges. In other words, 16% 
of both networks were not matched to the corresponding edges in the other network (table 4.30).  








No. of nodes (Drugs) No. of nodes (Drugs)
No. of edges No. of edges
Density Density













No. of nodes (Drugs)
No. of edges
Density







% of total network edges
Unique edges in 2014 network 11893 16 %
Unique edges in 2013 network 12243 16 %
Total unique edges in both networks (unmatched) 24136 16 %
Common edges in both networks (=compare network) 62809 84 %
Unique edges distribution in both networks
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Table 4.31: Anatomical ATC distribution in 2014 network, showing difference in percent from 2013 network 
 
 
Anatomical class ATC distribution (table 4.31) shows slight differences in percentages of 
different anatomical classes being involved in drug-drug combinations in day 0 and day 365 
networks. R-, A-groups had the highest change in percentages respectively. N-group remains 
with the highest proportion (20.4%) while V-group comes last with (0.26%). The 2014 network 
shows though less percentages of J-group ATC codes.  
 
Table 4.32: Drug-drug combining frequency change in 2013,2014 networks 
 
 
Table 4.32 show that 50% of all drug combinations to be higher used in 2013 than 2014 










Anatomical group No. of times involved in a combination Pecent (change from 2013)
N   Nervous system 15241 20.40 (-0.15%)↓
C   Cardiovascular system 13911 18.62 (-0.14%)↓
A   Alimentary tract and metabolism 11457 15.34 (+0.31%)↑
R   Respiratory system 8556 11.45 (+0.35%) ↑
B   Blood and blood forming organs 4507 6.03 (+0.28%)↑
G   Genito-urinary system, sex hormones 4154 5.56 (-0.03%) ↓
M  Musculo-skeletal system 3885 5.20 (-0.25%)↓
L  Antineoplastic, immunomodulating agents 3871 5.18 (-0.23%)↓
J   Anti-infectives for systemic use 3829 5.13 (-0.07%)↓
H  Systemic hormonal, ex. sex hormones and insulins 2356 3.15 (+0.02%)↑
S   Sensory organs 2119 2.84 (-0.04%)↓
P   Antiparasitic products, insecticides and repellents 319 0.43 (-0.07%)↓
D  Dermatologicals 303 0.41 (+0.03%)↑
V  Various 194 0.26 (0.0%)=
    Frequency Percent
Lower combination frequency in 2013 than 2014 19381 31 %
No change 11861 19 %
Higher combination frequency in 2013 than 2014 31567 50 %
Total 62809 100 %
Drug combination frequency comparison (2013-2014)
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Table 4.33: The top most used drugs in 2014 more 2013 according to ratio of users 
 
 
The top prevalent ratios of drugs users in 2014 network compared to 2013 network (table 4.33) 
shows dapagliflozin (Forxiga®) is the highest medicine to be used in 2014 with about 65 times 
more compared to 2013. Apixaban (Eliquis®) comes next with almost 32% more users in 2014 
than 2013. 
 
Table 4.34: The least used drugs in 2014 than 2013 according to ratio of users 
 
 
On the other hand, the least used medicines in 2014 were alfuzosin (Xatral®) with significant 
lower ratio. Isoniazid, ribavirin, oseltamivir and digitoxin comes next with notably lower 
percentage of users compared to 2013 users. 
 
 
ATC Substance Drug name in Norway Ratio no. of users 2014/2013
A10BK01 Dapagliflozin Forxiga® 64.7
B01AF02 Apiksaban Eliquis® 31.6
R01AD58 Flutikason, combinations Dymista® 20.4
G04BD12 Mirabegron Betmiga® 16.4
A10BJ03 Liksisenatid Lyxumia® inj 16
L02BB04 Enzalutamid Xtandi® 14.3
A10BD11 Metformin og linagliptin Jentadueto® 12.4
A06AX04 linaclotide Constella® 12.0
C01EB17 Ivabradin Procoralan® 9.0
R03BB06 glycopyrronium bromide Seebri® breezhaler 8.07
R03AK11 Formoterol og flutikason Flutiform® inh aeros 7.5
R03BB05 aclidinium bromide Eklira Genuair inh pulv ® 6.4
A06AX05 Prukaloprid Resolor ® 6.0
B03BA05 Mekobalamin Mekobalamin®  inj 6.0
B01AF01 Rivaroksaban Xarelto® 5.9
Top most used medicines 2014 comparing with 2013 acc. to no. of users
ATC Substance Drug name in Norway Ratio no. of users 2014/2013
G04CA01 Alfuzosin Xatral ® 0.04
J04AC01 Isoniazid Isoniazid NAF ® 0.14
J05AB04 ribavirin Copegus ® 0.2
J05AH02 Oseltamivir Tamiflu caps ® 0.2
C01AA04 Digitoksin Digitoxin nycomed ® 0.202
R03CC02 Salbutamol Ventoline mixture ® 0.24
N02CA52 Ergotamin, comb. except psykoleptics Cafergot® 0.25
N02CA72 Ergotamin, comb. with psykoleptics Anervan supp ® 0.254
J01FA02 Spiramycin Rovamycin tab 3mill IE ® 0.286
L01XE07 Lapatinib Tyverb tab® 0.285
C10AD02 Nikotinsyre Niaspan ® 0.33
J01MA14 Moksifloksacin Avelox tab ® 0.33
R01AB06 xylometazoline Otrivin Comp ® 0.36
N05AA01 Klorpromazin Chlorpromazine ® 0.42
A06AH01 methylnaltrexone bromide Relistor inj ® 0.42
Top least used medicines 2014 comparing with 2013 acc. to no. of users
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Table 4.35: The top drug-drug combinations which were more used in 2013 than 2014. Ratio represents number 




The table 4.35 shows digitoxin combined with methotrexate is the combination with highest 
proportion of users in 2013 than 2014. Digitoxin is also involved in three other combinations 
in the most used combinations in 2013. Alfuzosin combination with Tamsulosin comes last of 
the list with 15 times higher usage in 2013 compared to 2014. 
 
Table 4.36: The top drug-drug combinations which were more used in 2014 than 2013. Ratio represents number 
of patients combined the two medicine (edges) in 2014 over 2013 
 
 
Table 4.36 shows that dapagliflozin (antidiabetic) and apixaban (antithrombotic agent, factor 








ATC Substance ATC2 Substance 2 Ratio of users (2013/2014)
C01AA04 Digitoxin L04AX03 Methotrexate 21
B01AB04 Deltaparin (Fragmin ®) M01AB55 Diclofenac, combinations 19
C01AA04 Digitoxin R03BA02 Budesonide 17
A11CC01 Ergocalciferol (AFI-D2 forte ®) J01CA04 Amoxicillin 16
C01AA04 Digitoxin C09AA01 Captopril 16
M01AB05 Diclofenac N02AB01 Ketobemidone (Ketorax ®) 16
A04AA01 Ondansetron (Zofran ®) J01EE01 Sulfamethoxazole and Trimethoprim 15
C01AA04 Digitoxin N06AA09 Amitriptyline 15
C01DA08 Isosorbide dinitrate J01CE02 Phenoxymethylpenicillin 15
C03EA01 HCT/Pot.sparing agents P01AB01 Metronidazole 15
G04CA01 Alfuzosin (Xatral ®) G04CA02 Tamsulosin 15
ATC Substance ATC2 Substance 2 Ratio of users (2014/2013)
A10BK01 Dapagliflozin (Forxiga ®) C10AA05 Atorvastatin 143
B01AF02 Apixaban (Xarelto ®) C07AB07 Bisoprolol 102
C09DA04 Irebsartan/HCT (CoAprovel®) G04BD12 Mirabegron (Betmiga ®) 74
A10BA02 Metformin A10BK01 Dapagliflozin (Forxiga ®) 73
A10BK01 Dapagliflozin (Forxiga ®) B01AC06 Acetyl salicylic acid 71
B01AF02 Apixaban (Xarelto ®) C01DA14 Isosorbide mononitrate 71
A10BK01 Dapagliflozin (Forxiga ®) C10AA01 Simvastatin 70
A02BC02 Pantoprazole B01AF02 Apixaban (Xarelto ®) 68
B01AF02 Apixaban (Xarelto ®) C09CA01 Losartan 64




Figure 4.9: Day 365 (2014 network) with no filters applied, bigger nodes indicate greater number of co-
medications 
 
The full network in PDF format (full resolution) is available here: 
https://www.dropbox.com/s/9e128evrkl1f395/dag%20365%20nw%20no%20filters%20no%20edges.pdf?dl=0  
 
Cardiovascular systems nodes in the orange color shows many large nodes indicating being 
involved in many drug-drug combinations (e.g. simvastatin, metoprolol). Nervous system drugs 
in purple has also many big nodes (e.g. zopiclone, paracetamol). Acetyl salicylic acid represents 







Figure 4.10: Compare network, node size indicates ratio of users in 2014/2013 the bigger nodes the greater 
proportion of users in 2014 compared to 2013. 
The full network in PDF format in which node size indicates ratio of users is available here: 
https://www.dropbox.com/s/0vllaawnod9ud9a/compare%20nw%20no%20of%20users.pdf?dl=0 
 
The network (figure 4.10) shows relatively smaller nodes than the other two networks because 
it represents the ratio of users between day 0 and day 365 network not the number of users. 
Dapagliflozin and apixaban are the biggest nodes in the network indicating more users in day 
365 network. It is noticed that platelet aggregation inhibitors in the light red color (e.g. 
apixaban, ticagrelor, rivaroxaban) have many big nodes in the network. In general, relatively 
newer substances or combinations have bigger nodes indicating more users. Notice that this 
network differs from the following network (figure 4.11) in that node size here indicates ratio 
of users while the following network node size indicates the number edges (i.e. bigger nodes 





























Figure 4.11: Representing the three full networks (2013, 2014 and the compare network) in form of nodes. Bigger 
nodes indicate being involved in a greater number of co-medication (edges). 
Full compare network in PDF in which node size indicates edges degree is available here: 
https://www.dropbox.com/s/4u7tj64lrxng3qd/compare%20nw%20no%20filters%20bigger%20nodes%20degree.pdf?dl=0  
2013 full Network 2014 full Network 
Compare Network (full) 
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4.3 Part III: Comparison of the selected five counties 
 
Table 4.37: Prescriptions’ distribution in the five counties 
 
 
Table 4.37 represents number and percentage of prescriptions of the overall prescriptions in the 
dataset in the five counties. The prescription from all the five counties forms 41% of the overall 
prescriptions in the dataset. 
 
Table 4.38: A comparison between network characteristics for the 5 counties 
 
 
Table 4.38 shows slight differences in networks characteristics in the five counties. Number of 













Name of county No. Of prescriptions precentage
Akershus  1885949 10 %
Hordaland  1704633 9 %
Nordland  1015113 6 %
Oslo  1622358 9 %
Rogaland 1319689 7 %
Total prescriptions for the chosen counties 7547742 41 %
Distribution of prescriptions in the 5 counties 
No. of nodes No. of edges Edges max. value Density Weight Direction
Akershus 592 37009 8150 0.21 Weighted Undirected
Hordaland 572 35176 6996 0.22 Weighted Undirected
Nordland 524 27618 5095 0.20 Weighted Undirected
Oslo 598 34901 6998 0.20 Weighted Undirected
Rogaland 555 32902 6220 0.21 Weighted Undirected
Network characteristics
 58 




(Table 4.39) shows almost the same combinations in all counties with slight differences of 
combinations’ order.  
 
Table 4.40: Eigenvector Centrality comparison for top 10 high-scored nodes in the 5 counties 
 
 
(Table 4.40) shows the top 10 high-scored nodes to be almost the same between the five 
counties with slight difference in order between them. Acetyl salicylic acid has the highest score 
representing the most important node in all networks.  
 
The full networks in PDF format (full resolution) are available here: 
Akershus: https://www.dropbox.com/s/wwz77unnqai9rll/Akershus.pdf?dl=0  
Hordaland: https://www.dropbox.com/s/424v2mqerusyg4i/Hordaland.pdf?dl=0  
Nordland: https://www.dropbox.com/s/m5j4sfznnerk2m6/Nordland.pdf?dl=0  
Oslo: https://www.dropbox.com/s/pudxits9a5k9h16/Oslo.pdf?dl=0  
Rogaland: https://www.dropbox.com/s/rwwd8k8u8gu2dqb/Rogaland.pdf?dl=0 
 
Drug 1 Drug 2 No. Comb. Drug 1 Drug 2 No. Comb. Drug 1 Drug 2 No. Comb.
Acetylsalisylsyre Simvastatin 8150.0 Acetylsalisylsyre Simvastatin 6996.0 Acetylsalisylsyre Simvastatin 5093.0
Acetylsalisylsyre Metoprolol 5313.0 Acetylsalisylsyre Atorvastatin 4594.0 Acetylsalisylsyre Metoprolol 3468.0
Acetylsalisylsyre Atorvastatin 4935.0 Acetylsalisylsyre Metoprolol 4140.0 Acetylsalisylsyre Amlodipin 2712.0
Metoprolol Simvastatin 3607.0 Acetylsalisylsyre Amlodipin 3103.0 Metoprolol Simvastatin 2291.0
Acetylsalisylsyre Amlodipin 3137.0 Metoprolol Simvastatin 2592.0 Acetylsalisylsyre Atorvastatin 2056.0
Acetylsalisylsyre Zopiklon 3081.0 Acetylsalisylsyre Zopiklon 2447.0 Amlodipin Simvastatin 1734.0
Amlodipin Simvastatin 2158.0 Amlodipin Simvastatin 2162.0 Acetylsalisylsyre Zopiklon 1649.0
Acetylsalisylsyre Ramipril 2140.0 Acetylsalisylsyre Ramipril 2018.0 Metoprolol Amlodipin 1424.0
Metoprolol Atorvastatin 2005.0 Acetylsalisylsyre Furosemid 1744.0 Acetylsalisylsyre Furosemid 1374.0
Metformin Acetylsalisylsyre 1948.0 Metformin Acetylsalisylsyre 1576.0 Acetylsalisylsyre Levotyroksin 1233.0
Hordaland Nordland
The 5 counties' most combined drugs
Akershus
Drug 1 Drug 2 No. Comb. Drug 1 Drug 2 No. Comb.
Acetylsalisylsyre Simvastatin 6998.0 Acetylsalisylsyre Simvastatin 6220.0
Acetylsalisylsyre Metoprolol 4211.0 Acetylsalisylsyre Atorvastatin 3405.0
Acetylsalisylsyre Atorvastatin 3412.0 Acetylsalisylsyre Metoprolol 3357.0
Metoprolol Simvastatin 3095.0 Metoprolol Simvastatin 2626.0
Acetylsalisylsyre Zopiklon 2670.0 Acetylsalisylsyre Zopiklon 2220.0
Acetylsalisylsyre Amlodipin 2621.0 Acetylsalisylsyre Amlodipin 2205.0
Simvastatin Zopiklon 1783.0 Simvastatin Zopiklon 1787.0
Amlodipin Simvastatin 1755.0 Amlodipin Simvastatin 1730.0
Metformin Acetylsalisylsyre 1557.0 Acetylsalisylsyre Ramipril 1601.0
Acetylsalisylsyre Levotyroksin 1436.0 Metoprolol Atorvastatin 1311.0
Oslo Rogaland
Drug Score Drug Score Drug Score Drug Score Drug Score
Acetylsalisylsyre 1.0 Acetylsalisylsyre 1.0 Acetylsalisylsyre 1.0 Acetylsalisylsyre 1.0 Acetylsalisylsyre 1.0
Zopiklon 0.985 Simvastatin 0.986 Simvastatin 0.984 Simvastatin 0.988 Zopiklon 0.994
Simvastatin 0.983 Zopiklon 0.985 Zopiklon 0.976 Zopiklon 0.987 Simvastatin 0.993
Metoprolol 0.978 Metoprolol 0.974 Metoprolol 0.976 Metoprolol 0.979 Paracetamol 0.978
Paracetamol 0.976 Furosemid 0.969 Amlodipin 0.973 Atorvastatin 0.969 Metoprolol 0.975
Atorvastatin 0.974 Atorvastatin 0.968 Paracetamol 0.971 Paracetamol 0.965 Amlodipin 0.968
Amlodipin 0.967 Esomeprazol 0.967 Esomeprazol 0.968 Levotyroksinnatrium 0.963 Prednisolon 0.965
Levotyroksinnatrium 0.9667 Paracetamol 0.962 Pantoprazol 0.967 Amlodipin 0.963 Levotyroksinnatrium 0.964
Esomeprazol 0.966 Amlodipin 0.962 Levotyroksinnatrium 0.962 Kodein og paracetamol 0.959 Atorvastatin 0.958









































































docusate sodium, incl. combinations



















































































































































































































































































































































Kodein og par etamol
Tramadol
Tapentadol
Fenazon, kombinasjoner ekskl. psykoleptika
Paracetamol
Paracetamol, kombinasjoner ekskl. psykoleptika














































































































































































































docusate sodium, incl. combinations











































































































































Losart  og diuretika
Eprosartan og diuretika
Valsartan og diuretika





















































































































Oseltamivir Zidovudin og lamivudin
Lamivudin og abakavir
Tenofovirdisoproksil og emtricitabin




























































































Fenazon, kombinasjoner ekskl. psykoleptika
Paracetamol
Cannabinoider

































































































































































































































docusate sodium, incl. combinations


























































































































































































































































































































































Fenazon, kombinasjoner ekskl. psykoleptika
Paracetamol
Cannabinoider

























Lev dopa og dekarboksylasehemmer






























































































































































































docusate sodium, incl. combina...





































































































































































































































































































































































































































































































































docusate sodium, incl. combinations


















































































































































































































































































Zidovudin, lamivudin og abakavir
Emtricitabin, tenofovirdisoproksil og efavirenz




























































































Fenazon, kombinasjoner ekskl. psykoleptika
Paracetamol
Cannabinoider
Ergotamin, kombinasjoner unntatt psykoleptika

























































































































































































4.4 Part IV: Drug-drug severe interactions network 
 




Severe interactions represent approximately 16% (table 4.41) of the total drug-drug interaction 
in the dataset. After exclusions, only 113,413 of the severe interactions were left (methods 
3.3.2).  
 
Table 4.42:  Drug-drug severe interactions network characteristics. 
 
 
The network represents a qualitative relation; that is why the edges are either 0 or 1 (i.e. the 




Figure 4.13: A heat map of anatomical groups severe interactions, the darker the color the more interactions the 
group is involved in. 
Total Interactions without exclusions 1st grade (severe) 2nd grade (moderate) 3rd (low risk)
933783 153354 477022 303407
DDI from FEST
No. of nodes (Drugs)
No. of edges
Density
Edges range (min.-max.) 
Weight 







A B C D G H J L M N P R S V
A 380
B 20 192
C 84 76 3452
D 1 0 0 17
G 0 0 16 0 463
H 6 0 0 0 0 1
J 361 60 739 110 852 160 35871
L 124 119 227 1 107 36 2777 74
M 7 101 1 0 0 0 42 197 1617
N 265 91 960 31 1131 11 876 523 61 2027
P 0 0 12 0 2 0 34 12 0 39 278
R 1 1 6 1 31 0 163 92 56 922 0 17
S 0 0 0 0 0 0 1 0 0 209 0 0 15
V 68 1 744 1 9 2 23 15 3 55 3 10 0 58
Total 1317 641 6157 161 2595 210 39787 913 1737 3252 281 27 15 58 57151
Heat map for ATC 1st grade interactions on the anatomical class level
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The heat map (figure 4.13) shows severe interactions between each anatomical group and the 
others. The highest number of severe interactions lies between (J-J) anatomical group with a 
total 35871 DDI.  
It shows also how many severe interactions were between each of the anatomical groups. The 
total number of ATC codes was 1699 (total number of nodes). J- group has the highest number 
of ATC codes (370) followed by N-group (264) and L-group with (262). ATC classes S, R, V, 
H and D had the fewest severe interactions. 
(L-J), (N-N), (N-G), (N-C) anatomical groups have also a high number of interactions as seen 
from the red color in the figure. Other groups had no severe interaction, e.g. (H-B) and (S-A) 
among others.  
 
Total number of severe interactions was (57151). The J-group had the highest number of severe 
interactions (39787) followed by C-group (6157), while the lowest number of severe 
interactions was observed in group S- and group R- with 15 and 27 DDI, respectively. 
 
Table 4.43:  The 10 ATC codes with highest number of interactions in the severe drug-drug interactions network 
 
 
As shown in (table 4.43), ATC codes with the greatest number of severe DDI all belong to 
anatomical J-group (anti-infectives for systematic use) except Prikkpericum (Hypericum 
perforatum, known as (St John's-wort) which belongs to N-group and used for treating mild to 
moderate depression and related symptoms. The most interacted medicines and detailed notes 






ATC Name No. of severe DDI
J07AP01 Tyfoid, oral, levende, svekket 537
J01FA01 Erytromycin 343







J07AN01 Tuberkulose, levende, svekket 277
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Figure 4.14: Full severe DDI Network, colors indicate anatomical groups, bigger nodes indicates greater number 
of interactions 
The severe DDI network (figure 4.14) shows J-group in the sky-blue color to have the largest 
nodes of size indicating high number of severe interactions. Nervous system group, in purple, 
represents spreading in the top half of the network with a share of large nodes as well. 
Cardiovascular group, in orange color, is extensively in two parts of the network. In general, 
we can notice a sort of color grouping (clusters) in the network.  
Due to the complexity of the network with a considerable amount of information, it may be 
easier to use the original PDF files with original resolution to visualize and navigate across the 
whole network. 
- The whole severe drug-drug interactions available here (with labels): 
https://www.dropbox.com/s/55pxvcuz4gifgwd/DDI%20gengeral%20whole%20no%20labels.pdf?dl=0  
- The whole severe drug-drug interactions (no labels) available here(figure 4.14): 
https://www.dropbox.com/s/55pxvcuz4gifgwd/DDI%20gengeral%20whole%20no%20labels.pdf?dl=0  
- Labeled severe drug-drug interactions with filtering of nodes which have less than 10 
interactions (604 nodes are filtered, about 36% of network) with edges available here: 
https://www.dropbox.com/s/fe2egep8om7i4mz/DDI%20general%20filtered%3E10%20degree.pdf?dl=
0  
- Labeled 1st grade drug-drug interactions with less than 10 interactions nodes filtered 




4.4.1 Betweenness centrality  
 
Table 4.44: Represents the medicines with the highest betweenness centrality score in severe DDI network 
 
 
Table 4.44 represents drugs with highest betweenness centrality score, and the number of 
interactions these drugs are involved in. All drugs with the highest score belong to B-, C-, J-, 
L-, N- anatomical groups. Typhoid vaccine, tuberculosis vaccine shows the highest score in J-
group with 537, 277 interaction with other drugs. The highest scored antibiotic was linezolid 
followed by erythromycin. Itraconazole was the only anti-fungal drug among the highest-scored 
drugs. Only one anti-coagulant drug is included in the table which is warfarin.  
 
 
Figure 4.15: DDI network filtered for betweenness centrality to show only the top 20 scored drugs in betweenness 
centrality score (score>2323687), bigger nodes indicate higher score. 
Substance ATC No. of DDI involoved in Betweenness Cen. Score
Typhoid vaccine oral J07AP01 537 191027
Prikkperikum (St John's-wort) N06AX25 335 172959
Tuberculose vaccine J07AN01 277 95628
Ginkgo Folium N06DX02 148 83581
Histamin dihydrochlorid L03AX14 122 83348
Linezolid J01XX08 311 65302
Erythromycin J01FA01 343 64118
Warfarin B01AA03 90 45646
Itraconazol J02AC02 157 42317
Klarithromycin J01FA09 327 41059
Methotrexat L01BA01 90 40464
Ciclosporin L04AD01 58 39192
Moxifloxacin J01MA14 312 37677
Sodium oxybate N01AX11 72 26242
Aliskiren/HTC C09XA52 76 26202
Aliskiren/Amlodipin/HCT C09XA54 76 26202
Panobinostat L01XX42 76 24878
Chloramfenicol J01BA01 287 23808
Betweenness centrality
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We located the 20 nodes with highest betweenness score in the network (figure 4.16) and 
filtered them out of the whole network (figure 4.15). 
 
Figure 4.16: Whole DDI network showing location of top 20 betweenness centrality drugs in the network 
To clarify the potential importance of using this measure for drug prescription networks we 
removed one of these highe-scored nodes which is Histamine Hydrochloride and regenerated 
the network (figure 4.17). 
Figure 4.17: DDI network after removing Histamine HCL node showing disconnection of a part of the network 
A group of ATC codes were completely isolated from the network after removing histamine 
node which has high betweenness centrality in the network (figure 4.17). 
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4.4.2 Applying DDI network on co-medication network (day 0) 
Table 4.45: Day 0 severe interacted medicines network characteristics, edges range here indicates how many 
users have combined these interacted drugs  
 
 
Matching severe DDI network on co-medication day 0 network allowed us to discover severe 
interactions in the elderly polypharmacy. Pairing these two networks revealed 229 drugs with 
total 662 severe drug-drug interactions with combination frequency from 1- 2320 times (table 
4.45) 
 
Figure 4.18: Weighted network of severe DDI in day 0 network, no filters applied, thicker edges indicate higher 
frequency of combinations, bigger nodes indicate greater number of users. 
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Figure 4.19: Weighted network of severe DDI in day 0 network filtered for >900 users for drugs (nodes). Bigger 
nodes indicate greater number of users 
Figure 4.19 shows the severe DDI in day 0 network. The network shows actual DDI between 
clopidogrel with PPIs (esomeprazole, lansoprazole, and omeprazole). Tramadol and 
codeine/paracetamol combinations shows also a thick edge.  
 















Table 4.46: The most 30 frequent severe DDI in day 0 network  
 
 
Table 4.46 shows the top 30 interactions in the network sorted from highest to lowest number 
of combining times. Combinations in the red color are more likely to be the actual interactions 
in the network. On the other hand, combinations in black are medicines with less possibility of 
being actually combined. Combining tramadol and codeine/paracetamol combination comes 
with the highest frequency of usage (855) patients. Esomeprazole and clopidogrel come next 
with (823) users. The top 200 drug-drug interactions are attached in (appendixes 7). 
 
For the online access to the folder which contains all the networks (in case of broken links): 








No. Drug 1 Drug 2 No. of times combined (users) 
1 Simvastatin Atorvastatin 2320
2 Losartan Losartan og diuretika 1253
3 Kodein og paracetamol Tramadol 855
4 Esomeprazol Klopidogrel 823
5 Pantoprazol Esomeprazol 603
6 Simvastatin Karbamazepin 480
7 Metoprolol Paroksetin 454
8 Pivmecillinam Metenamin 411
9 Metoprolol Verapamil 380
10 Flutikason Salmeterol og flutikason 359
11 Esomeprazol Naproksen og esomeprazol 352
12 Budesonid Formoterol og budesonid 343
13 Lansoprazol Klopidogrel 308
14 Diklofenak Ibuprofen 305
15 Diazepam Oksazepam 300
16 Karbamazepin Zopiklon 280
17 Pravastatin Atorvastatin 279
18 Omeprazol Klopidogrel 277
19 Amitriptylin Escitalopram 277
20 Omeprazol Esomeprazol 265
21 Warfarin Diklofenak 254
22 Atorvastatin Rosuvastatin 251
23 Simvastatin Erytromycin 220
24 Hydroksyzin Escitalopram 212
25 Lansoprazol Esomeprazol 203
26 Salmeterol og flutikason Flutikason 199
27 Diklofenak Naproksen og esomeprazol 183
28 Warfarin Dabigatran eteksilat 182
29 Nitrofurantoin Metenamin 180




Our study is a population study based on the Norwegian prescriptions dataset (NorPD) for the 
elderly from 2012 to 2014. There are many differences between the entire population study 
which is based on electronic registers and studies based on population samples. One difference 
is that in sample-based studies, the researchers collect and target their own data according to 
the subject of study, while in case of recorded databases, data is extracted from registers and 
this somehow limits the control of data collection. Another difference is that in the population-
based studies the influence of selection bias is limited. Mathematical oriented statistical 
analysis, hypothesis testing tests, and sample error, as a source of uncertainty, may not be 
relevant in the case of register-based studies (69). Finally, in the population studies, we don’t 
need to calculate the power of the study since the study includes almost all the population. 
  
Our thesis has two main objectives (figure 5.1), a methodological objective and a clinical one. 
The methodological part is represented in two things; the first is how to define co-medication 
in the most reliable, flexible, and practical way as much as possible. The second is using 
network analysis as an approach to the study of drug-drug relations. Since network analysis has 
been mostly employed for studying many aspects from the social point of view and less effort 
was done to take network analysis from this template to use it on medicines’ relations, this 
approach needs to be evaluated in terms of usefulness and efficacy to this particular part of 
public health study. This testing of network analysis allows us to decide if NA can be used 
efficiently in mapping drug-drug relations and extracting their relevant information or not. The 












medication patterns Studying DDI
 69 
After representing the results and visualizing them in the form of networks, comes the clinical 
objectives which are co-medication patterns in elderly and drug-drug severe interactions study. 
We tried to balance between these two objectives as much as we could but going in details in 
each point was not possible especially in the clinical part since geriatric medicine is a whole 
branch of medicine study. 
 
 
We chose to define co-medication as treatment episodes depending on the time of dispensing 
of prescription and defined daily dose (DDD) of each medicine combined with Proportion of 
days covered (PDC) as a measure of patient’s adherence, allowing 14 days as an accepted gap 
between the two treatment episodes. This approach allows us to capture the co-medication in 
any prevalence time points (i.e. date) we choose. Although determining the GAP period should 
be based on the pharmacological properties of the drug and the treatment situation (70), it was 
difficult to agree on a gap period which takes in consideration all the medical recommendations 
with such variety of medicines and indications with different pharmacological and severity 
aspects.  
 
There are many alternative approaches to use (1). For example, to consider the whole three 
years as a one treatment episode, this may create a bias in the study in terms of types and amount 
of medicines combined (e.g. medicines which are sporadically used). Another approach is to 
define co-medication as a prevalence period (e.g. 90 days) regardless of the drug defined dose 
and patient’s compliance. This also is not entirely convenient. Other more restricted ways of 
defining co-medication have been also used, like studying the prescriptions that were prescribed 
in the same day or from the same prescriber. The advantage of our approach of defining co-
medication is that it has combined simultaneous use of medicines and their defined daily dose 
along with possible patient’s adherence giving a more relevant, flexible, and reliable way of 
defining.  
 
There are plenty of ways to examine the data like spreadsheets, bar graphs, line graphs or 
timelines. All of these ways help to look at quantities or qualities. However, it is needed 
sometimes to see the connections between data objects to fully understand the pattern they have. 
Here is what network analysis can uniquely do among all the previous ways of data visualizing. 
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In this thesis we introduced Network Analysis (NA) as an approach to studying two forms of 
relations between medicines; the former was co-medication: by applying this approach on the 
Norwegian prescription database for elderly in a period of three years (2012-2014), and the 
latter was severe interactions (severe interactions) by using FEST database which is widely and 
officially used in Norway. In both types of relations, drugs represented network actors (nodes) 
in all generated networks, while edges varied according to the studied part representing 
simultaneous use (quantitatively) in co-medication part and severe interactions (qualitative 
relation) in the DDI part. 
 
Network analysis can be used in many applications in epidemiological studies as a tool of data 
visualization with unique descriptive features. Defining what nodes and edges represent allows 
us to visualize any kind of relational data we have. As an example, here with our data, we can 
investigate the degree of following the clinical guidelines by physicians by simply replacing 
what edges represent from co-medication to how many times a physician prescribed these nodes 
(ATC codes) together. 
 
As a summary of what Network analysis is capable of doing; NA is capable of plotting any kind 
of relational data in a network form (i.e. visualizing), after visualizing we can describe the 
network to extract the important information/features of it (i.e. network description); like the 
most central actors or the most important/frequently used relations. Applying different network 
measures can allow us to extract/confirm the patterns lies in the network (i.e. pattern study), in 
some cases networks can also predict/expect some unseen results as we mentioned before (i.e. 
predicting) (figure 5.2). 
 
Figure 5.2: A summary of network analysis possible functions 
 
The information and results extracted from the networks are either common with other 
descriptive/statistical ways or unique in itself. The relation between objects (edges list) is an 
example of these unique information. Unique measures for network analysis are like Centrality 
and its different measure (degree centrality, closeness centrality, betweenness centrality), 



















Some measures are shared in purpose with other statistical ways but remain unique in the 
approach like modularity classes extraction which has common functions with factor analysis 
and clustering analysis, more comes later in modularity classes study. 
 
In this thesis, we used network analysis to visualize (all networks), describe networks’ 
characteristics and information (Day 0 network), extract sub-patterns (Day 0 network), 
compare to study temporal change (network 2013, 2014) and spatial change (five selected 
Norwegian counties in day 0 network), and use unique network feature (eigenvector centrality, 
betweenness centrality). 
 
As mentioned before, we used two different datasets NorPD and interactions dataset from 
FEST. One of the aims of NorPD dataset which is mentioned in the Regulations on the 
collection of health information in NorPD §1-3 is to: 
1. “Describe drug use patterns, highlighting changes over time” (71) which is one of the 
main purposes of this thesis. 
 
The NorPD database has its strengthens and weaknesses, one of the strengthens is that it makes 
it possible to follow up drug dispersion over the years both on public and particular scale. This 
gives a rich content for pharmacoepidemiologic studies since it gives complete but anonymous 
information on the patient, prescriber, and medicines (i.e. exposure) and also mortality 
incidence (i.e. outcome). Another advantage that it gives information on prescriptions 
dispensing rather than prescribing. This approach, partially, eliminates a potential bias in 
researching which arises from the probability of non-conformity between prescribing and actual 
patient usage as in medical records. 
  
Entirely elimination of recall bias is also an advantage of using recorded databases over surveys 
and questionnaires. At last, owning the database by a researching organization which only allow 
sharing of anonymized data is ideal ethically. 
 
On the other hand, one of the limitations related to this dataset is that it does not include 
information on dispensed medications under hospital stay or in nursing homes on the individual 
scale which results in underestimating the overall drug usage in the population (56). 
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The other dataset we used is the interactions dataset form FEST dataset. The interactions 
database was built in FEST to be able to collect groups of the ATC codes or active substances 
under the same interaction. In other words, the interactions are mentioned in the dataset on both 
anatomical and therapeutic group level and on the complete ATC level as well.  
Active substances with several ATC codes, all relevant ATC codes are included in the 
appropriate substance group (For example, Ephedrine: C01CA26, R03CA02, the two ATC 
codes are stored in the database). The dataset  is also designed so that they should never be 
confused with approved substances at WHOCC (with an agreement with them), but they have 
real interactions (72). ATC is a drug-classification system based on their Anatomical, 
Therapeutic, Chemical characteristics. The complete ATC code has some levels. The 
anatomical level forms the 1st part of the code; there are fourteen anatomical groups. The 2nd 
level represents either therapeutically or pharmacological groups. The 3rd and 4th levels are the 
therapeutic and chemical subgroups while the 5th one is the chemical substance (73).  
 
The Norwegian Medicines Agency (SLV) informs that the most important sources for FEST 
are; 1. Systematic studies on patients and healthy subjects, 2. information from pharmaceutical 
manufacturers, 3. case reports (which are based on the individual experiences and is marked as 
“case report”), and 4.indirect documentations which means that the interactions are not 
documented, but can be predicted based on knowledge of the pharmacokinetic or 
pharmacodynamic properties (74). It should be taken into consideration that FEST does not 
contain absolutely all of the interactions, other sources could have more DDI based on their 
interactions’ definition like uptodate.com or drugs.com for example. 
 
Interactions in FEST are classified into three categories: the first is severe interactions which 
Should be avoided, the second is moderate in severity marked with “Precautions should be 
taken” label and the last is minor in severity and marked with “No action required” (75). Our 
concern in this study is the first section “severe” or 1st-grade interaction which should be 
avoided.  
 
We studied our primary network which captures co-medication in the treatment episode around 
1st of January 2013. It is the start of a new year and right after Christmas vacation in Norway. 
The Norwegian Health Economics Administration (Helfo) is responsible for direct payments 
of medicines which are prescribed as reimbursed prescriptions. After a specific amount of 
money, the patient pays, Helfo will cover the costs of medicines to the rest of this calendar year. 
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Patients will start to pay this particular amount of money again at the beginning of the next 
calendar year (76). This is why December month is considered a rush period for prescriptions’ 
pickups. The reason for why we mention this here is to explain that in 1st of January -
theoretically- all patients or the majority of them have their medicines. Therefore, it is a period 
we can say is most reliable to study co-medicating. 
 
Considering the distribution of anatomical groups in the drug-drug combinations of this 
network (table 4.3), drugs which affect the nervous system and cardiovascular system were 
involved in about 21%, 19% of drug combinations (edges) respectively. While dermatologicals 
and various medicines groups come last with less than 1% of overall combinations. It should 
be taken into consideration that prescriptions without DDD were excluded; this can affect the 
frequency of some groups like dermalogicals (D-group). 
 
We should also keep in mind that these percentages are not the amount or number of users or 
the percent of dispensed drugs which belongs to these anatomical classes, but they represent 
how frequent were these anatomical groups were involved in drug-drug combinations. 
Although drugs from (A-, B-, and C- anatomical groups) had the greatest proportion of users in 
2013-2017 (77), N-anatomical group drugs represent the highest percentage of being combined 
with other drugs. This also gives a clear example of what different results can networks 
represents comparing to traditional descriptive analysis ways. 
 
As mentioned before, most of the interactions in our dataset is mentioned in a directional way. 
This explains why the number of edges in the network (57,151) (i.e. interactions) is almost half 
of the number of severe interactions after exclusions (113,413). 
 
We showed then in (table 4.4) the most important drugs in this network according to 
“Eigenvector centrality”; a unique network measure we mentioned before. Results show that 
Acetylsalicylic acid (ASA) and simvastatin are the most important nodes in the network. This 
introduces another measure which can be essential to consider and asses for many aspects like, 
which medicines should be prioritized for reimbursement from the government and which drugs 
should the responsible authorities take rapid action in cases of medicines deficiency. This seems 
to be less important with respect to these 10 medicines listed in (table 4.4) but when it comes 




One of the most important and unique things that network analysis can represent is node-node 
relation (edges), in (table 4.5) we showed the most 20 combined medicine in the network. 
Drugs groups in this table are; drugs to prevent blood clotting (Acetylsalicylic acid, Warfarin), 
Heart and blood pressure medicines from different groups (Amlodipine, Beta-blockers, ACE 
inhibitors, Diuretics (Furosemide), Calcium antagonists, Isosorbide mononitrates), lipid-
modifying drugs (Statins), Anti-diabetic (Metformin), Non-opioid analgesic (Paracetamol), 
Hypnotics (Zopiclone) and Thyroid hormone (Levothyroxine). Norwegian national geriatric 
health maintenance guidelines suggest many measures as primary prophylaxis of many 
expected diseases in the elderly. Acetylsalicylic acid, blood pressure regulation, dyslipidemia 
are measures which proved efficacy for prevention (primary prevention) of both cardiovascular 
disease and stroke (78). These results were expected and reflect applying the guidelines 
Norwegian ministry of health for primary prophylaxis in the elderly (79) (i.e. quality of 
prescribing).  
 
Figure 5.3 Norwegian ministry of health guidelines for primary prophylaxis in elderly considering both clinical and 
economic point of views. (source: National guidelines, Norwegian ministry of health) 
 
We moved after to another network analysis unique feature which is “Modularity” or 
“community detection”. In general, there are many statistical ways for identifying patterns in 
datasets like cluster analysis and Factor Analysis (FA).  
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Cluster analysis is an exploratory data analysis tool which aims to sorting different objects in 
the same dataset into specific groups based on the degree of association between these objects. 
This means, if there is an association (similar objects) then these objects will belong to the same 
group otherwise not (80). Cluster analysis can be used to discover these hidden structures in 
data but without providing an explanation/interpretation.  
 
Factor analysis (FA) is another statistical method that has some explanation purposes by 
reducing number of variables by extracting latent (i.e. unknown or unobservable) variables if 
any  from the observed data and empirically figuring out data structures (creating a theory of 
data structure) from underlying variables (81) and evaluating whether the observed variables 
clusters in the theoretic expected way (82).  
 
Another way of detection of data structure is “Modularity” which is a specific feature for 
network analysis. Four modules were detected in our network (figure 4.2) the most complicated 
was module [0] which represents almost 70% of the network. To be able to discover the sub-
patterns under module [0] we shortened ATC codes to the anatomical, therapeutic level (three 
characters) (table 4.7) and summed up the number of users for each ATC group. We ended up 
with (47) different ATC groups under this module (total ATC codes were 530). Sorting these 
ATC codes needed assessing based on assumed clinical indication and number of users for each 
group to able to neglect groups with insignificant numbers of users and to give priority to the 
groups with a high number of users.  
 
As an example of how we tried to sort module [0]; if we notice there (table 4.7), Nervous and 
respiratory system (N- and R- groups) drugs are just found in module [0], while Cardiac-, 
Alimentary-, Blood- (C-, A-, B- groups) are common groups with modules [1] and [2], but with 
looking at the number of users in each module we can locate in which module these ATC groups 
represent the most importance. For example, some cardiac groups (C03 Diuretics, C07 Beta-
blockers, C10 Lipid modifying agents) are common between two or more modules but (C03) 
is shown to be with the greatest number of users in module [1] (70,736) users, while (C07) 
comes with the greatest number of users in module [2] (128,165) patients. Most number of users 
for (C10) is also located in module [2] (258,050). This reveals less importance of these ATC 
codes for module [0] and much more value for the other modules. In other words, these ATC 
codes are not central for module [0] as much as they are for the other modules. After sorting, 
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we were able to obtain some patterns shown in (table 4.8). It is interesting to relate these patterns 
under module [0] in terms of co-morbidity, but this actually needs further assessment and 
cannot be confirmed as a clinical outcome based only on mathematical bases. 
 
Some drugs in module [0] couldn’t be sorted in these three assumed patterns under it because 
they can belong to many therapeutic indications or are used to avoid the side effect of some 
other drugs. Some others have a certain clinical indication but with a lower number of users 
than they are in other modules (e.g. C03 diuretics, C07 beta-blocking agents). 
 
Module [1] is assumed to be a cardiac pattern as it contains diuretics (C03) with highest 
proportion of users, antithrombotics (B01), cardiac therapy (C01), beta-blockers (C07) and 
calcium channel blockers (C08). Module [2] has Renin-Angiotensin agents which are indicated 
for treatment of hypertension in case diabetes (83), antithrombotic agents (B01) as patient with 
diabetes have more risk for deep-vein thrombosis and pulmonary embolism (84), lipid 
modifying agents (C10) and ophthalmologicals (S01) as diabetes can lead to many eye 
complications. 
 
Another confirmatory step to these patterns was done to verify  these patterns; by comparing 
the patterns we found to the patterns revealed by another study held in Spain in 2008 to 
demonstrate polypharmacy patterns using Exploratory Factor Analysis (EFA), regarding 
(79,089) adults, researchers identified seven patterns (six of them were more applicable for the 
elderly) of co-medication in adults classified depending type of diagnosis. These seven patterns 
were Cardiovascular pattern, Depression-Anxiety pattern, Acute Respiratory Infection (ARI), 
Chronic Obstructive Pulmonary Disease (COPD), Rhinitis-Asthma, Pain, and Menopause 
pattern (67). 
 
The importance of this comparison is that these patterns (ours and the Spanish study patterns) 
that they were conducted using two different statistical methods. The mentioned paper 
depended on Exploratory Factor Analysis (EFA), while ours depended on obtaining 
substructures in the full network (modules). Modularity was done, as mentioned before, by 
Louvian method which measures the density of edges inside communities to edges outside 
communities and assigns a theoretical value results in the best possible grouping of the nodes 
inside a network. Revealing consistency between the two results despite the differences in 
methods and populations can affirm results’ reliability. 
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Our assessed patterns were Anxiety, Acute respiratory infection (ARI), Chronic obstructive 
pulmonary diseases (COPD), Hormones-related, Cardiac, and Diabetes patterns. While in the 
other study they conducted six patterns applicable for elderly which were Anxiety, 
Cardiovascular, ARI, COPD, Pain and Menopause patterns. We used then these anatomical 
group to extract and isolate each of sub-networks from the whole network according to the 
therapeutic indications. 
 
As the highly prevalent diseases are common in the elderly and already known, this pattern 
extraction is considered a confirmatory pattern extraction. However, in the case of ambiguous 
patterns, this approach of pattern extraction can reveal unknown patterns or negates hypothetic 
ones.  
 
We moved then to the studying of these sub-networks separately starting with the cardiac 
pattern. Under this clinical category there are a lot of diseases (e.g. arrhythmia, congestive heart 
failure, atrial fibrillation, hypertension, etc.). In this network, we had 108 nodes which all 
belong to three anatomical groups (A-, B-, and C- groups).  
Therapeutic groups under these patterns are anticoagulants, lipid-modifying agents, 
hypertensive drugs, beta-blockers, diuretics, Nitrates, digoxin, acid-related disorders drugs, 
diabetes drugs, and insulins.  
 
Anticoagulants (warfarin) and antithrombotics (acetylsalicylic acid, clopidogrel) are widely 
used in many cardiovascular diseases like atrial fibrillation, heart attack, and also for primary 
prophylaxis. One thing to notice here is that the network shows low number of users of direct 
factor Xa inhibitors like apixaban and rivaroxaban. These drugs were released in the Norwegian 
market around 2011 (85) and the reimbursement Helfo approval was after January 2013 (86) 
(i.e. after the treatment episode we study).   
 
Lipid-modifying agents are used to prevent many coronary and vascular diseases like 
atherosclerosis. Hypertension drugs, beta-blockers, and diuretics are also related to many 
indications. Most used drugs of those were metoprolol, furosemide, and ramipril. Vasodilator 
used in cardiac diseases like isosorbide mononitrates also had a good share of users (21,286) it 
is used in case of Angina pectoris. Digoxin is used for heart failure and atrial fibrillation. Proton 
pump inhibitors (PPIs) (esomeprazole, pantoprazole, lansoprazole, and omeprazole) are widely 
 78 
used in this network. It is interesting here because these drugs are used in case of cardiovascular 
diseases to protect against the adverse effects of some antiplatelet medications like 
acetylsalicylic acid and clopidogrel or NSAIDs, for example, but on the other hand, many 
studies related them to an increased risk of cardiovascular morbidity (87) (88). 
 
Anxiety pattern involves three anatomical groups (H-, M-, and N- groups). It is obvious that 
medicines belong to N-anatomical group (Anxiolytics, Anti-psychotics, Dopaminergic agents, 
Anti-depressants) are indicated for anxiety, depression and related sleeping problems. 
Corticosteroids for systematic use (prednisolone, methylprednisolone, dexamethasone, 
triamcinolone, etc.) are being used quite frequent by patients in this group. The relation between 
pain and depression is also quite clear (89). Prednisolone is the most used medicine in this 
network (table 4.14). Some studies related the using of corticosteroids to the incidence of fear 
and anxiety by inducing specific chemical changes in particular sets of neurons (90). There are 
two possible directions here when we think about corticosteroids use, the first is that they were 
used as anti-inflammatory agents with pain killers and in this case the depression or anxiety is 
caused by pain and corticosteroids are used as a consequence of pain. The second, is the other 
way around is that the depression was caused because of long term use of corticosteroids but 
the common thing between pain-killers and prednisolones that they indirectly related to anxiety 
or depression incidence.  
The network showed also that oxazepam is commonly combined with escitalopram (table 4.15) 
which is consistent with Norwegian guidelines for the treatment of depression (91) and sleeping 
disorders (92). 
 
Acute respiratory infection (ARI) is a serious infection that prevents normal breathing function. 
It usually begins as a viral infection that can lead to many complications including death in case 
of weak immunity or not being treated. Examples of infections are pneumonia and flu. (67)  
 
All ATC codes in this network belong to R- and J-groups. It is remarkable that few numbers of 
antibiotics and antivirals were involved in drug-drug combinations in this network despite that 
we included all antibiotics and antivirals for systemic use (J01, J05) which reflects the low 
percentage of misprescribing of antibiotics by prescribers. Phenoxy methyl penicillin, 
erythromycin, sulfamethoxazole/trimethoprim combination were the highest frequently used 
antibiotics in this network. Valaciclovir and acyclovir were the highest antivirals used here. 
Some antibiotics which are not indicated for upper respiratory tract infections were also 
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involved in combinations like Pivmecillinam, this occurred because we involved all systemic 
antibiotics and antivirals in the network, and they were used by some patients who were using 
also some medicines belong to this pattern. 
 
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous collection of diseases with 
different causes, pathogenic mechanisms, and physiological effects (93). It is a poorly 
reversible disease of the lungs that is one of the major causes of morbidity and mortality 
worldwide. Typical medical treatment includes Beta2-agonists (both short- and long-acting), 
anticholinergics (short- and long-acting), inhaled and systemic corticosteroids (94).  
 
Anatomical groups under this pattern (A-, H-, R-, and M-groups). Proton pump inhibitors (PPIs)  
and other drugs for acid disorders (which belongs to group A) are high-frequently used in this 
pattern for two main reasons, the first is that studies show that the relative risk of a COPD 
exacerbation over two years in those with gastroesophageal reflux disease (GERD) higher than 
in those without (GERD) (95) and the second is to protect the stomach against the adverse effect 
of systemic corticosteroids (96). Pain (M-group) is a common problem for patients with chronic 
obstructive pulmonary disease (COPD) (97) that’s why many analgesics are present in this 
pattern. Anatomical group H contains systemic corticosteroids (mainly prednisolone). 
 
In the pain pattern, as pain is not an indication in itself but a symptom for a disease or a disorder, 
we cannot tell for sure for which indication was each analgesic was prescribed. Analgesics in 
these groups belong to (M- and N-) anatomical groups.  
Unexpectedly, the top ten used drugs in the network had only three analgesics. Other top used 
drugs were either indicated for COPD or PPIs. Some indications are clear here like pain in case 
of COPD when the analgesic is combined with an inhaled active substance. Studies show that 
pain is more prevalent in patients with COPD than others (98).  
 
It is well known that low estrogen level in women in post-menopausal is one of the most 
influential risk factors for osteoporosis (99). The menopause pattern is clear, and the main 
actors are few. Calcium/vitamin D3 combination with Alendronic acid was the most combined 
medicines in the network (16,325) with a significant difference from the next combination 
(860). Denosumab (Prolia®) combination with calcium/vitamin D3 is also a common 
combination for treatment of osteoporosis. Other hormones like estriol, estradiol, and tibolone 
are all used for symptoms of estrogen deficiency. 
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We moved then to the next part of results which is using network analysis for comparison 
purposes. Using NA for comparison purposes was also possible. Comparison can occur 
between different information between two time points, places or patterns. In our thesis, we 
used network analysis to compare in term of time (Temporal difference) and palace (Spatial 
difference). 
 
To our knowledge, there is no specific software which can automatically compare two or more 
networks except for one software called (CompNet) (100) which, unfortunately, was damaged 
and not completely supported from developers. It could be much easier if such tools are 
available and well-supported.  
 
For temporal change study, we used two approaches of comparison a direct comparison which 
means we compared the two network of 2013 and 2014 in terms of characteristics (table 4.28), 
anatomical groups distribution (table 4.31), top used medicines and combinations, and indirect 
comparison by generating a new network which represents the division of 2013 network over 
2014 network (methods 3.8). 
 
The reason nodes in the generated network were less (table 4.29) is that when we generated the 
new network by the division of the two networks, unique edges (drug combinations) of both 
were divided by 0 (were not matched in Stata) which caused these nodes to be eliminated in the 
new network. Unique edges were identified and stored for comparison purposes (appendix 6). 
 
The generated network allowed us to see many things, for example, the ratio of users, the ratio 
of combination usage (edges) and unique edges in each network. 16% of total edges in both 
networks were unmatched to corresponding edges in the other network, while 84% were 
matched (table 4.30). Only 19% of drug-drug combination remains constant in both years, while 
31% of overall combinations are higher frequented in 2014 than in 2013 and 50% of them are 
higher in 2013 than in 2014 (table 4.32). 
 
This is an example of the change that which occurred on medical dispensing in a short period 
(i.e. only one year). Even more significant quantitative and qualitative changes are expected if 
the time gap between studied networks is longer.  
 
 81 
Anatomical groups distribution (table 4.31) shows 2014 network to have less percentages of J-
group ATC codes which may reflect increased awareness towards anti-infectives for systemic 
use e.g. antibiotics. 
 
Top most used drugs in 2014 compared to the same period in 2013 were Forxiga® 
(dapagliflozin) and Eliquis® (apixaban). Forxiga® was approved in the Norwegian market in 
1st of February 2013, so it is logic to be higher frequented in 2014. Eliquis® 5mg tablets was 
approved on the 15th February 2013. The same was with the other drugs; either they were 
approved in the Norwegian market later in 2013 or during 2014.  
 
Two remarkable medicines were in the list the first is Procoralan® (ivabradine) which is 
indicated for chronic angina pectoris for patients who can’t use beta-blockers, this medicine 
was approved for selling in the Norwegian market in 1st of June 2015, but it was approved for 
use (without approval for selling on the general scale=MT-dato) (101) in 25th of October 2005. 
This means the physician can apply for approval exemption for individual patients although the 
medicines they need isn’t for sale in Norway (102), so it is possible as it is a specific medicine 
for a few patient’s populations that it was imported from another European country. Going back 
to the original networks shows nine users in 2014 to only one user in 2013 (very few numbers 
with respect to the total number of patients). Mecobalamin (vitamin B12) is also a medicine 
which needs a special approval exemption (24 users in 2014 to four users in 2013). Market 
approval and relevant information can be checked in at https://www.legemiddelsok.no/ website. 
 
On the other hand, some drugs indicate significantly lower ratios of usage from 2014 to 2013 
in terms of the number of users (table 4.34). By checking these drugs, we can, mostly, find the 
reason behind the withdrawal of usage. For example, alfuzosin (Xatral®) was discontinued 
from the market in 2013 (103). Patients used to receive Digitoxin changed to Digoxin because 
of the former adverse effects (104) some other drugs need further assessing to see if there was 
a change in guidelines or date of registering as a reimbursed medicine for example.  
 
Drug combinations that were higher used in 2013 show some discontinued drugs like digitoxin 
which is involved in four of the highest 10 combinations. Some combinations show a drug-drug 
interaction (Deltaparin and Diclofenac) increases bleeding risk (105) (table 4.35).  
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Most of the combinations with higher usage in 2014 contained one of the drugs were approved 
late 2013 (later than January -our treatment episode-) or in 2014 (dapagliflozin, apixaban, 
metformin/vildagliptin, mirabegron) (table 4.36).  
 
We moved then to another type of comparison which is spatial comparison. We extracted the 
prescriptions for five counties in Norway (Akershus, Hordaland, Nordland, Oslo, and 
Rogaland). It was considered to choose counties from different places in Norway to study if 
medicine usage patterns represent any change. As expected in advance, the top used medicines 
and top used combinations are almost the same in the five counties. Norway is a country with 
a relatively low population (a little over 5 million in 2013) (57), well-established data system 
and a lot official electronic sources which make it quite easy to check, follow and keep updates 
concerning guidelines and medicines related information. That is the reason may be that spatial 
study shows almost typical results in all of the previous places. Spatial change in different 
countries or countries with higher population and less organized electronic data systems can be 
imagined to be much greater than what we found here. The primary purpose here was to show 
that network analysis approach is capable of introducing an alternative way of comparison than 
the commonly used statistical ways. 
 
The other central part of our thesis is drug-drug network severe interactions study based on 
FEST database. Severe interaction forms about 16% of the total interactions in the database 
(table 4.41). We represented the interactions between each anatomical group in the form of a 
heat map. A Heat map is a matrix that represents the frequency in the form of colors instead of 
numbers, the darker the color, the higher the frequency the color represents (106). The most 
severe interaction belongs to J-J group interactions. J- anatomical group includes, among others, 
antibacterial, antivirals, and vaccines. Injecting with vaccines which have weak or parts of 
viruses will for sure affect the immunity and any other drugs which affect the immuno-system 
as well affect the vaccine response. Also, antibacterial groups contain some of the medicines 
which are well known to have several interactions with other medication, for example, 
erythromycin, ciprofloxacin, moxifloxacin, and chloramphenicol. (detailed information of 
interactions for each anatomical group with some notes on this is attached in appendix 8). The 
top severely interacted drugs with other drugs all belong to J-group except St John's-wort which 
belongs to N-group. That is why some countries have banned using it like France (107). The 
lowest frequency of severe interactions was for S- and R- anatomical groups. 
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We tried to clarify, remove the overlapping between nodes and nodes labels to make the 
network quite clear for visualizing, so by magnifying the network to maximal size in PDF 
format (link attached in results figure 4.14) the reader will be able to extract a lot of information 
out of it. The network consists of about 1700 nodes (quite complex) but quite low density (0.04) 
which says something about connectivity between its nodes.  
 
The very first look to the network (figure 4.14) after coloring it according to anatomical groups 
that the most appeared colors in the network is violet and light blue which represent J-, N- 
anatomical groups and that network visualizing gives an indication of a sort of partitioning 
(except the middle).  This led us to think to use another unique measure for network analysis 
which is “Betweenness centrality”. 
 
Betweenness is based on the number of shortest paths a node lies on between any two other 
nodes (45). The higher number of shortest paths this node is involved in, the higher betweenness 
centrality score it gets. The original application of the centrality idea is in the study of 
communication in small groups. Betweenness centrality importance in any network arises from 
its potential great impact on the process being examined in a network (108). In our case, we 
measured betweenness centrality for the drug-drug severe interactions network to find out the 





Figure 5.4: An example of betweenness centrality score on a small graph. Source: Accelerating Graph 
Betweenness Centrality with CUDA by Adam McLaughlin (https://devblogs.nvidia.com/accelerating-graph-
betweenness-centrality-cuda/), showing node 4 to have the highest score, while marginal nodes 2, 8 and 9 with 
score= 0. 
 
We showed then the impact of removing one of these nodes (histamine Hydrochloride). This 
resulted in separating of a whole part of the network (R06A) Antihistamines for systemic use 
(Amino alkyl ethers).  
 84 
If we look closer at Histamine Hydrochloride interactions, we will find that it has interactions 
with five ATC groups: N05AF03 Chlorprothixene (Antipsychotic), H02AB (Glucocorticoids), 
H02B (Corticosteroid for systemic use), R06A (Antihistamines for systemic use),  
N06AA (Antidepressants, Non-selective monoamine reuptake inhibitors). Removing this node 
from the network has completely cut the connection between R06A group and the network and 
the group could be filtered out of the network. 
 
More disconnections will take place in the network if we remove nodes with high scores of 
betweenness centrality which indicates these nodes potentiality for DDI. One or more nodes 
with high betweenness can attach two nodes/groups in the network which don’t interact 
themselves but will be interacting in the presence of these high-between-centered nodes. 
 
The main point here is to conclude is that the presence of a drug with a high betweenness score 
will increase the potentiality of the presence of DDI between interacting or even non-interacting 
parts in the network. Betweenness centrality can also be applied on the co-medication network 
to highlight the most important medicines in terms of this measure. 
 
We used then the DDI network to obtain the severe interactions in 2013 network by matching 
the similar edges between the two networks (using DDI as a master network and keeping only 
the edges which are similar from Day 0 network). Using DDI network and matching its edges 
to any other Drug prescription network will easily allow us to visualize these interactions in the 
networks we study. 
 
Something to notice here is that as we defined co-medication as treatment episodes, it should 
be put into consideration that some interactions could be untrue. As shown in (table 4.46), there 
are some interacted medicines have the same clinical indication and appear as co-medicated 
medicines in the same treatment episode. There is a low possibility that the patients have 
actually used these medicines together. As an example, a patient used one small package of 
atorvastatin and then his doctor decided to stop it and start over with simvastatin, this 
combination will appear as a co-medication in the patient’s treatment episode, so assessment of 
such combinations is needed. 
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We highlighted the combinations which seem to be “true” interactions in (table 4.46) in red. 
Using tramadol and codeine causes a depressive effective on Central Nervous System (CNS) 
results in increasing the risk for sedation.  
 
The second interaction is between clopidogrel and esomeprazole. Patients who use this 
combination have the risk for reduced effect of clopidogrel (risk for thrombus formation). 
Clopidogrel is a prodrug which is activated through metabolizing inside the body. 
Esomeprazole is known to be (CYP2C19) metabolism enzyme inhibitor, this will lead to 
reduced concentration of clopidogrel active metabolite leading to reducing of its effect.  
 
Simvastatin contra carbamazepine is the next most used combination with severe DDI in the 
network. Carbamazepine is (CYP3A4) inducer, the enzyme which is responsible for 
metabolizing of simvastatin resulting in a higher metabolism rate of the cholesterol medicine 
and lacking its effect. These were three examples of observed severe interactions in 2013 
network, other examples in (table 4.46) and the 200 most frequented interactions are attached 
in (appendix 7).  
(all interactions and relevant information about their mechanisms can be checked at 
https://www.felleskatalogen.no/medisin/interaksjon or http://interaksjoner.azurewebsites.net/) 
 
As there were few studies used social network analysis on prescriptions databases, we had not 
a definitive and organized methodology of how exactly we will do this, and which 
results/outcomes to expect from this approach. We tried to represent the general features of 
each network and to summarize the information with short explanations but going in depth in 
each detail of these networks is a very time and effort consuming. Because we chose to 
represent the nodes of most influence in each network, some of the results can seem to be 
unimportant to study with such new complicated approach but going deeper to other nodes 
which aren’t the same famous or less familiar may represent important/unexpected results. It is 
important to say here that the main point was to show that this approach (network analysis) 
is/isn’t capable of introducing an approach to study drugs consumption flow. Some other results 
were actually surprising like medicine with most severe interactions and medicine with high 
betweenness score.  
We think that the part of extracting sub-patterns from the general network represents one of the 
most important uses of network analysis in the studying prescription databases. Comparing this 
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pattern extraction with other statistical ways (e.g. Clustering and FA) is important to confirm 
the pattern and eliminate errors as much as possible. 
 
Strengths and limitations 
1. Large scale of data on both scales patients and observations (prescriptions) (a population 
study). 
2. No selection bias as the data is already registered. Independence between data collection 
and the research eliminates targeting of certain cases to get specific results. 
3. The data are collected prospectively. 
4. The entire population is always combined with adjustment for confounders (69).  
5. The quality of data in NorPD is quite high; the data system is well-established and has 
been used for a quite long time. 
6. Our co-medication definition combines many useful medical aspects which makes it 
more reliable and flexible than many other approaches. It allows us to choose any 
prevalence points which makes comparing different treatment episodes possible.   
7. We used network analysis on a large scale of patients and prescriptions. To our 
knowledge, no published study has used this approach on drug-drug relations on such 
large scale and with such variety usage of network measures.  
 
While limitations are: 
1. Using Network analysis as an approach is challenging in itself because it requires 
studying social network analysis before starting to use it. In addition to that, there 
was no scheme or clear steps to follow regarding how we would use this approach 
on medicines study and which results are expected to get from this method of 
studying. 
 
2. Differences between using medicines and people as actors (nodes) in a network 
should be carefully taken into consideration. Motives, behavior, human interactions, 
and many other aspects which distinguish people from objects will keep the use of 
network approach relatively limited in case of studying objects rather than people.  
 
3. Depending on the Defined Daily Dose (DDD) as an approach to the defining of co-
medication has its limitations. Many drugs have a wide dose range, for instance, 
Prednisolone (ATC code H02AB06) had a DDD of 10 mg/day while it can be -
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practically- used more than 100 mg/day if necessary, besides it can be used less than 
that upon withdrawal. This can result in biasing the start and end of the treatment 
episodes for these drugs. Moreover, some drug formulations have no defined DDD 
like dermatologicals. Another thing related to DDD and should be taken into 
consideration is patient’s compliance which is usually not perfect. 
 
4. Visualizing of networks on a sheet of paper remains to be limited representative, 
digital visualizing with all the possibilities of using many filters and applying 
different algorithms is the ideal form for showing a network so far. Therefore, we 
uploaded all the generated networks in PDF format with the original resolution. To 
be able to apply filters and different algorithms on networks, visualizing platforms 
(like Gephi) must be used.  
 
5. Changing the date of dispensing variable to a difference in days from 1st of January 
2013 are expected to create some bias in the treatment episodes because the day of 
hospitalizing of each patient is unknown for us. Meanwhile, this bias is not expected 
to significantly affect the results for some reasons: first that the total number of 
hospitalized patients is much smaller than patients of NorPD. The second is that 
each patient has his own date of hospitalizing which means the date we chose will 
randomly be right matched with a share of patients and unmatched with another 
share, we could have said that this way of matching time dispensing variables can 
greatly affect the results if the hospitalizing difference date was one certain 
unknown day for all patients. The ideal situation was to study each dataset of these 
two separately but on the other hand, it would be much more difficult to study the 
double number of networks and conveniently combine the results of both.  
 
6. Choosing of 1st of January 2013 had its advantages but the disadvantage of it was 
that we couldn’t study the same time at the 2012 year because if we go back in time 
365 this will correspond the 1st day of the study and the treatment episode then is 
interrupted (a part of treatment episode which is before 1st January 2012 isn’t 
included in the study period). A better approach was to take this day in the middle 
point of the study (June 2013 for example). 
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7. Adherence percent of 80% is an assumption, there is no known way can safely 
confirm a certain adherence in addition adherence percentage varies a lot between 
patients. 
8. As we mentioned before some drug combinations showed in results are biased and 
needs an assessment example (Atorvastatin, Simvastatin in DDI most unfortunate 
combined drugs as an example, table 4.46). 
9. A deeper understanding of different network algorithms and some mathematical 
basics is necessary to get the rightest results using this approach. 
10. Although our study was done on a large scale of patients (approximately 96% of 
total the elderly population), the dataset we used from NorPD doesn’t include 
absolutely all the elderly prescriptions. Medicines dispensed under hospital stay or 






















6. Future work 
 
1. Further testing of our co-medication definition approach efficacy can be done by 
applying other different co-medication definitions on the same dataset and compare the 
accuracy and reliability of the results. 
 
2. Other network measures which haven’t been used in this thesis can be useful as well. 
For example, Ego Networks for certain important medicines can be done to study the 
influence of these particular medicines on the other medicine. Ego-centric network is to 
create a network from only a specific node perspective. In other words, to show only 
this drug and its relations to other drugs (50). Furthermore, we can use Ego networks 
for certain co-medications, following these combinations over years will allow us to 
study the probability of shifting or turning over to other drugs/combinations as a 
consequence of using these first combinations.  
 
3. Having network analysis as apart of descriptive analysis in medical research can also 
show some importance even if network analysis is not the primary concern for the study. 
Using network measures to specify the importance of each drug node in the network 
compared to others can play an important role in Pharmacoeconomics decision making 
and prioritizing of for example reimbursed medicines. Using NA to notice the change 
of intensity of DDI over time or in different places critical for pattern study in the 
medical field.  
 
4. Using Networks as a visualizing comparing tool can also be useful in studying 
medicines patterns and flow over the years. We believe yet that networks analysis can 
open a wide field for researchers in studying drug-drug relation-based information. 
 
5. In the Pharmacoeconomics field, network analysis can introduce new and supportive 
measures to the normal descriptive ways which are normally used. It can also support 
the decision makers to take the right decisions when it comes to prioritizing of drugs in 
terms of their value and importance. 
 
6. Using network analysis to visualize DDI can be used as an important part of discovering 
unwanted drug combinations on the large scale to evaluate the quality of prescribing 
and to take the necessary measures against the undesired adverse effects. 
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7. We think that network analysis can be used for prediction of the possible change in 
patterns if these specific patterns are followed up over the years. For example, if the 
patients of a certain co-medication for some cardiac disease and by following these 
patients’ co-medication patterns we can see that some other medicines gradually appears 
in the pattern over time so we can conduct the possibility of using a drug after a 






























Network analysis can be used as a new, convenient way of studying relations between drugs 
and extracting medication patterns.  Furthermore, it represents a group of measures that the 
traditional descriptive and statistical analysis cannot measure. Plotting the overall drugs’ 
consumption in a network to visualize it, is interesting in itself but for sure not enough. Further, 
extracting patterns and using the descriptive measures of network analysis to shed light on the 
clinical outcomes is a necessary part. A group of network analysis measures can be effectively 
used in the study of drug-drug relations (e.g. edges intensity, centrality measures, betweenness 
measures).  
Defining co-medication as treatment episodes allows flexibility in choosing of the studied 
prevalence points. Moreover, including many measures, like DDD and PDC, makes it more 
reliable to capture the co-medication. 
Network analysis was effectively used to obtain the relevant clinical information for both co-
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Appendix 1: STATA coding 
//1-Data preparation  
// a. split the 15 data files into 2 types of files according to time of despinsing 
variable (date or difference) 
preserve  
drop if diff_utleveringdato ==. //dropping all missing for diff_utleveringdato 
drop utleveringsdato //optional (you can keep it) 
save as 
restore  
drop if utleveringsdato =="" 
drop diff_utleveringdato //optional  
save as "" 
// b. merge using "append comman" all datafiles for dispensing difference 1 file 
and 1 file for dispensing date variable 















// save into 2 big datafiles  
save "/Users/mohsengamalsaad/Desktop/Msc data full/Data all in 2 
files.nosync/utleveringsdatoall.dta" 
// and the same fordifference in date of dispensing 
//filter out age 
drop if pasientfodtar >1948 
drop if atckode=="" 
drop if atckodedddverdi=="" 
// to find out mean age  
use "/Volumes/Mohsen/Master data after filters/Merged/All filtered.dta" 
gen alder=0 
replace alder =(2013-pasientfodtar) 
// for date of dispensing data file, make a variable which is difference between 
dispencing day and 01.01.2013 
// change date variable to numeric  
gen utleveringsdato2 = date(utleveringsdato, "YMD") 
// take difference  
gen differnse = utleveringsdato2-19359 // 19359 is the stata date format for 
01.01.2013 
drop utleveringsdato2 
rename differnse diff_utleveringdato 
// sort the used variables: 
sort pasientlopenr atckode diff_utleveringdato 
// must first convert ordinasjonantallddd from string to numeric  
gen test = subinstr(ordinasjonantallddd,",",".",9) 
destring test, replace 
// rename test and drop 
drop ordinasjonantallddd  
rename test ordinasjonantallddd 
//2- co-medication coding and creating treatment episodes 
// make a new variable which sums up ordinasjonantallddd 
by pasientlopenr atckode diff_utleveringdato: egen test = sum(ordinasjonantallddd)  
 
keep pasientlopenr atckode diff_utleveringdato ordinasjonantallddd 
duplicates drop 
// make lag and lead variables to take differece between observations in the same 
column (dispensing variable column)  
by pasientlopenr atckode: gen lag_dato = diff_utleveringdato[_n-1] 
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by pasientlopenr atckode: gen lead_dato = diff_utleveringdato[_n+1] 
gen delta_dager = lead_dato - diff_utleveringdato  
recode delta_dager (.=0) 
// Same with DDD 
by pasientlopenr atckode: gen ddd = ordinasjonantallddd  
by pasientlopenr atckode: gen lag_ddd = ordinasjonantallddd[_n-1] 
by pasientlopenr atckode: gen lead_ddd = ordinasjonantallddd[_n+1] 
 
// ADHERENCE 0.8 and create lag and lead for DDD as well 
by pasientlopenr atckode: gen ddd_80p_adh = ordinasjonantallddd /0.8 //0.8 betyr 
80% adherence, denne kan endres ved behov 
by pasientlopenr atckode: gen lag_ddd_80p_adh = ordinasjonantallddd[_n-1] /0.8 
by pasientlopenr atckode: gen lead_ddd_80p_adh = ordinasjonantallddd[_n+1] /0.8 
 
// create a variable for how long a prescription will cover pateint's dose 
by pasientlopenr atckode: gen resept_dekning_dager = ddd_80p_adh - delta_dager 
//choosing  80% adherence  
// removing the negative values (this means a patient has minus number of tablets 
for example, this -obviously- can't be taken to next treatment episode 
recode resept_dekning_dager (min/0=0)  
// create a lag variable for resept coverage period  
by pasientlopenr atckode: gen lag_rx_dekn_dag = resept_dekning_dager[_n-1] 
recode lag_rx_dekn_dag  (.=0) 
// create carryover variable for amount of DDD (tabletter) left with the patient 
(pateint still has an amount of medicine to carry over to the end of this treatment 
episode (PDC adherence definintion) 
by pasientlopenr atckode: gen carryover=  (ddd_80p_adh - delta_dager) + 
lag_rx_dekn_dag //må lage lag_resept_dekning_dager så det ikke genereres missings 
her 
by pasientlopenr atckode: gen lag_carryover = carryover[_n-1] 
codebook carryover 
// create treatmet episodes 
// 1 = defines treatment epsode start time (either missing value= start of a period 
(no precriptions before that) or  the patient had a medicine-free period for more 
than 14 days (gap period) 
gen treatment_episode = 0  
replace treatment_episode = 1 if lag_carryover==.  
replace treatment_episode = 1 if lag_carryover < -14  
// 3= defines treatment episode end (lead date is missing or carry over is less 
than -14 
recode treatment_episode (0=3) if carryover < -14  
recode treatment_episode (0=3) if lead_dato==.  
 
// generate a treatmet_start variable 
gen treatment_start = diff_utleveringdato if treatment_episode==1 
// filling out missing values 
by pasientlopenr: replace treatment_start = treatment_start[_n-1] if 
missing(treatment_start) 
replace treatment_episode =3 if carryover < -14 //hvis det er mer mindre enn 14 
dager minus så er gapet for stort til neste at det avsluttes 
replace treatment_episode =3 if lead_dato==. //første behandlingsepisode per 
legemiddel vil være  
  
// generate treatment_end variable  
gen treatment_end = diff_utleveringdato + ddd_80p_adh if treatment_episode==3 
//turning sorting for to fill out treatment end  (so, 3 (slutt) is over and 1 is 
under) 
gsort pasientlopenr atckode -diff_utleveringdato  
// filling out missing values 
by pasientlopenr: replace treatment_end = treatment_end[_n-1] if 
missing(treatment_end) 
sort pasientlopenr atckode diff_utleveringdato 
keep if treatment_episode==3 
keep pasientlopenr atckode treatment_start treatment_end 
//after that we can choose a period of study (prevelence period or point) to study 
//for 2013 netwrok 
keep if treatment_start <= 0  
keep if treatment_end >= 0  
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// for 2014 netwrok 
keep if treatment_start <= 365  
keep if treatment_end >= 365 
//3- networks generating 
preserve 
keep atckode pasientlopenr 
duplicates drop  
save "" 
rename atckode atckode2 
joinby pasientlopenr using "" 
bysort atckode atckode2 :egen edges=count(pasientlopenr) 
drop if atckode == atckode2 
drop pasientlopenr 
duplicates drop 
nwfromedge atckode atckode2 edges, undirected keeporiginal 
nwexport 
nwexport, type(pajek) replace 
//4- coding for importing different attributes to GEPHI 
import delimited "/Users/mohsenaskar/Desktop/CSV from gephi/DDI co weighed as 
edges.csv", clear  
drop timeset 
//merging wanted attributes (variables)  
//merging drug name 
merge 1:m label using "/Users/mohsenaskar/Desktop/vareregister.dta" 
//merging substance name 
merge 1:m label using "/Users/mohsenaskar/Desktop/ATC+substence name.dta" 
keep if _merge==3 
drop _merge 
rename varenavn name 
gen gruppe =substr(label,1,1) 
//for colors 
gen color="." 
replace color="#AD2516" if gruppe=="A" 
replace color="#EE1E23" if gruppe=="B" 
replace color="#F7BE4D" if gruppe=="C" 
replace color="#FFFC54" if gruppe=="D" 
replace color="#9FCD5F" if gruppe=="G" 
replace color="#4FAC5C" if gruppe=="H" 
replace color="#4CACF2" if gruppe=="J" 
replace color="#2B71B7" if gruppe=="L" 
replace color="#0A1F59" if gruppe=="M" 
replace color="#673897" if gruppe=="N" 
replace color="#7C7B79" if gruppe=="P" 
replace color="#7B5E21" if gruppe=="R" 
replace color="#6E74F8" if gruppe=="S" 
replace color="#6E74F8" if gruppe=="V" 
drop gruppe 
merge 1:m label using "/Volumes/Mohsen/2. forsøk/All antall brukere av ATC dag 
0.dta" 
keep if _merge==3 
drop _merge 
export delimited using "/Users/mohsenaskar/Desktop/CSV from gephi/CSV to 
gephi/Rogaland.csv", replace 
// import to GEPHI 
// 5- Six patterns networks  
// creating a file for each pattern (6 patterns) 
//cardiac,ARI,COPD,Anexiety,Menopause,Pain 
use "/Volumes/Mohsen/2. forsøk/All nw.dta", clear 
keep if treatment_start <= 0  
keep if treatment_end >= 0 
drop treatment_start treatment_end 
keep if substr(atckode,1,1) == "R" | substr(atckode,1,1) == "M" | 
substr(atckode,1,1)=="N" //fungerer 
keep if strpos(atckode,"R01A")>0 | strpos(atckode,"R01B")>0 | 
strpos(atckode,"R03A")>0 | strpos(atckode,"R03A")>0 | strpos(atckode,"R05CA")>0| 
strpos(atckode,"R05D")>0 | strpos(atckode,"R06A")>0 | strpos(atckode,"N06A")>0| 
strpos(atckode,"N06B")>0 | strpos(atckode,"C09A")>0| strpos(atckode,"C10A")>0 
preserve 
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keep atckode pasientlopenr 
duplicates drop 
save "/Users/mohsenaskar/Desktop/Menopause.dta" 
rename atckode atckode2 
joinby pasientlopenr using "/Users/mohsenaskar/Desktop/Menopause.dta" 
bysort atckode atckode2 :egen edges=count(pasientlopenr) 
drop if atckode == atckode2 
duplicates drop 
drop pasientlopenr 
nwfromedge atckode atckode2 edges, xvars undirected keeporiginal name(Menopause) 
nwexport, type(pajek) replace 
save "/Volumes/Mohsen/2. forsøk/7 PATTERNS/Dag 0/ARI.dta" 
// use (all nw) to find out how many useres for each ATC  
//for Day 0 
keep if treatment_start <= 0  
keep if treatment_end >= 0 
drop treatment_start treatment_end 
sort pasientlopenr atckode 
by pasientlopenr: gen n3=[_n-1] 
sort atckode 
by atckode: gen n4=_N 
rename n4 antallbrukere 
keep atckode antallbrukere 
duplicates drop 
rename atckode label 
// use merge command to merge number of users with 0 network 
drop _merge 
save "/Volumes/Mohsen/2. forsøk/All antall brukere av ATC dag 0.dta" 
// same is done with 365 network and compare network 
export delimited using "/Users/mohsenaskar/Desktop/CSV from gephi/CSV to gephi/All 
365 m3e antallnrukere.csv", replace 
//Now a file for ATC codes with number of users is created 
// anatomical groups  
keep if substr(atckode,1,1) == "A" | substr(atckode,1,1) == "B" | 
substr(atckode,1,1)=="C" 
keep if strpos(atckode,"A02B")>0 | strpos(atckode,"A10A")>0 | 
strpos(atckode,"A10B")>0 | strpos(atckode,"B01A")>0 | strpos(atckode,"C01A")>0| 
strpos(atckode,"C01D")>0 | strpos(atckode,"C03")>0 | strpos(atckode,"C07A")>0| 
strpos(atckode,"C08D")>0 | strpos(atckode,"C09A")>0| strpos(atckode,"C10A")>0 
sort antallbrukere 
//6- Interactions data 
//filtering and preparation of data 
//keep just ATC codes (remove groups og categories) 
drop if length(ATC1)<7 
drop if length(ATC2)<7 //114802 deleted 
//the opposite can be done if we want to study interactions on the groups level 
keep if length(ATC1)<=5  
keep if length(ATC2)<=5  
drop if ATC1=="NULL" 
drop if ATC2=="NULL" 
//remove if ATC1=ATC2 
drop if ATC1==ATC2 
//making a variable indicating combinations  
gen komb=0 
replace komb=1 if strpos(Lm1,"kombinasjon")>0 
replace komb=1 strpos(Lm2,"kombinasjon")>0  
 
//remove if drug 1 and 2 has the same substence 
drop if Lm1== Lm2 
//keep severe interactions (1st grade) indicated by number 1 in FEST database 
keep if Grad==1 
keep ATC1 ATC2 Grad 
// for creating of frequency DDI tablet between the anatomical groups  
gen atckode1=substr(ATC1,1,1) 
gen atckode2=substr(ATC2,1,1) 
tab atckode1 atckode2 
// to confirm the number of edges we founf in the general DDI netwrok  
use "/Volumes/Mohsen/2. forsøk/DDI/DDI atc code level 1 grad.dta" 
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keep ATC1 ATC2 Grad 
gen pairing = ATC1 + ATC2 
gen pairing2 = ATC2 + ATC1 
stack pairing pairing2, into(combined) 
duplicates drop combined,force // we got 114.302 observations which are (57151*2) 
 
// to create DDI nw for co-medication 
use "/Volumes/Mohsen/2. forsøk/All nw.dta" 
keep if treatment_start <= 0  
keep if treatment_end >= 0 
drop treatment_start treatment_end 
preserve 
keep atckode pasientlopenr 
duplicates drop  
save "/Users/mohsenaskar/Desktop/all joinby.dta" 
rename atckode atckode2 
joinby pasientlopenr using "/Users/mohsenaskar/Desktop/all joinby.dta" 
bysort atckode atckode2 :egen edges=count(pasientlopenr) 
drop if atckode == atckode2 
drop if length(atckode)<7 
drop if length(atckode2)<7 
drop pasientlopenr 
duplicates drop 
rename atckode ATC1 
rename atckode2 ATC2 
joinby ATC1 ATC2 using "/Volumes/Mohsen/Master oppgave 2018/interaksjoner/DDI med 
grad.dta" 
keep if Grad==1 
//Grade as edges (unweighted) 
keep ATC1 ATC2 Grad 
nwfromedge ATC1 ATC2 Grad, xvars undirected keeporiginal name(DDI comedication all 
grades) 
nwexport, type(pajek) replace  
 
//co-medication as edges (weighed)  
keep ATC2 ATC1 edges 
**network 
nwfromedge ATC1 ATC2 edges, xvars undirected keeporiginal name(DDI comedication 
comedicationa as edges) 
nwexport, type(pajek) replace  
 
//7-studying modularity classes medicines 
//import from gephi to stata (cvs) 
import delimited "/Users/mohsenaskar/Desktop/CSV from gephi/CSV to gephi 
substance/All 0.csv", clear  
 
//to covert ATC to the 4th level 
gen gruppe =substr(label,1,3) //which indicates theraputic use  
preserve 
gsort + modularity_class - antallbrukere   
keep if modularity_class ==1 
keep antallbrukere gruppe 
sort gruppe 
// to sum all users under the same group 
egen sumbrukere = sum(antallbrukere), by(gruppe) 
sort antallbrukere 
gsort - antallbrukere 
duplicates drop gruppe, force 
drop antallbrukere 
gsort -sumbrukere 
// and the same with each modularity class (1,2,3
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Topicals incl. Drops others Others Injections Tablets/capsules
Proctosedyl salve C05AA01 Betnovat m/chinoform krem D07BC01 Liposomal B12/Methylfolate drp B03BA Vitamin E NAF vet drp 50mg/ml QA11HA03 Myrratinktur NAF A01AB11 Neurobion inj A11DB Tricycline kaps A
Scheriproct rektalsalve+stikkp C05AA04 Synalar med Chinoform krem D07BC02 Kloramfenikol tak øyesalve 1% S01AA01 Karsivan vet tab 50mg QC04AD90 Mutaflor kaps A07 Pabrinex IM high potency inj A11EB Marinol tab 2,5mg A04AD10
Rectogesic rektalsalve 4mg/g C05AE01 Fucidin-Hydrocortison krem D07CA01 Aureomycin øyesalve 1% S01AA02 Fortekor vet tab  2,5mg QC09AA07 Olje-glyserol NAF rektalvæske A06AG04 Helixate NexGen inj sub 2000IE B02BD02 OFA urtete NAF A06AB20
Anoheal krem 2% C05AX Mycolog salve D07CB01 Garamycin øyedr 3mg/ml S01AA11 Sulfatiazol NAF vet salve 10% QD06BA02 Oljeklyster SA rektalvæske A06AG06 Feiba inf subst 1000E B02BD03 Pepto-Bismol tyggetab 262mg A07BB
Alcos-Anal salve C05AX03 Fucibet krem D07CC01 Tobrex Depot dep øyedr 3mg/ml S01AA12 Fuciderm vet gel QD07CC01 Prednisolon SA stikkpille 15mg H02AB06 Octanine inj subst 1000IE B02BD04 Ther-Biotic Complete kaps A07FA
Hirudoid salve 3mg/g C05BA01 Hydrokort SA krem 1% i karbamD07XA01 Fucithalmic øyedr 10mg/g S01AA13 Jod-kamfersalve NAF vet QD08AG53 Mirena intrauterin 20mcg/24t G02BA03 Haemate inj subst 1000IE B02BD06 Bififlor tab A07FA51
Canesten krem 1% D01AC01 Diprosalic lin D07XC01 Azyter øyedr 15mg/g endos S01AA26 Perlutex vet tab 5mg QG03DA02 Kaliumjodid recip tab 65mg V03AB21 Act-HIB inj subst J07AG01 Mycopryl 680 kaps A07XA
Daktar krem 2% D01AC02 Alsol vandig oppl 1% D08AB Terramycin-Polymyxin B øyesalv S01AA30 Clamoxyl vet inj 150mg/ml QJ01CA04 ReadiSorb Lipo Glutathion miks V03AB32 NeisVac-C inj 10mcg/spr J07AH07 Daosin kaps A09AA
Pevaryl pudder 1% D01AC03 Brulidine krem 0,15% D08AC01 Zovirax øyesalve 3% S01AD03 Noroclav vet tab 400/100mg QJ01CR02 Resonium-Calcium pulv V03AE01 Menveo inj subst J07AH08 Inte-zyme kaps A09AA02
Fungoral krem 20mg/g D01AC08 Hibiscrub lin 40mg/ml D08AC02 Cilox øyedr 3mg/ml S01AE03 Tribrissen vet tab QJ01EW10 True Test panel 1+2+3 plaster V04CL Boostrix inj spr J07AJ52 InterFase Plus kaps A09AC02
Pevisone krem D01AC20 Braunovidon salve 10% D08AG02 Betadine ster ophtalm oppl 5% S01AX18 Antirobe vet kaps 150mg QJ01FF01 UltraClear PLUS pH pulv vanilj V06DB Pneumovax inj J07AL01 Auralife kaps A11
Krystallfiolett NAF lin 0,1% D01AE02 Jod NAF lin 2% D08AG03 Spersadex øyedr 1mg/ml S01BA01 Genta-Kel 10 vet inj 100mg/ml QJ01GB03 Na kl fres t par br 9mg/ml pl V07AB Prevenar 13 inj spr J07AL02 Anabolic flow kaps A11AA03
Onytec medis neglelakk 80mg/g D01AE14 Pyrisept salve 1mg/g D08AJ03 Ultracortenol øyesalve 5mg/g S01BA04 Baytril vet tab  15mg QJ01MA90 Eter NAF V07AZ Tetavax inj J07AM01 Carotaben kaps 25mg A11CA02
Terbinafin hexal krem 10mg/g D01AE15 Sølvnitrat SA lin 0,25% D08AL01 Flurolon øyedr 1mg/ml S01BA07 Metacam vet miks 0,5mg/ml katt QM01AC06 Utlevering m/tilsyn - Metadon N07BC02 DiTeBooster inj J07AM51 Immunothione kaps A11EX
Loceryl medisinsk neglelakk 5% D01AE16 Microcid krem 1% D08AX01 Visucloben øyedr 1mg/ml S01BA09 Rimadyl vet tab  50mg QM01AE91 VSL#3 pulv nøytral A07FA01 BCG-vaksine inj SSI sett I+II J07AN01 Riboflavin solgar tab 50mg A11HA04
Lassars pasta NAF D02AB Kaliumpermang NAF til badev 3%D08AX06 Vexol øyedr 10mg/ml S01BA13 Baycox Bovis vet mikst 50mg/ml QP51AJ01 Hirudo medicinalis blodigler C05 Vivotif enterokaps J07AP01 P-5-P kaps 50mg A11HA06
Canoderm krem 5% D02AE01 Fucidin impr kompress 10x10cmD09AA02 Efemolin øyedr S01BB03 Drontal vet tab QP52AA51 L-glutamin pulv A16AA03 Typhim Vi inj 25mcg/spr J07AP03 Phosphate-sandoz brustab 500mg A12
Salisylsyre NAF olje lin  5% D02AF Zipzoc salvestrømpe impr kompr D09AB01 Voltaren Ophtha øyedr 1mg/ml S01BC03 Panacur vet past 187,5mg hu/ka QP52AC13 Fortyn saltsyre NAF drp 2mol/l A09AB03 TicoVac inj  2,4mcg/spr J07BA01 Calcium citrate tab A12AX
Miniderm krem 20% D02AX Kamferspiritus NAF lin D10A Nevanac øyedr 1mg/ml S01BC10 Banminth vet pasta  2,2% hund QP52AF02 Gingi-Pak Cord 2-ply 10120 A01AD01 Ixiaro inj 6mcg/spr J07BA02 Kalium hausmann brusetab A12BA30
Bepanthen krem 5% D03AX03 Aberela krem 0,05% D10AD01 Yellox øyedr 0,9mg/ml S01BC11 Exspot vet påflekk 715mg/ml QP53AC04 Mouth preparations Vaxigrip inj spr J07BB02 Magnesium Diasporal kaps 150mg A12CC10
Fenistil gel 1mg/g D04AA13 Avibon pomade D10AD02 Maxitrol øyedr S01CA01 Scalibor vet halsb 40mg/g hund QP53AC11 Andolex munnskyll 1,5mg/ml A01AD02 Engerix-B inj 20mcg/spr J07BC01 Fosfat SA mikst 1mmol/ml A12CX
Xylocain salve 5% D04AB01 Differin krem 1mg/g D10AD03 Atropin Minims øyedr 10mg/ml S01FA01 Frontline vet påfl væ 100mg/ml QP53AX15 Duraphat tannpasta 5mg/g A01AA01 Havrix inj 1440 ELISA U/spr J07BC02 Pregnenolone depottab 100mg A14A
Eurax krem 10% D04AX Zalna gel 10+0,25mg/g D10AD51 Cyclopentolat Minim øyedr 10mg S01FA04 Milbemax vet tab 16/40 katt QP54AB51 Klobetasol munngel 0,025% A01AC Twinrix Voksen inj spr J07BC20 DHEA douglaskaps 50mg A14AA07
Alphosyl 2 i 1 sjampo D05AA Epiduo gel 0,1/2,5% D10AD53 Tropikamid Minims øyedr 5mg/ml S01FA06 Fucithalmic vet øyedr 1% QS01AA13 Kenacort A orabase pasta 0,1% A01AC01 Imovax Polio inj spr J07BF03 Beet flow kaps A16
Dithrocream krem 0,25% D05AC01 Basiron AC Wash gel 5% D10AE01 Metaoxedrin Minims øyedr 100mg S01FB01 Optimmune vet øyesalve 2mg/g QS01XA18 Dentinox NAF oppl t tannkjøtt A01AD11 Rabies-Imovax inj subst J07BG01 L-Phenylalanine kaps A16AA
Calcipotriol san krem 0,05mg/g D05AX02 Dalacin lin emulsjon 10mg/ml D10AF01 Antistin-Privin øyedr S01GA51 Varilrix inj subst J07BK01 Molsidomin depottab 8mg C01DX12
Silkis salve 3mcg/g D05AX03 Zineryt pulv t/liniment 40mg D10AF02 Spersallerg øyedr S01GA52 Stamaril inj subst J07BL01 Elmiron kaps 100mg C05BA04
Xamiol gel D05AX52 Finacea gel 15% D10AX03 Lomudal øyedr 40mg/ml u/kons S01GX01 Gardasil inj J07BM01 Venoruton kaps 300mg C05CA01
Fumaderm tab D05BX51 Scott-Mathiesens hudv NAF lin D10AX30 Livostin øyedr 0,5mg/ml S01GX02 Systemic 140 Creams/Topical 115 Boostrix Polio inj spr J07CA02 Venastat depotkaps C05CX03
Aureomycin salve 3% D06AA02 Selsun sjampo 25mg/ml D11AC03 Tilavist øyedr 20mg/ml S01GX04 Non-systemic 217 Mouth preparations 5 Albumin baxter inf  50g/l B05AA01 HypoCol kaps C10
Terramycin-Polymyxin B salve D06AA03 Verucid lin D11AF Emadine øyedr 0,05% S01GX06 Total 357 Topicals incl. Drops others 52 Glucos fres inf  50mg/ml freef B05BA03 Remifemin tab 2,5mg G02CX04
Fucidin salve 2% D06AX01 Protopic salve 0,1% D11AH01 Lastin øyedr 0,5mg/ml S01GX07 Vet. Prepartions 25 SmofKabiven inf 1600kcal/p B05BA10 Armour Thyroid tab  30mg H03AA05
Bacimycin salve D06AX05 Elidel krem 10mg/g D11AH02 Zaditen øyedr 0,25mg/ml S01GX08 others 19 Na kl fres inf 9mg/ml freeflex B05BB01 Glucosamine Plus kap 500/360mg M01AX
Bactroban krem 2% D06AX09 Pigmanorm krem (Sveits) D11AX Opatanol øyedr 1mg/ml S01GX09 injections 80 Karbolytt inf 2000kJ/l freefl B05BB02 Reumacon ent kaps 50mg M01CX
Altargo salve 1% D06AX13 Recrea Forte lin 5% D11AX01 Oxibuprokain Minims øyedr 4mg S01HA02 tablets 50 Physioneal 40 glu 22,7mg skr B05DB Valerina forte tab N05CM09
Flamazine krem 10mg/g D06BA01 Vaniqa krem 11,5% D11AX16 Tetrakain Minims øyedr 10mg/ml S01HA03 suspensions 10 Kaliumkl braun infkon 1mmol MP B05XA01 5-HTP douglas kaps 50mg N06AX01
Zovirax krem 5% D06BB03 Solaraze gel 3% D11AX18 Alcaine øyedr 5mg/ml S01HA04 Na hyd karb br infkons 0,5mmol B05XA02 L-Tryptophan ratio tab 500mg N06AX02
Condyline lin 5mg/ml D06BB04 Mirvaso gel 3mg/g D11AX21 Fluoresceinna Minim øyedr 20mg S01JA01 Na kl braun infkon 1mmol/ml MP B05XA03 Bio-Biloba tab 100mg N06DX02
Vectavir krem 1% D06BB06 Uva Ursi Max-V kaps 200mg G01A Na kl i Emulgon apl øyesalv 5% S01XA03 Magnesiumsulfat inf kons 1mmol B05XA05 Dimaval kaps 100mg V03AB09
Aldara krem 5% D06BB10 Eddiksyre SA lin 2% G01AD02 Restasis øyedr 0,05% endos S01XA18 Monokaliumfosf inf kons 1mmol B05XA06 Ferriprox tab  500mg V03AC02
Veregen salve D06BB12 Albothyl vaginalvæske G01AX03 Ophtasiloxan øyedr S01XA20 Calciumklorid inf kons 1mmol B05XA07 Exjade dispergerbar tab 500mg V03AC03
Rozex gel 0,75% D06BX01 Orudis gel 2,5% M02AA10 Kloramfenikol NAF øred 100mg/g S02AA01 Tracel inf kons B05XA31 Osvaren tab 435/235mg V03AE04
Picato gel 150mcg/g endosetube D06BX02 Ibumetin gel 5% M02AA13 Borsyre SA øredr 30mg/ml S02AA03 L-Arginine kaps 700mg B05XB01 Folinic-folic acid kaps 0,8mg V03AF
Hydrok/Svov i cetyl SA kr 1/3% D07AA Voltarol  gel 11,6mg/g M02AA15 Diproderm øredr 0,05% endos S02BA07 Dipeptiven inf kons 200mg/ml B05XB02 Uromitexan tab 400mg V03AF01
Mildison Lipid krem 1% D07AA02 Termo medisinert plaster M02AB01 Locorten Vioform øredr S02CA02 Vitalipid adult inf kons B05XC Proglicem kaps  25mg V03AH01
Locoid lin 0,1% D07AB02 Algesal salve M02AC Cetraxal Comp øred 3+0,25mg/ml S02CA05 Aethoxysklerol inj 0,5% C05BB02 Aminess tab V06DD
Apolar krem 0,1% D07AB08 Hvit kamferolje NAF lin M02AX10 Sofradex øye-/øredr S03CA01 Premixel inf pl 840kj/l B05B Livertone kaps V06DX
Betnovat krem 0,1% D07AC01 Diltiazem SA rektalsalve 2% C08DB01 Terra-Cortril Polymyx B øredr S03CA04 Vamin Elektrol fri inf 14g N/l B05BA01 Placebo SA kaps V07A
Ibaril krem 0,25% D07AC03 Nystatin krem 100000IE D01AA01 Na kl SA øyedr 50mg/ml S01 Nexavir inj D Diabact UBT tab 50mg V04CX
Synalar gel 0,025% D07AC04 Testosteron SA krem 2% G03BA03 Kamferdråper NAF V03AX Protaminsulf leo inf/inj 10mg V03AB14 Hamburgerte NAF urtete A06AB56
Metosyn salve 0,05% D07AC08 Lugols joddråper SA oppl 5% H03CA Bactroban Nasal eurom salve 2% R01AX06 Naloxon braun inf/inj 0,4mg/ml V03AB15 Suspension or liquids
Elocon krem 0,1% D07AC13 Topicale anesthet gel raspberr N01BA05 Koffein/difen SA stikp 100/100 R06AA52 Flumazenil hameln inj 0,1mg/ml V03AB25 Cytra-K crystals pulv t mikst A02A
Flutivate krem 0,05% D07AC17 Xylocain gel 2% engangsspr N01BB02 Cilox øyedr 3mg/ml S01AE03 Alutard SQ Timot inj 100 000sq V01AA02 Vismutmikst/vann 1:3 SA mikst A02BX12
Dermovat krem 0,05% D07AD01 Emla krem 25+25mg/g N01BB20 Alutard SQ Der pter 503 100000 V01AA03 Tagitol V mikst 40% w/v V08BA01
Apolar med dekvalin salve D07BB02 Capsina krem 0,075% N01BX04 Alutard SQ Bjørk inj 100 000sq V01AA05 Ketovite Liquid mikst A11JA
Morfin SA steril gel 0,1% N02AA01 Alutard SQ Vepsegift 100 000sq V01AA07 Dukoral susp+brusegran t mikst J07AE01
Nix sjampo 1% P03AC04 Alutard SQ Burot inj 100 000sq V01AA10 Frølichs hostemikstur NAF R05CA10
Benzylbenzoat NAF lin 33% P03AX01 Alutard SQ Hundehår inj start V01AA11 Flow C dråper V03
Prioderm lin 0,5% P03AX03 Gammanorm inj 165mg/ml J06BA01 Brekkmiddel til barn NAF mikst V03AB01
Arnikatinktur NAF lin M02 Octagam inf  50mg/ml J06BA02 A-vitamin oljeoppl NAF mikst V04CB01
Hepatect CP inf 50 IE/ml J06BB04 Solhattinktur NAF dråper R05
Botox inj subst 100E M03AX01
Fentanyl hameln inj 50mcg/ml N01AH01
Standard EDA blanding SA inf N01AH51
Ketalar inj 50mg/ml N01AX03
Marcain inj 5mg/ml N01BB01
Carbocain inj 20mg/ml N01BB03
Ropivacain fre inf 2mg/ml free N01BB09
Marcain-Adr inj 2,5mg+5mcg/ml N01BB51
Xylocain-Adr inj 2%+5mcg/ml N01BB52
Carbocain adren inj 20mg+5mcg N01BB53
Citanest Dent Octapressin inj N01BB54
Septocaine F inj 40mg+10mcg sy N01BB58
Isofluran baxt væ t inh damp N01AB06
Valoid inj 50mg/ml R06AE03
Na kl SA inh væske 70mg/ml R07A
Gastrografin m & r 370mg I/ml V08AA01
Omnipaque inj 300mg I/ml USB V08AB02
Adrenalin base NAF injkons 1mg V03A
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Appendix 3: Variables description 
Variable name Variable description Variable type 1 Comment 
1. Prescriber information: 
forskriverlopenr Physician’s anonymous ID Numeric (long)  
forskriverfodtar Physician’s birth date Numeric (int.)  
forskriverkjonn Physician’s sex Numeric (byte)  
forskriverutenid Physician’s without an ID 
2 Numeric (byte)  
2. Patient information: 
pasientlopenr Patient’s anonymous ID Numeric (long) Central variable 
4 
pasientfodtar Patient’s birthdate Numeric (int.)  
pasientkjonn Patient’s sex Numeric (byte)  
pasientbostedfylkenr Patient’s municipality no  Numeric (byte)  
pasientbostedfylkenavn Patient’s municipality String (str30)  
pasientdodsar Patient’s death date Numeric (int.)  
pasientdodsmnd Patient’s death month Numeric (byte)  
pasientutenid Patient’s without ID Numeric (byte)  
3. Dispensing information: 
diff_utleveringdato Difference between 
dispensing for 
hospitalized patients 
Numeric (byte) Central variable 
4 
utleveringsaar Dispensing year Numeric (int.)  
utleveringsdato Dispensing date String (str10) Central variable 
4 
4a. Prescription information (Reimbursement info): 
kategori  String (str83)  
kategorinr  Numeric (byte)  
hjemmel  String (str62)  
hjemmelnr  Numeric (byte)  
refusjonkodeicdnr Blue prescription, 
reimbursement ICD 
code 
String (str5) Indicates type of diagnosis 
refusjonkodeicpcnr Blue prescription, 
reimbursement ICPC 
code 
String (str3) Indicates type of diagnosis 
4b. Prescription information (Medicines info): 
ordinasjonantallpakninger No. of packages 
dispensed 
String (str7)  
ordinasjonantallddd Total DDD dispensed String (str9) Central variable 
4 
varenr Medicine number 
3 Numeric (long)  
varenavn Medicine name String (str32)  
atckode ATC code String (str8) Central variable 
4 
atckodedddverdi DDD for this ATC code String (str7)  
atckodedddenhet Concentration in gram or 
mg or others 






Table shows dataset variables. 
1 Variables types according to STATA variable types. 
2 In some cases the pharmacist can dispense a prescription without a physician’s ID (for instance emergency 
cases, or a prescription from outside Norway) 
3 Each medicine in Norway has a registration number. 
















No. Drug 1 Drug 2 No. of times combined
1 118 - Acetyl salicylic acid 224 - Simvastatin 82948.0
2 118 - Acetyl salicylic acid 185 - Metoprolol 52577.0
3 118 - Acetyl salicylic acid 228 - Atorvastatin 42753.0
4 185 - Metoprolol 224 - Simvastatin 36792.0
5 118 - Acetyl salicylic acid 191 - Amlodipin 32628.0
6 118 - Acetyl salicylic acid 608 - Zopiklon 29173.0
7 191 - Amlodipin 224 - Simvastatin 22554.0
8 118 - Acetyl salicylic acid 201 - Ramipril 19660.0
9 224 - Simvastatin 608 - Zopiklon 18845.0
10 70 - Metformin 118 - Acetyl salicylic acid 18507.0
11 118 - Acetyl salicylic acid 172 - Furosemid 18175.0
12 185 - Metoprolol 228 - Atorvastatin 17266.0
13 118 - Acetyl salicylic acid 314 - Levotyroksinnatrium 16654.0
14 118 - Acetyl salicylic acid 520 - Paracetamol 16380.0
15 185 - Metoprolol 191 - Amlodipin 16271.0
16 111 - Warfarin 185 - Metoprolol 16005.0
17 70 - Metformin 224 - Simvastatin 15647.0
18 118 - Acetyl salicylic acid 210 - Kandesartan 14306.0
19 118 - Acetyl salicylic acid 157 - Isosorbidmononitrat 14236.0
20 118 - Acetyl salicylic acid 213 - Losartan og diuretika 14007.0
21 185 - Metoprolol 608 - Zopiklon 13801.0
22 10 - Pantoprazol 118 - Acetylsalisylsyre 13560.0
23 111 - Warfarin 224 - Simvastatin 13483.0
24 172 - Furosemid 185 - Metoprolol 13118.0
25 201 - Ramipril 224 - Simvastatin 12907.0
26 172 - Furosemid 224 - Simvastatin 12536.0
27 12 - Esomeprazol 118 - Acetylsalisylsyre 12430.0
28 520 - Paracetamol 608 - Zopiklon 12193.0
29 185 - Metoprolol 201 - Ramipril 12153.0
30 224 - Simvastatin 314 - Levotyroksinnatrium 12006.0
31 118 - Acetyl salicylic acid 206 - Losartan 10883.0
32 118 - Acetyl salicylic acid 307 - Prednisolon 10347.0
33 118 - Acetyl salicylic acid 217 - Kandesartan og diuretika 10319.0
34 213 - Losartan og diuretika 224 - Simvastatin 10312.0
35 224 - Simvastatin 520 - Paracetamol 10139.0
36 118 - Acetyl salicylic acid 495 - Alendronsyre 9897.0
37 118 - Acetyl salicylic acid 119 - Dipyridamol 9877.0
38 210 - Kandesartan 224 - Simvastatin 9774.0
39 191 - Amlodipin 228 - Atorvastatin 9748.0
40 118 - Acetyl salicylic acid 195 - Lerkanidipin 9731.0
41 118 - Acetyl salicylic acid 292 - Tamsulosin 9511.0
42 118 - Acetyl salicylic acid 173 - Bumetanid 9366.0
43 70 - Metformin 185 - Metoprolol 9292.0
44 118 - Acetyl salicylic acid 199 - Enalapril 9186.0
45 70 - Metformin 73 - Glimepirid 9152.0
46 191 - Amlodipin 608 - Zopiklon 9075.0
47 118 - Acetyl salicylic acid 737 - Cetirizin 8962.0
48 228 - Atorvastatin 608 - Zopiklon 8785.0










49 10 - Pantoprazol 224 - Simvastatin 8757.0
50 157 - Isosorbidmononitrat 224 - Simvastatin 8618.0
51 185 - Metoprolol 520 - Paracetamol 8472.0
52 12 - Esomeprazol 224 - Simvastatin 8310.0
53 157 - Isosorbidmononitrat 185 - Metoprolol 8218.0
54 73 - Glimepirid 118 - Acetylsalisylsyre 8146.0
55 314 - Levotyroksinnatrium 608 - Zopiklon 8020.0
56 185 - Metoprolol 314 - Levotyroksinnatrium 7961.0
57 172 - Furosemid 608 - Zopiklon 7869.0
58 118 - Acetyl salicylic acid 707 - tiotropium bromide 7814.0
59 118 - Acetyl salicylic acid 194 - Nifedipin 7753.0
60 118 - Acetyl salicylic acid 697 - Salmeterol og flutikason 7728.0
61 201 - Ramipril 228 - Atorvastatin 7562.0
62 111 - Warfarin 172 - Furosemid 7489.0
63 118 - Acetyl salicylic acid 626 - Escitalopram 7426.0
64 173 - Bumetanid 185 - Metoprolol 7384.0
65 217 - Kandesartan og diuretika 224 - Simvastatin 7354.0
66 206 - Losartan 224 - Simvastatin 7346.0
67 70 - Metformin 191 - Amlodipin 7115.0
68 140 - Folsyre 466 - Metotreksat 7078.0
69 697 - Salmeterol og flutikason 707 - tiotropium bromide 6930.0
70 199 - Enalapril 224 - Simvastatin 6831.0
71 185 - Metoprolol 213 - Losartan og diuretika 6811.0
72 118 - Acetyl salicylic acid 513 - Kodein og paracetamol 6775.0
73 118 - Acetyl salicylic acid 186 - Atenolol 6751.0
74 10 - Pantoprazol 185 - Metoprolol 6740.0
75 73 - Glimepirid 224 - Simvastatin 6721.0
76 224 - Simvastatin 495 - Alendronsyre 6682.0
77 111 - Warfarin 228 - Atorvastatin 6640.0
78 224 - Simvastatin 737 - Cetirizin 6608.0
79 691 - Salbutamol 697 - Salmeterol og flutikason 6599.0
80 195 - Lerkanidipin 224 - Simvastatin 6591.0
81 185 - Metoprolol 210 - Kandesartan 6472.0
82 111 - Warfarin 608 - Zopiklon 6461.0
83 70 - Metformin 228 - Atorvastatin 6458.0
84 173 - Bumetanid 224 - Simvastatin 6391.0
85 172 - Furosemid 520 - Paracetamol 6366.0
86 118 - Acetyl salicylic acid 137 - Cyanokobalamintanninkompleks 6360.0
87 10 - Pantoprazol 608 - Zopiklon 6316.0
88 118 - Acetyl salicylic acid 216 - Irbesartan og diuretika 6270.0
89 191 - Amlodipin 213 - Losartan og diuretika 6265.0
90 12 - Esomeprazol 608 - Zopiklon 6265.0
91 224 - Simvastatin 292 - Tamsulosin 6243.0
92 224 - Simvastatin 307 - Prednisolon 6240.0
93 65 - Insulin (human) 118 - Acetylsalisylsyre 6207.0
94 228 - Atorvastatin 314 - Levotyroksinnatrium 6187.0
95 118 - Acetyl salicylic acid 754 - timolol, combinations 6165.0
96 513 - Kodein og paracetamol 608 - Zopiklon 6144.0
97 12 - Esomeprazol 185 - Metoprolol 6104.0










99 118 - Acetyl salicylic acid 691 - Salbutamol 6048.0
100 307 - Prednisolon 608 - Zopiklon 6030.0
101 118 - Acetyl salicylic acid 226 - Pravastatin 5984.0
102 172 - Furosemid 191 - Amlodipin 5959.0
103 172 - Furosemid 201 - Ramipril 5959.0
104 116 - Klopidogrel 118 - Acetylsalisylsyre 5943.0
105 495 - Alendronsyre 608 - Zopiklon 5911.0
106 608 - Zopiklon 626 - Escitalopram 5658.0
107 185 - Metoprolol 195 - Lerkanidipin 5634.0
108 118 - Acetyl salicylic acid 489 - Allopurinol 5622.0
109 118 - Acetyl salicylic acid 138 - Hydroksokobalamin 5435.0
110 210 - Kandesartan 228 - Atorvastatin 5427.0
111 118 - Acetyl salicylic acid 170 - Bendroflumetiazid og kalium 5420.0
112 224 - Simvastatin 697 - Salmeterol og flutikason 5417.0
113 118 - Acetyl salicylic acid 140 - Folsyre 5406.0
114 111 - Warfarin 191 - Amlodipin 5387.0
115 119 - Dipyridamol 224 - Simvastatin 5368.0
116 111 - Warfarin 118 - Acetylsalisylsyre 5356.0
117 691 - Salbutamol 707 - tiotropium bromide 5335.0
118 118 - Acetyl salicylic acid 698 - Formoterol og budesonid 5324.0
119 118 - Acetyl salicylic acid 755 - latanoprost 5263.0
120 185 - Metoprolol 217 - Kandesartan og diuretika 5225.0
121 11 - Lansoprazol 118 - Acetylsalisylsyre 5208.0
122 118 - Acetyl salicylic acid 215 - Valsartan og diuretika 5208.0
123 12 - Esomeprazol 228 - Atorvastatin 5207.0
124 118 - Acetyl salicylic acid 200 - Lisinopril 5160.0
125 224 - Simvastatin 707 - tiotropium bromide 5134.0
126 191 - Amlodipin 520 - Paracetamol 5115.0
127 111 - Warfarin 173 - Bumetanid 5107.0
128 191 - Amlodipin 314 - Levotyroksinnatrium 5098.0
129 185 - Metoprolol 199 - Enalapril 5088.0
130 9 - Omeprazol 118 - Acetylsalisylsyre 5067.0
131 186 - Atenolol 224 - Simvastatin 5056.0
132 185 - Metoprolol 307 - Prednisolon 5050.0
133 118 - Acetyl salicylic acid 593 - Diazepam 5049.0
134 65 - Insulin (human) 224 - Simvastatin 5011.0
135 194 - Nifedipin 224 - Simvastatin 5002.0
136 10 - Pantoprazol 520 - Paracetamol 4969.0
137 595 - Oksazepam 608 - Zopiklon 4955.0
138 172 - Furosemid 228 - Atorvastatin 4955.0
139 224 - Simvastatin 626 - Escitalopram 4937.0
140 201 - Ramipril 608 - Zopiklon 4929.0
141 173 - Bumetanid 201 - Ramipril 4873.0
142 608 - Zopiklon 737 - Cetirizin 4852.0
143 118 - Acetyl salicylic acid 178 - Hydroklortiazid og kaliumsparende midler 4827.0
144 307 - Prednisolon 520 - Paracetamol 4812.0
145 314 - Levotyroksinnatrium 520 - Paracetamol 4754.0
146 10 - Pantoprazol 228 - Atorvastatin 4751.0
147 185 - Metoprolol 206 - Losartan 4718.0







149 224 - Simvastatin 513 - Kodein og paracetamol 4663.0
150 228 - Atorvastatin 520 - Paracetamol 4662.0
151 118 - Acetyl salicylic acid 240 - Ezetimib 4648.0
152 191 - Amlodipin 217 - Kandesartan og diuretika 4603.0
153 216 - Irbesartan og diuretika 224 - Simvastatin 4582.0
154 118 - Acetylsalisylsyre 595 - Oksazepam 4580.0
155 118 - Acetyl salicylic acid 208 - Valsartan 4575.0
156 691 - Salbutamol 706 - ipratropium bromide 4536.0
157 118 - Acetyl salicylic acid 187 - Bisoprolol 4533.0
158 210 - Kandesartan 608 - Zopiklon 4507.0
159 213 - Losartan og diuretika 228 - Atorvastatin 4489.0
160 191 - Amlodipin 201 - Ramipril 4467.0
161 118 - Acetyl salicylic acid 752 - timolol 4444.0
162 593 - Diazepam 608 - Zopiklon 4433.0
163 185 - Metoprolol 194 - Nifedipin 4407.0
164 118 - Acetyl salicylic acid 203 - Enalapril og diuretika 4407.0
165 12 - Esomeprazol 520 - Paracetamol 4404.0
166 65 - Insulin (human) 70 - Metformin 4387.0
167 172 - Furosemid 314 - Levotyroksinnatrium 4352.0
168 118 - Acetyl salicylic acid 295 - Finasterid 4345.0
169 191 - Amlodipin 210 - Kandesartan 4340.0
170 118 - Acetyl salicylic acid 358 - Metenamin 4336.0
171 116 - Klopidogrel 224 - Simvastatin 4324.0
172 157 - Isosorbidmononitrat 608 - Zopiklon 4311.0
173 224 - Simvastatin 489 - Allopurinol 4303.0
174 118 - Acetylsalisylsyre 189 - Karvedilol 4279.0
175 157 - Isosorbidmononitrat 191 - Amlodipin 4254.0
176 185 - Metoprolol 495 - Alendronsyre 4249.0
177 698 - Formoterol og budesonid 707 - tiotropium bromide 4202.0
178 116 - Klopidogrel 228 - Atorvastatin 4173.0
179 495 - Alendronsyre 520 - Paracetamol 4148.0
180 118 - Acetyl salicylic acid 192 - Felodipin 4129.0
181 73 - Glimepirid 185 - Metoprolol 4098.0
182 157 - Isosorbidmononitrat 172 - Furosemid 4097.0
183 608 - Zopiklon 697 - Salmeterol og flutikason 4092.0
184 754 - timolol, combinations 755 - latanoprost 4086.0
185 185 - Metoprolol 489 - Allopurinol 4046.0
186 224 - Simvastatin 754 - timolol, combinations 4026.0
187 118 - Acetyl salicylic acid 721 - Acetylcystein 4013.0
188 307 - Prednisolon 691 - Salbutamol 4000.0
189 12 - Esomeprazol 191 - Amlodipin 3993.0
190 157 - Isosorbidmononitrat 228 - Atorvastatin 3982.0
191 224 - Simvastatin 691 - Salbutamol 3971.0
192 118 - Acetyl salicylic acid 209 - Irbesartan 3963.0
193 70 - Metformin 172 - Furosemid 3950.0
194 608 - Zopiklon 707 - tiotropium bromide 3944.0
195 213 - Losartan og diuretika 608 - Zopiklon 3942.0
196 185 - Metoprolol 292 - Tamsulosin 3939.0
197 10 - Pantoprazol 191 - Amlodipin 3915.0
198 185 - Metoprolol 737 - Cetirizin 3905.0
199 111 - Warfarin 520 - Paracetamol 3857.0
200 170 - Bendroflumetiazid og kalium 224 - Simvastatin 3855.0
(1)The number before substance indicates node number in th network
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Appendix 5: Top 200 combination used in 2014 network 
 
 
No. Drug 1 Drug 2 No. of times combined
1 125 - Acetylsalisylsyre 234 - Simvastatin 73456.0
2 125 - Acetylsalisylsyre 193 - Metoprolol 47895.0
3 125 - Acetylsalisylsyre 238 - Atorvastatin 46548.0
4 193 - Metoprolol 234 - Simvastatin 32120.0
5 125 - Acetylsalisylsyre 200 - Amlodipin 30796.0
6 125 - Acetylsalisylsyre 609 - Zopiklon 27198.0
7 200 - Amlodipin 234 - Simvastatin 20299.0
8 125 - Acetylsalisylsyre 211 - Ramipril 18871.0
9 193 - Metoprolol 238 - Atorvastatin 18815.0
10 77 - Metformin 125 - Acetylsalisylsyre 17178.0
11 234 - Simvastatin 609 - Zopiklon 16786.0
12 125 - Acetylsalisylsyre 321 - Levotyroksinnatrium 16030.0
13 125 - Acetylsalisylsyre 181 - Furosemid 15970.0
14 125 - Acetylsalisylsyre 523 - Paracetamol 15709.0
15 193 - Metoprolol 200 - Amlodipin 15311.0
16 13 - Pantoprazol 125 - Acetylsalisylsyre 14829.0
17 77 - Metformin 234 - Simvastatin 14080.0
18 125 - Acetylsalisylsyre 220 - Kandesartan 13948.0
19 118 - Warfarin 193 - Metoprolol 13514.0
20 125 - Acetylsalisylsyre 223 - Losartan og diuretika 13063.0
21 193 - Metoprolol 609 - Zopiklon 12973.0
22 125 - Acetylsalisylsyre 164 - Isosorbidmononitrat 12584.0
23 15 - Esomeprazol 125 - Acetylsalisylsyre 12337.0
24 523 - Paracetamol 609 - Zopiklon 11786.0
25 193 - Metoprolol 211 - Ramipril 11621.0
26 211 - Ramipril 234 - Simvastatin 11573.0
27 181 - Furosemid 193 - Metoprolol 11553.0
28 234 - Simvastatin 321 - Levotyroksinnatrium 10938.0
29 118 - Warfarin 234 - Simvastatin 10844.0
30 200 - Amlodipin 238 - Atorvastatin 10742.0
31 181 - Furosemid 234 - Simvastatin 10653.0
32 125 - Acetylsalisylsyre 216 - Losartan 10213.0
33 125 - Acetylsalisylsyre 227 - Kandesartan og diuretika 9953.0
34 125 - Acetylsalisylsyre 126 - Dipyridamol 9669.0
35 238 - Atorvastatin 609 - Zopiklon 9665.0
36 125 - Acetylsalisylsyre 205 - Lerkanidipin 9510.0
37 234 - Simvastatin 523 - Paracetamol 9396.0
38 125 - Acetylsalisylsyre 300 - Tamsulosin 9272.0
39 125 - Acetylsalisylsyre 497 - Alendronsyre 9271.0
40 223 - Losartan og diuretika 234 - Simvastatin 9210.0
41 220 - Kandesartan 234 - Simvastatin 9022.0
42 125 - Acetylsalisylsyre 314 - Prednisolon 9001.0
43 125 - Acetylsalisylsyre 182 - Bumetanid 8925.0
44 13 - Pantoprazol 234 - Simvastatin 8921.0
45 77 - Metformin 193 - Metoprolol 8715.0
46 125 - Acetylsalisylsyre 742 - Cetirizin 8709.0
47 200 - Amlodipin 609 - Zopiklon 8600.0






49 193 - Metoprolol 523 - Paracetamol 8279.0
50 125 - Acetylsalisylsyre 209 - Enalapril 8264.0
51 77 - Metformin 80 - Glimepirid 7971.0
52 321 - Levotyroksinnatrium 609 - Zopiklon 7799.0
53 193 - Metoprolol 321 - Levotyroksinnatrium 7779.0
54 15 - Esomeprazol 234 - Simvastatin 7683.0
55 125 - Acetylsalisylsyre 203 - Nifedipin 7678.0
56 125 - Acetylsalisylsyre 710 - tiotropium bromide 7638.0
57 13 - Pantoprazol 193 - Metoprolol 7630.0
58 182 - Bumetanid 193 - Metoprolol 7325.0
59 147 - Folsyre 467 - Metotreksat 7314.0
60 125 - Acetylsalisylsyre 698 - Salmeterol og flutikason 7231.0
61 164 - Isosorbidmononitrat 193 - Metoprolol 7194.0
62 164 - Isosorbidmononitrat 234 - Simvastatin 7179.0
63 80 - Glimepirid 125 - Acetylsalisylsyre 7153.0
64 181 - Furosemid 609 - Zopiklon 6950.0
65 125 - Acetylsalisylsyre 628 - Escitalopram 6862.0
66 13 - Pantoprazol 609 - Zopiklon 6821.0
67 77 - Metformin 238 - Atorvastatin 6820.0
68 238 - Atorvastatin 321 - Levotyroksinnatrium 6805.0
69 227 - Kandesartan og diuretika 234 - Simvastatin 6776.0
70 216 - Losartan 234 - Simvastatin 6721.0
71 77 - Metformin 200 - Amlodipin 6683.0
72 698 - Salmeterol og flutikason 710 - tiotropium bromide 6627.0
73 118 - Warfarin 238 - Atorvastatin 6524.0
74 193 - Metoprolol 223 - Losartan og diuretika 6357.0
75 13 - Pantoprazol 238 - Atorvastatin 6330.0
76 193 - Metoprolol 220 - Kandesartan 6311.0
77 220 - Kandesartan 238 - Atorvastatin 6216.0
78 209 - Enalapril 234 - Simvastatin 6131.0
79 234 - Simvastatin 497 - Alendronsyre 6108.0
80 205 - Lerkanidipin 234 - Simvastatin 6098.0
81 72 - Insulin (human) 125 - Acetylsalisylsyre 6032.0
82 15 - Esomeprazol 609 - Zopiklon 6025.0
83 15 - Esomeprazol 193 - Metoprolol 5997.0
84 118 - Warfarin 181 - Furosemid 5992.0
85 234 - Simvastatin 742 - Cetirizin 5991.0
86 125 - Acetylsalisylsyre 194 - Atenolol 5982.0
87 234 - Simvastatin 300 - Tamsulosin 5972.0
88 691 - Salbutamol 698 - Salmeterol og flutikason 5961.0
89 181 - Furosemid 523 - Paracetamol 5957.0
90 182 - Bumetanid 234 - Simvastatin 5937.0
91 125 - Acetylsalisylsyre 758 - timolol, combinations 5911.0
92 200 - Amlodipin 223 - Losartan og diuretika 5901.0
93 15 - Esomeprazol 238 - Atorvastatin 5799.0
94 125 - Acetylsalisylsyre 226 - Irbesartan og diuretika 5798.0
95 125 - Acetylsalisylsyre 144 - Cyanokobalamintanninkompleks 5733.0
96 80 - Glimepirid 234 - Simvastatin 5697.0
97 125 - Acetylsalisylsyre 492 - Allopurinol 5561.0
98 125 - Acetylsalisylsyre 145 - Hydroksokobalamin 5545.0
99 497 - Alendronsyre 609 - Zopiklon 5538.0









101 125 - Acetylsalisylsyre 236 - Pravastatin 5507.0
102 125 - Acetylsalisylsyre 691 - Salbutamol 5458.0
103 118 - Warfarin 609 - Zopiklon 5455.0
104 193 - Metoprolol 205 - Lerkanidipin 5438.0
105 13 - Pantoprazol 523 - Paracetamol 5437.0
106 125 - Acetylsalisylsyre 514 - Kodein og paracetamol 5406.0
107 181 - Furosemid 200 - Amlodipin 5389.0
108 118 - Warfarin 211 - Ramipril 5374.0
109 181 - Furosemid 238 - Atorvastatin 5288.0
110 181 - Furosemid 211 - Ramipril 5277.0
111 314 - Prednisolon 609 - Zopiklon 5237.0
112 125 - Acetylsalisylsyre 699 - Formoterol og budesonid 5161.0
113 125 - Acetylsalisylsyre 147 - Folsyre 5156.0
114 200 - Amlodipin 523 - Paracetamol 5120.0
115 609 - Zopiklon 628 - Escitalopram 5118.0
116 234 - Simvastatin 314 - Prednisolon 5111.0
117 514 - Kodein og paracetamol 609 - Zopiklon 5110.0
118 200 - Amlodipin 321 - Levotyroksinnatrium 5021.0
119 125 - Acetylsalisylsyre 250 - Ezetimib 4999.0
120 125 - Acetylsalisylsyre 225 - Valsartan og diuretika 4975.0
121 182 - Bumetanid 211 - Ramipril 4966.0
122 193 - Metoprolol 227 - Kandesartan og diuretika 4952.0
123 691 - Salbutamol 710 - tiotropium bromide 4946.0
124 125 - Acetylsalisylsyre 759 - latanoprost 4942.0
125 126 - Dipyridamol 234 - Simvastatin 4920.0
126 234 - Simvastatin 698 - Salmeterol og flutikason 4832.0
127 234 - Simvastatin 710 - tiotropium bromide 4825.0
128 223 - Losartan og diuretika 238 - Atorvastatin 4819.0
129 14 - Lansoprazol 125 - Acetylsalisylsyre 4792.0
130 211 - Ramipril 609 - Zopiklon 4762.0
131 321 - Levotyroksinnatrium 523 - Paracetamol 4716.0
132 203 - Nifedipin 234 - Simvastatin 4703.0
133 125 - Acetylsalisylsyre 218 - Valsartan 4685.0
134 118 - Warfarin 182 - Bumetanid 4684.0
135 609 - Zopiklon 742 - Cetirizin 4665.0
136 182 - Bumetanid 609 - Zopiklon 4645.0
137 125 - Acetylsalisylsyre 178 - Bendroflumetiazid og kalium 4615.0
138 125 - Acetylsalisylsyre 210 - Lisinopril 4615.0
139 123 - Klopidogrel 125 - Acetylsalisylsyre 4613.0
140 193 - Metoprolol 209 - Enalapril 4598.0
141 12 - Omeprazol 125 - Acetylsalisylsyre 4592.0
142 118 - Warfarin 200 - Amlodipin 4539.0
143 125 - Acetylsalisylsyre 195 - Bisoprolol 4531.0
144 15 - Esomeprazol 523 - Paracetamol 4529.0
145 72 - Insulin (human) 234 - Simvastatin 4519.0
146 220 - Kandesartan 609 - Zopiklon 4507.0
147 193 - Metoprolol 314 - Prednisolon 4496.0
148 193 - Metoprolol 216 - Losartan 4484.0
149 200 - Amlodipin 227 - Kandesartan og diuretika 4450.0








151 193 - Metoprolol 203 - Nifedipin 4407.0
152 118 - Warfarin 125 - Acetylsalisylsyre 4392.0
153 597 - Oksazepam 609 - Zopiklon 4384.0
154 200 - Amlodipin 211 - Ramipril 4379.0
155 13 - Pantoprazol 200 - Amlodipin 4377.0
156 194 - Atenolol 234 - Simvastatin 4373.0
157 200 - Amlodipin 220 - Kandesartan 4356.0
158 314 - Prednisolon 523 - Paracetamol 4319.0
159 125 - Acetylsalisylsyre 595 - Diazepam 4272.0
160 123 - Klopidogrel 238 - Atorvastatin 4250.0
161 125 - Acetylsalisylsyre 359 - Metenamin 4249.0
162 699 - Formoterol og budesonid 710 - tiotropium bromide 4222.0
163 125 - Acetylsalisylsyre 756 - timolol 4204.0
164 164 - Isosorbidmononitrat 238 - Atorvastatin 4177.0
165 216 - Losartan 238 - Atorvastatin 4150.0
166 125 - Acetylsalisylsyre 303 - Finasterid 4136.0
167 125 - Acetylsalisylsyre 186 - Hydroklortiazid og kaliumsparende midler 4125.0
168 497 - Alendronsyre 523 - Paracetamol 4089.0
169 234 - Simvastatin 492 - Allopurinol 4086.0
170 205 - Lerkanidipin 238 - Atorvastatin 4039.0
171 226 - Irbesartan og diuretika 234 - Simvastatin 4034.0
172 72 - Insulin (human) 77 - Metformin 4026.0
173 125 - Acetylsalisylsyre 597 - Oksazepam 4025.0
174 15 - Esomeprazol 200 - Amlodipin 4022.0
175 13 - Pantoprazol 181 - Furosemid 4012.0
176 227 - Kandesartan og diuretika 238 - Atorvastatin 4004.0
177 125 - Acetylsalisylsyre 213 - Enalapril og diuretika 3979.0
178 691 - Salbutamol 709 - ipratropium bromide 3973.0
179 758 - timolol, combinations 759 - latanoprost 3965.0
180 125 - Acetylsalisylsyre 198 - Karvedilol 3957.0
181 193 - Metoprolol 492 - Allopurinol 3943.0
182 193 - Metoprolol 497 - Alendronsyre 3925.0
183 193 - Metoprolol 300 - Tamsulosin 3923.0
184 193 - Metoprolol 742 - Cetirizin 3907.0
185 181 - Furosemid 321 - Levotyroksinnatrium 3895.0
186 609 - Zopiklon 698 - Salmeterol og flutikason 3849.0
187 609 - Zopiklon 710 - tiotropium bromide 3829.0
188 125 - Acetylsalisylsyre 201 - Felodipin 3826.0
189 164 - Isosorbidmononitrat 609 - Zopiklon 3790.0
190 13 - Pantoprazol 314 - Prednisolon 3777.0
191 182 - Bumetanid 523 - Paracetamol 3775.0
192 164 - Isosorbidmononitrat 200 - Amlodipin 3774.0
193 238 - Atorvastatin 742 - Cetirizin 3750.0
194 234 - Simvastatin 758 - timolol, combinations 3721.0
195 223 - Losartan og diuretika 609 - Zopiklon 3691.0
196 125 - Acetylsalisylsyre 219 - Irbesartan 3683.0
197 200 - Amlodipin 216 - Losartan 3673.0
198 314 - Prednisolon 497 - Alendronsyre 3661.0
199 125 - Acetylsalisylsyre 230 - Valsartan og amlodipin 3647.0
200 234 - Simvastatin 514 - Kodein og paracetamol 3639.0
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ATC Substeance name ATC2 Substeance name3
A03AD01 Papaverin A01AB04 amphotericin B 
A04AA03 Tropisetron A01AD02 benzydamine 
A06AD17 sodium phosphate A02AA04 Magnesiumhydroksid
A10BX03 Nateglinid A03AA04 Mebeverin
A11CA01 Retinol (Vit A) A03AB02 Glykopyrroniumbromid
A16AA01 Levokarnitin A03AD01 Papaverin
B02BA01 Fytomenadion A03BA01 Atropin
C01BA01 Kinidin A06AD12 lactitol 
C01EB15 trimetazidine A07AA01 Neomycin
C03CA04 Torasemid A07AA12 Fidaksomicin
C07AA03 Pindolol A10BD10 Metformin og saksagliptin
C07AA06 Timolol A10BD15 Metformin og dapagliflozin
C10AD52 Nikotinsyre, kombinasjoner A14AB01 Nandrolon
G03AA07 Levonorgestrel og etinyløstradiol B02BA01 Fytomenadion
G03AA09 Desogestrel og etinyløstradiol C01BA01 Kinidin
G03AA13 Norelgestromin og etinyløstradiol C01EB18 Ranolazin
G03AC09 Desogestrel C02CA01 Prazosin
G03GA01 chorionic gonadotrophin C03BA08 Metolazon
G03HB01 Cyproteron og østrogen C07AA03 Pindolol
G04BE04 Johimbin C07AA06 Timolol
G04BX16 tiopronin C07AB12 Nebivolol
H01BB02 Oksytocin C08CA06 Nimodipin
H05AA03 parathyroid hormone C10AA08 Pitavastatin
H05BA01 calcitonin (salmon synthetic) G01AF05 Ekonazol
J01AA08 Minosyklin G03AA07 Levonorgestrel og etinyløstradiol
J01CA01 Ampicillin G03AA13 Norelgestromin og etinyløstradiol
J01CF05 Flukloksacillin G03CA57 conjugated estrogens 
J01DC02 Cefuroksim G03GA01 chorionic gonadotrophin
J01DD04 Ceftriakson G04BX16 tiopronin
J01DH02 Meropenem H05BA01 calcitonin (salmon synthetic)
J01MA12 Levofloksacin J01AA08 Minosyklin
J01XA01 Vankomycin J01DH03 Ertapenem
J02AB02 Ketokonazol J01MA12 Levofloksacin
J04AM05 Rifampicin, pyrazinamid og isoniazid J04AB04 Rifabutin
J05AF01 Zidovudin J05AF01 Zidovudin
J05AF02 Didanosin J05AF09 Emtricitabin
J05AH01 zanamivir L01AA01 Syklofosfamid
L01AA01 Syklofosfamid L01AA02 Klorambucil
L01AA02 Klorambucil L01AX03 Temozolomid
L01AX03 Temozolomid L01BC01 Cytarabin
L01BB02 Merkaptopurin L01XE04 Sunitinib
L01CB01 Etoposid L01XE18 Ruksolitinib
L01XC02 Rituksimab L01XE21 Regorafenib
L01XE10 Everolimus L01XE23 Dabrafenib
L01XX14 Tretinoin L01XX35 Anagrelid
L01XX17 Topotekan L03AB03 Interferon gamma
L03AX03 BCG vaccine L03AX03 BCG vaccine
M05BA01 Etidronsyre L04AA31 Teriflunomid
M05BB01 Etidronsyre og kalsium, sekvensielle L04AX06 Pomalidomid
N04AA04 Procyklidin M01CC01 Penicillamin
N04BX01 Tolkapon N02AJ13 Tramadol og paracetamol
N05AH05 Asenapin N02BB02 metamizole sodium 
N05BC01 meprobamate N03AX22 Perampanel
P01AB02 tinidazole N05AD08 Droperidol
P01BC02 Meflokin N05CM05 Skopolamin
P02CA03 Albendazol P01BC02 Meflokin
S01EA01 Adrenalin R03AC19 Olodaterol
V03AE07 calcium acetate R03AK10 Vilanterol og flutikasonfuroat
R03AL04 Indakaterol og glykopyrroniumbromid
R03DA02 Kolinteofyllinat
R03DA05 Teofyllinetylendiamin
Unique nodes 2013 network Unique nodes 2014 network
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No. Drug 1 Drug 2 No. of combinations 
1 61 - Simvastatin 65 - Atorvastatin 2320.0
2 49 - Losartan 53 - Losartan og diuretika 1253.0
3 148 - Kodein og paracetamol 149 - Tramadol 855.0
4 6 - Esomeprazol 15 - Klopidogrel 823.0
5 4 - Pantoprazol 6 - Esomeprazol 603.0
6 61 - Simvastatin 157 - Karbamazepin 480.0
7 35 - Metoprolol 194 - Paroksetin 454.0
8 82 - Pivmecillinam 106 - Metenamin 411.0
9 35 - Metoprolol 44 - Verapamil 380.0
10 213 - Flutikason 216 - Salmeterol og flutikason 359.0
11 6 - Esomeprazol 138 - Naproksen og esomeprazol 352.0
12 212 - Budesonid 217 - Formoterol og budesonid 343.0
13 5 - Lansoprazol 15 - Klopidogrel 308.0
14 131 - Diklofenak 135 - Ibuprofen 305.0
15 179 - Diazepam 180 - Oksazepam 300.0
16 157 - Karbamazepin 183 - Zopiklon 280.0
17 63 - Pravastatin 65 - Atorvastatin 279.0
18 3 - Omeprazol 15 - Klopidogrel 277.0
19 189 - Amitriptylin 197 - Escitalopram 277.0
20 3 - Omeprazol 6 - Esomeprazol 265.0
21 12 - Warfarin 131 - Diklofenak 254.0
22 65 - Atorvastatin 66 - Rosuvastatin 251.0
23 61 - Simvastatin 92 - Erytromycin 220.0
24 181 - Hydroksyzin 197 - Escitalopram 212.0
25 5 - Lansoprazol 6 - Esomeprazol 203.0
26 216 - Salmeterol og flutikason 220 - Flutikason 199.0
27 131 - Diklofenak 138 - Naproksen og esomeprazol 183.0
28 12 - Warfarin 21 - Dabigatran eteksilat 182.0
29 105 - Nitrofurantoin 106 - Metenamin 180.0
30 90 - Trimetoprim 106 - Metenamin 174.0
31 3 - Omeprazol 4 - Pantoprazol 171.0
32 4 - Pantoprazol 5 - Lansoprazol 153.0
33 145 - Oksykodon 147 - Oksykodon og nalokson 151.0
34 12 - Warfarin 22 - Rivaroksaban 150.0
35 12 - Warfarin 135 - Ibuprofen 144.0
36 135 - Ibuprofen 138 - Naproksen og esomeprazol 142.0
37 212 - Budesonid 219 - Budesonid 142.0
38 99 - Ciprofloksacin 106 - Metenamin 135.0
39 12 - Warfarin 136 - Naproksen 129.0
40 12 - Warfarin 138 - Naproksen og esomeprazol 127.0
41 61 - Simvastatin 154 - Fenobarbital 127.0
42 61 - Simvastatin 67 - Simvastatin og ezetimib 124.0
43 61 - Simvastatin 156 - Fenytoin 120.0
44 77 - Doksysyklin 81 - Amoksicillin 118.0
45 77 - Doksysyklin 83 - Fenoksymetylpenicillin 118.0
46 83 - Fenoksymetylpenicillin 106 - Metenamin 118.0
47 15 - Klopidogrel 17 - Dipyridamol 116.0
48 217 - Formoterol og budesonid 219 - Budesonid 115.0
49 35 - Metoprolol 39 - Karvedilol 114.0
50 35 - Metoprolol 37 - Bisoprolol 113.0






51 61 - Simvastatin 63 - Pravastatin 111.0
52 82 - Pivmecillinam 90 - Trimetoprim 110.0
53 35 - Metoprolol 36 - Atenolol 108.0
54 189 - Amitriptylin 193 - Citalopram 106.0
55 189 - Amitriptylin 223 - Alimemazin 105.0
56 213 - Flutikason 220 - Flutikason 103.0
57 34 - Sotalol 35 - Metoprolol 101.0
58 131 - Diklofenak 136 - Naproksen 96.0
59 158 - Levodopa og dekarboksylasehemmer 159 - Levodopa, dekarboksylasehemmer og COMT-hemmer 96.0
60 81 - Amoksicillin 106 - Metenamin 94.0
61 82 - Pivmecillinam 99 - Ciprofloksacin 94.0
62 61 - Simvastatin 66 - Rosuvastatin 93.0
63 174 - Klorprotiksen 197 - Escitalopram 90.0
64 195 - Sertralin 197 - Escitalopram 90.0
65 193 - Citalopram 197 - Escitalopram 89.0
66 135 - Ibuprofen 136 - Naproksen 88.0
67 81 - Amoksicillin 83 - Fenoksymetylpenicillin 87.0
68 81 - Amoksicillin 94 - Klaritromycin 84.0
69 83 - Fenoksymetylpenicillin 92 - Erytromycin 83.0
70 37 - Bisoprolol 44 - Verapamil 82.0
71 12 - Warfarin 132 - Diklofenak, kombinasjoner 81.0
72 154 - Fenobarbital 183 - Zopiklon 80.0
73 65 - Atorvastatin 67 - Simvastatin og ezetimib 79.0
74 28 - Flekainid 197 - Escitalopram 78.0
75 61 - Simvastatin 94 - Klaritromycin 78.0
76 77 - Doksysyklin 106 - Metenamin 78.0
77 35 - Metoprolol 192 - Fluoksetin 77.0
78 82 - Pivmecillinam 105 - Nitrofurantoin 74.0
79 65 - Atorvastatin 154 - Fenobarbital 70.0
80 42 - Nifedipin 157 - Karbamazepin 69.0
81 43 - Lerkanidipin 44 - Verapamil 68.0
82 181 - Hydroksyzin 193 - Citalopram 68.0
83 12 - Warfarin 134 - Meloksikam 66.0
84 132 - Diklofenak, kombinasjoner 135 - Ibuprofen 66.0
85 136 - Naproksen 138 - Naproksen og esomeprazol 66.0
86 187 - Trimipramin 197 - Escitalopram 66.0
87 65 - Atorvastatin 126 - Ciklosporin 65.0
88 132 - Diklofenak, kombinasjoner 138 - Naproksen og esomeprazol 64.0
89 81 - Amoksicillin 99 - Ciprofloksacin 62.0
90 29 - Amiodaron 197 - Escitalopram 61.0
91 83 - Fenoksymetylpenicillin 84 - Dikloksacillin 58.0
92 131 - Diklofenak 133 - Piroksikam 58.0
93 81 - Amoksicillin 82 - Pivmecillinam 57.0
94 43 - Lerkanidipin 126 - Ciklosporin 56.0
95 82 - Pivmecillinam 91 - Sulfametoksazol og trimetoprim 56.0
96 156 - Fenytoin 183 - Zopiklon 56.0
97 83 - Fenoksymetylpenicillin 96 - Klindamycin 55.0
98 91 - Sulfametoksazol og trimetoprim 106 - Metenamin 53.0
99 194 - Paroksetin 197 - Escitalopram 53.0









101 77 - Doksysyklin 92 - Erytromycin 51.0
102 33 - Propranolol 35 - Metoprolol 50.0
103 181 - Hydroksyzin 189 - Amitriptylin 50.0
104 131 - Diklofenak 132 - Diklofenak, kombinasjoner 49.0
105 15 - Klopidogrel 138 - Naproksen og esomeprazol 48.0
106 83 - Fenoksymetylpenicillin 99 - Ciprofloksacin 47.0
107 82 - Pivmecillinam 83 - Fenoksymetylpenicillin 46.0
108 90 - Trimetoprim 105 - Nitrofurantoin 44.0
109 205 - Donepezil 206 - Rivastigmin 44.0
110 120 - Tamoksifen 123 - Letrozol 42.0
111 36 - Atenolol 44 - Verapamil 40.0
112 131 - Diklofenak 134 - Meloksikam 40.0
113 133 - Piroksikam 135 - Ibuprofen 40.0
114 43 - Lerkanidipin 157 - Karbamazepin 39.0
115 201 - Mirtazapin 228 - Brimonidin 39.0
116 12 - Warfarin 133 - Piroksikam 37.0
117 61 - Simvastatin 126 - Ciklosporin 37.0
118 77 - Doksysyklin 99 - Ciprofloksacin 37.0
119 174 - Klorprotiksen 193 - Citalopram 36.0
120 21 - Dabigatran eteksilat 30 - Dronedaron 35.0
121 61 - Simvastatin 64 - Fluvastatin 35.0
122 133 - Piroksikam 138 - Naproksen og esomeprazol 35.0
123 134 - Meloksikam 135 - Ibuprofen 35.0
124 3 - Omeprazol 5 - Lansoprazol 34.0
125 15 - Klopidogrel 19 - Tikagrelor 34.0
126 39 - Karvedilol 44 - Verapamil 34.0
127 43 - Lerkanidipin 48 - Enalapril og lerkanidipin 34.0
128 165 - Selegilin 166 - Rasagilin 34.0
129 43 - Lerkanidipin 92 - Erytromycin 33.0
130 99 - Ciprofloksacin 105 - Nitrofurantoin 33.0
131 12 - Warfarin 141 - Nabumeton 32.0
132 91 - Sulfametoksazol og trimetoprim 99 - Ciprofloksacin 32.0
133 96 - Klindamycin 99 - Ciprofloksacin 32.0
134 17 - Dipyridamol 140 - Etorikoksib 31.0
135 84 - Dikloksacillin 106 - Metenamin 31.0
136 187 - Trimipramin 223 - Alimemazin 29.0
137 11 - Kaliumsitrat 106 - Metenamin 28.0
138 21 - Dabigatran eteksilat 22 - Rivaroksaban 28.0
139 12 - Warfarin 137 - Ketoprofen 27.0
140 134 - Meloksikam 138 - Naproksen og esomeprazol 27.0
141 170 - Haloperidol 197 - Escitalopram 26.0
142 13 - Dalteparin 22 - Rivaroksaban 25.0
143 15 - Klopidogrel 140 - Etorikoksib 25.0
144 83 - Fenoksymetylpenicillin 91 - Sulfametoksazol og trimetoprim 25.0
145 84 - Dikloksacillin 96 - Klindamycin 25.0
146 90 - Trimetoprim 99 - Ciprofloksacin 25.0
147 200 - Mianserin 228 - Brimonidin 25.0
148 49 - Losartan 156 - Fenytoin 24.0
149 84 - Dikloksacillin 99 - Ciprofloksacin 24.0









151 131 - Diklofenak 137 - Ketoprofen 24.0
152 181 - Hydroksyzin 205 - Donepezil 24.0
153 186 - Klomipramin 223 - Alimemazin 24.0
154 187 - Trimipramin 193 - Citalopram 24.0
155 189 - Amitriptylin 224 - Prometazin 24.0
156 192 - Fluoksetin 197 - Escitalopram 24.0
157 28 - Flekainid 193 - Citalopram 23.0
158 43 - Lerkanidipin 45 - Diltiazem 23.0
159 77 - Doksysyklin 91 - Sulfametoksazol og trimetoprim 23.0
160 135 - Ibuprofen 137 - Ketoprofen 23.0
161 37 - Bisoprolol 40 - Bisoprolol og tiazider 22.0
162 63 - Pravastatin 66 - Rosuvastatin 22.0
163 81 - Amoksicillin 90 - Trimetoprim 22.0
164 99 - Ciprofloksacin 184 - Melatonin 22.0
165 149 - Tramadol 165 - Selegilin 22.0
166 77 - Doksysyklin 95 - Azitromycin 21.0
167 81 - Amoksicillin 92 - Erytromycin 21.0
168 145 - Oksykodon 157 - Karbamazepin 21.0
169 17 - Dipyridamol 139 - Celekoksib 20.0
170 35 - Metoprolol 38 - Labetalol 20.0
171 77 - Doksysyklin 82 - Pivmecillinam 20.0
172 81 - Amoksicillin 105 - Nitrofurantoin 18.0
173 191 - Doksepin 197 - Escitalopram 18.0
174 193 - Citalopram 195 - Sertralin 18.0
175 6 - Esomeprazol 109 - Flukonazol 17.0
176 13 - Dalteparin 21 - Dabigatran eteksilat 17.0
177 26 - Disopyramid 35 - Metoprolol 17.0
178 34 - Sotalol 39 - Karvedilol 17.0
179 35 - Metoprolol 40 - Bisoprolol og tiazider 17.0
180 36 - Atenolol 39 - Karvedilol 17.0
181 43 - Lerkanidipin 154 - Fenobarbital 17.0
182 123 - Letrozol 124 - Eksemestan 17.0
183 10 - Budesonid 217 - Formoterol og budesonid 16.0
184 14 - Enoksaparin 22 - Rivaroksaban 16.0
185 28 - Flekainid 30 - Dronedaron 16.0
186 41 - Felodipin 157 - Karbamazepin 16.0
187 71 - Fesoterodin 157 - Karbamazepin 16.0
188 81 - Amoksicillin 91 - Sulfametoksazol og trimetoprim 16.0
189 83 - Fenoksymetylpenicillin 87 - Cefaleksin 16.0
190 83 - Fenoksymetylpenicillin 94 - Klaritromycin 16.0
191 135 - Ibuprofen 141 - Nabumeton 16.0
192 174 - Klorprotiksen 181 - Hydroksyzin 16.0
193 181 - Hydroksyzin 187 - Trimipramin 16.0
194 181 - Hydroksyzin 206 - Rivastigmin 16.0
195 189 - Amitriptylin 222 - Deksklorfeniramin 16.0
196 43 - Lerkanidipin 94 - Klaritromycin 15.0
197 44 - Verapamil 92 - Erytromycin 15.0
198 87 - Cefaleksin 106 - Metenamin 15.0
199 131 - Diklofenak 141 - Nabumeton 15.0
200 132 - Diklofenak, kombinasjoner 136 - Naproksen 15.0
 119 








ATC Name No. of DDI involoved in Notes
A02BD07 Lansoprazol, amoksicillin og klaritromycin 62
A02BD04 Pantoprazol, amoksicillin og klaritromycin 61
A02BD05 Omeprazol, amoksicillin og klaritromycin 61
A02BD06 Esomeprazol, amoksicillin og klaritromycin 61
A02BD09 Lansoprazol, klaritromycin og tinidazol 61
A02BD11 Pantoprazol, amoksicillin, klaritromycin og metronidazol 61




















C07FX05 Metoprolol og ivabradin 122
C07FX06 Karvedilol og ivabradin 120
C07FB02 Metoprolol og felodipin 114
C07FB03 Atenolol og nifedipin 114
C07AA05 Propranolol 99
C07BA05 Propranolol og tiazider 98
C07FX01 Propranolol og andre kombinasjoner 98
C08DA01 Verapamil 97









Most interacted ATC codes (combined or none combined)
Group A anatomical class
Most interacted ATC codes (combined or none combined)
1. Proton pump inhibitors: 
Esmoprazole has more interactions 
than omeprazole, lansoperzaole and 
the least is pantoprazole     
2. H2-receptor antagonists: Cimetidin, 
ranitidine, famotidin has same no. Of 
interactions (19)   Most interacted ATC codes uncombined (singel active sustance)
Group B anatomical class
combinations are rare in this 
group 
Group C anatomical class
1. Among diuretics: Tolvaptan has 
most interactions (18).                2. 
Among Beta-blockers propranolol 
most DDI with 99 interactions and 
Labetalol has least with 78 as a single 
substance.           3. Among Calcium 
channel blockers Verapamil has most 
97 and Nimodipine has least with 22.                  
4.Among Angiotensin reuptake 
inhibitors Aliskiren is themost with 
75, -sartans are the least 5-4 
interactins (C09)    5.Among lipid 
modifying (C10) simvastatin is most 
with 81, the leat is Gemfibrozil with 4 
(as single substances)       
Most interacted ATC codes (combined or none combined)












G03AB08 Dienogest og østradiol 64
G03AA14 Nomegestrol og østradiol 63
G02BB01 Vaginalring med progestogen og østrogen 62
G03CA01 Etinyløstradiol 62
G03HB01 Cyproteron og østrogen 62
G03AA01 Etynodiol og etinyløstradiol 62
G03AA02 Kingestanol og etinyløstradiol 62
G03AA06 Norgestrel og etinyløstradiol 62
G03AA08 Medroksyprogesteron og etinyløstradiol 62


























J07AN01 Tuberkulose, levende, svekket 277
J01MA02 Ciprofloksacin 273




J01E Sulphonmides around 260 
J01G Aminoglycosides 268
J01M QUINOLONE 265, 266 except Moxifloxacin 312
J01R-J01X Combinations and others 265 DDI
Group D anatomical class
Most interacted ATC codes uncombined (singel active sustance)
Almost no combinations in this group
Group G anatomical class
Most interacted ATC codes (combined or none combined)
1. A lot of combinations in this group 
(Hormons).       2. Among the Drugs 
used in erectile dysfunction sildenafil 
most (42), tadalafil least (31).
Most interacted ATC codes uncombined (singel active sustance)
Group H anatomical class
Significantly low interactions (cortisones), interactions are mostly with vaccines or immunosuppresents (J,L) groups
Group J anatomical class
Most interacted ATC codes 
1. J02 Antimycotics for systematic 
use: Most Itraconazol 157, Hakimycin 
is lowest with 13.         2.J04 
Antimycobacterial: Rifampicin and  
isoniazid 15 many comes with just 1 
DDI.    3. J05 Antivirals sys. Use: 
Telbivudin least with 1 DDI, many 
combinations. 4. Vaccines J07: most 
Tyfoid, oral, levende, svekket with 
absolute most DDI of all ATC 537, 
least is Yellow fever vac. with 248.Antibiotics for systematic use



























R07AX30 Ivakaftor og lumakaftor 53
R06AX28 Rupatadin 31
R05DA04 Kodein 25








1. Antineoplastic L01: most 
Padeliporfi with 192, least are 
Erlotinib, Sunitinib and Ruksolitinib 
with (1).            2. Endocrine theraby 
L02: most Enzalutamid with 111, least 
Abirateron with 1. 
3.Immunostimulants L03: most 
Histamindihydroklorid with 122, least 
Peginterferon alfa-2a with (1).          
4. Immunosuppressants L04: most 
Ciklosporin with 58, least Kladribin 
with (10).  
Group L anatomical class
Most interacted ATC codes 
Group M anatomical class
Most interacted ATC codes Uncombined
1. Almost 70% of ATC in this group had around 60 interactions.    2. Coxibs GROUP shows sig. Lower interactions than all the other 
infalmmatory ATCs.   3. All NSAIDs, Oxicams have equal interactions.
Group N anatomical class
Most interacted ATC codes Uncombined 1. Anaethtics N01: most 
Natriumoksybat with 72, least 
Alfentanil with (1). 2.Analgesics 
N02:  most Dihydroergotamin with 
39, least Cannabinoider with (1) 3. 
Antiepileptics N03: 
Metylfenobarbital, Fenobarbital, 
Primidon, Barbeksaklon, Metarbital 
most with 207, Beklamid lowest with 
(1).                  4. Anti-parkinson 
drugs N04: most Selegilin with 32, 
Melevodopa with lowest 23.
5. PSYCHOLEPTICS N05: highst Hydroksyzin with 87, lowst Klometiazol with (1).                     2. 
PSYCHOANALEPTICS N06: ginkoblad and citalopram comes first with 148 and 83, lowest is 
Reboksetin with (1).
Group V anatomical class
Group P anatomical class
Group R anatomical class 1. high combinations frequency. 2. 
Nasal preparations R01: fluticason 
combination comes with highst DDI 
18, while Fenylpropanolamin comes 
lowst with (13).         3. Throat 
preparations R02: just one medicine 
Flurbiprofen comes with highst 
number of interactions of all with  61 
DDI. 4. Obstructive air ways drugs 
R03: salmetrol highst 18, Roflumilast 
lowst (1).
Most interacted ATC codes 
5.Cough and cold prep. R05: codein most with 25, least are Etylmorfin, Hydrokodon with 2.            6. 
Antihistaminic for sys. Use R06: Rupatadin 31 highst, most famous lowest Desloratidine among others 
with 1 DDI.      7. Others N07: most is Natriumoksybat  with 72, many comes lowst with 2 interaction most 
famous Buprinorphine.
Group S anatomical class
